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As of 2009, about 56,000,000 single nucleotide polymorphisms (SNPs) have 
been deposited in the NCBI dbSNP database, Build 129 (dbSNP 129). Of these, 
>14,000,000 represent non-redundant SNPs and ~6,600,000 SNPs have been 
validated. Some of these SNPs are likely to affect phenotype and be causally 
associated with disease risk or drug response. However, identifying these phenotype-
affecting SNPs from a pool of >14 million poses significant challenges.  Several 
strategies have been proposed for the selection of a subset of SNPs that may be useful 
for disease- or drug-response gene-based or genome-wide association studies 
(GBAS/GWAS) (Jorgenson and Witte 2006; Rebbeck, Spitz and Wu 2004). 
This dissertation attempts to annotate the potential functionality of SNPs in 
dbSNP129 by integrating >40 different algorithms/resources to interrogate >14,000,000 
SNPs from this dbSNP database for SNPs of potential functional significance based on 
previously published reports, inferred potential functionality from genetic approaches as 
well as predicted potential functionality from sequence motifs.  A bioinformatics 
pipeline was first established and a data warehouse for potential functional SNPs 
(pfSNPs) identified from >40 resources was built.  A comprehensive, well-annotated, 
integrated pfSNP (potentially functional SNPs) Web Resource (http://pfs.nus.edu.sg/) 
which is aimed to facilitate better hypothesis generation through knowledge syntheses 
mediated by better data integration and a user-friendly web interface was then 
developed.  Its query-interface has the user-friendly „auto-complete, prompt-as-you-
type‟ feature and is highly customizable facilitating different combination of queries 
using Boolean-logic.  Additionally, to facilitate better understanding of the results and 
aid in hypotheses generation, gene/pathway-level information with text-clouds 
highlighting enriched tissues/pathways as well as detailed related information are also 
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provided on the results page.  Hence, this pfSNP resource will be of great interest to 
scientists focusing on association studies as well as those interested to experimentally 
address the functionality of SNPs. 
To demonstrate the applicability of the pfSNP resource, I employed this 
resource and examined pfSNPs to identify SNPs that are significantly associated with 
response to anti-cancer drugs (5FU/capecitabine and oxaliplatin) in metastatic 
colorectal cancer patients.  Notably, the minor allele of 2 non-synonymous SNPs 
potentially affecting exon-splice enhancers (ESE) and nonsense mediated decay 
(NMD) as well as a 3‟UTR SNP affecting miRNA binding at the UMPS gene was 
observed only in non-responders but not in responders when >100 patients are 
examined.  Due to the limited number of patients examined, these SNP did not pass 
multiple test correction. Future studies could examine more patients to evaluate if 
these SNPs with potential function are in fact the causative SNPs associated with 
response to these anti-cancer drugs. 
In summary, I have developed a useful resource that annotates the potential 
functionality of SNPs in the human genome. Employing these pfSNPs in pathways 
associated with 5FU, oxaliplatin and colorectal cancer, I identified 3 pfSNPs affecting 
ESE, NMD and miRNA binding that may play a role in determining differences in 
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CHAPTER I: GENERAL INTRODUCTION  
 
1.1 Overview of Single Nucleotide Polymorphisms (SNPs) 
 
1.1.1 SNPs and their role in human health 
 
Single nucleotide polymorphisms (SNPs) refer to single base differences at 
particular chromosome loci. More simply put, SNPs are copying errors that create 
variations between people, influencing a variety of differences in traits, disease 
susceptibility and drug response. SNPs arise from founder germ-line mutations, and 
such mutations are retained in the population through random genetic drift (when the 
mutation is evolutionarily neutral) (Kimura 1979) or positive selection if the mutation 
carries a selective advantage. In recent years, the distinction between rare SNP and 
mutation are blurred therefore in this thesis the term SNP may also refer to mutation 
as well.   
SNPs can act as useful genetic markers to identify genes that influence human 
health-related traits. Two methods, namely the family-based “linkage” mapping 
(Lander and Schork 1994) and population-based genetic association studies (Freimer 
and Sabatti 2004), can be used for gene discovery. The “linkage” mapping approach 
uses various genetic markers, such as microsatellites (otherwise known as short 
tandem repeats) and SNPs, to study segregated genetic markers amongst related 
individuals to ascertain the genetic basis of a certain phenotype, such as hair and eye 
colour. By comparison, genetic association studies attempt to find markers that have 
different allele distributions amongst affected and un-affected groups of unrelated 
individuals in the population. For these studies, SNPs are the marker of choice, as 
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recombination occurs extensively at the population scale and genetic fine-mapping 
using more markers will increase the power of such studies (Kruglyak 1997; Evans 
and Cardon 2004). As compared with microsatellites, SNPs are more abundant, with 
an initial estimated frequency of one per 100 - 300 base pairs (Cargill, Altshuler et al. 
1999). With the continuous effort of SNP discovery and the advent of new sequencing 
technology, SNPs are found widely spread across the human genome and the list of 
known SNPs is growing at an accelerated rate. More than 52 million SNPs have been 
catalogued in the latest release of the National Center for Biotechnology Information 
(NCBI) SNP database (dbSNP) (db135, as of June 2012), of which 12 million are 
newly reports. 
Notably, many SNPs reside in functionally important regions of genes and 
affect the molecular functions of the gene. Some of them may represent causal SNPs 
that can directly impact upon human health rather than merely acting as markers. One 
classical example is the SNPs in the glucose-6-phosphate dehydrogenase (G6PD) 
gene. G6PD gene deficiency is known to be the cause of sickle cell anaemia, but also 
confers protection against malaria (Ruwende, Khoo et al. 1995). It has been 
demonstrated that two SNPs (rs1050828, Val68Met and rs1050829, Asn126Asp) in 
the G6PD gene, which are both non-synonymous SNPs in the coding region, together 
cause a severe drop in the enzyme yield (Town, Bautista et al. 1992), and thus directly 
causes the G6PD gene deficiency. Currently, there are more than 160 SNPs or 
mutations found to cause G6PD deficiency in different world populations (Mason, 
Bautista et al. 2007). Besides G6PD deficiency, SNPs are also found to be directly 
causal in several other diseases, including cystic fibrosis (e.g. rs1800085, Val322Met 
in CFTR gene) (Bobadilla, Macek et al. 2002) and alpha thalassemia (e.g. 
5‟UR/T149709C in HBA1 gene) (De Gobbi, Viprakasit et al. 2006). 
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1.1.2 SNPs with varied molecular functions can be causal to human traits  
 
1.1.2.1 SNPs change protein functions 
 
Many of the identified causal SNPs are non-synonymous SNPs (Mason, 
Bautista et al. 2007); that is, these SNPs cause changes in the amino acids in the 
protein. Such SNPs may abolish or alter protein function, especially if the amino acid 
change occurs at a key residue in a motif that is crucial for protein function. In 
addition to GD6P gene deficiency, another example of a non-synonymous, causal 
SNP is the recently reported SNP (rs1804645, P1272S) in the SRC-1 gene (Hartmaier, 
Richter et al. 2012). This SNP causes a disruption to the phosphorylation site in the 
protein, and has been associated with decreased bone mineral density in breast cancer 
patients treated with an antagonist against the oestrogen receptor, called Tamoxifen. 
A non-synonymous SNP may also reside outside the functional domain and affect 
protein conformation, leading to a change in binding affinity to its substrate or to 
another protein partner. 
Besides non-synonymous SNP, other types of SNPs can also alter protein 
conformation and substrate specificity. Synonymous SNPs, which result in the coding 
of the same amino acid, had long been thought of as “silent”. However, studies now 
suggest the role of synonymous SNPs in the direct alteration of protein 
conformation/substrate specificity (Soranzo, Cavalleri et al. 2004; Kimchi-Sarfaty, Oh 
et al. 2007), with accumulating evidences such as the recent mutations identified in 
the cystic fibrosis trans-membrane conductance receptor (CFTR) gene (Bartoszewski, 
Jablonsky et al. 2010). Studies also show that synonymous SNPs implicated in human 
disease extensively (Sauna and Kimchi-Sarfaty 2011) with effect size similar to that 
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of the non-synonymous counterparts (Chen, Davydov et al. 2010). 
 
1.1.2.2 SNPs change protein expression level 
 
The G6PD deficiency example also shows that gene expression level is 
important in determining human traits and SNPs in different gene regions may well 
affect gene expression via different mechanisms. 
In the coding region, a SNP forming a stop codon instead of an amino acid 
residue change has long been implicated in causing human disease. Such SNPs reduce 
gene expression levels through a well-known mechanism named “Nonsense mediated 
mRNA decay” (NMD), which leads to the degradation of the mRNA containing the 
premature stop codon. In the CFTR gene, one such mutation reduces the mRNA level 
by more than 90% as compared with the wild-type allele (Hamosh, Rosenstein et al. 
1992). It is now known that a number of SNPs/mutations causing premature stop 
codon are implicated in cystic fibrosis, accounting for 5-10% of the total mutant 
alleles in cystic fibrosis patients (Kerem 2004).  
SNPs at the promoter region are known to affect gene expression at the 
transcriptional level by creating or disrupting transcription factor binding sites and 
thus leading to altered mRNA production. An example is the SNP in the α-globin 
cluster which results in α-thalassemia (De Gobbi, Viprakasit et al. 2006). This SNP 
(5‟UR/T149709C, rsNo unknown) creates a binding site for the transcription factor 
GATA-1 and thus induces a promoter-like element. The newly created promoter then 
competes with the native promoter of the α-globin cluster, leading to a reduction in 
the expression α-globin in the α-thalassemia phenotype. In the MDM2 gene, a similar 
promoter-forming SNP (rs2279744, I/1/T309G) leads to an enhanced SP1 binding site. 
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This SNP was later found to be associated with earlier tumour onset (Bond, Hu et al. 
2005).  
At the 3‟ UTR region, SNPs may affect gene expression by altering micro 
RNA (miRNA) binding. miRNA binds to its target mRNA at the 3‟UTR region and 
blocks translation. This is a mechanism recently demonstrated to be universal in gene 
expression regulation, with 30% of all the genes estimated to be regulated (Lewis, 
Burge et al. 2005). Although it is a relatively new gene regulation mechanism, as 
compared with transcription factor binding, some SNPs have already been shown to 
affect human health via this mechanism. In the papillary thyroid carcinoma, a SNP 
(rs17084733, E21/3UTR /G217A) in the miR221/222 binding site in the 3‟UTR 
region of the KIT gene deregulates KIT expression via miR-221/222, which are 
up-regulated and postulated to affect cancer progression (He, Jazdzewski et al. 2005). 
Another 3‟ UTR SNP in dihydrofolate reductase leads to gene overexpression and 
therefore methotrexate resistance, as the T allele disrupts miR-24 binding to the 
mRNA and abolishes miRNA-mediated suppression (Mishra, Humeniuk et al. 2007). 
 
1.1.2.3 SNPs cause differential splicing 
 
Protein function may also be affected by differential mRNA splicing. 
Differential mRNA splicing is seemingly universal, with more than 95% of all human 
genes estimated to produce more than one protein product (Pan, Shai et al. 2008; 
Wang, Sandberg et al. 2008). Traditionally, SNPs at the splicing donor and acceptor 
sites were considered important in this process (Zhang 1998). However, with the 
discovery of splicing enhancers and silencers in the exon and intron (Fairbrother, Yeh 
et al. 2002; Yeo, Nostrand et al. 2007), a higher incidence of SNP involvement may 
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be implicated. Furthermore, 15-50% of human disease mutations are estimated to 
affect splice site selection (Wang and Cooper 2007). The following Table 1.1 
summarizes the aforementioned major gene regulatory mechanisms affected by SNPs, 
and their links to human health conditions. 
 
Table 1.1: Gene regulatory mechanisms affected by SNPs in human disorders. 
 Function of SNP Examples in Human 
Health  
mRNA 
Reduce mRNA copy number by “Nonsense 
mediated mRNA decay” 
Cystic fibrosis (Hamosh, 
Rosenstein et al. 1992) 
Change transcript level by changing TF 
binding site 
1. α-thalassemia (De Gobbi, 
Viprakasit et al. 2006) 
2. Earlier tumour onset 
(Bond, Hu et al. 2005) 
Change translational efficiency of mRNA 
by changing miRNA binding site 
1. Progression of papillary 
thyroid carcinoma (He, 
Jazdzewski et al. 2005) 
2. Methotrexate resistance 
(Mishra, Humeniuk et al. 
2007) 
Change gene product by causing 
differential splicing 
15-50% of human disease 
mutations estimated to affect 
splice site (Wang and Cooper 
2007) 
Protein 
Reduce protein level by causing 




(sickle cell anaemia) (Town, 
Bautista et al. 1992) 
Affect protein function by changing 
functional motif directly 
Decreased bone mineral 
density in tamoxifen-treated 
women (Hartmaier, Richter et 
al. 2012) 
Affect protein function by changing protein 
conformation 
Cystic fibrosis (Bartoszewski, 
Jablonsky et al. 2010) 
 
1.1.3 Strategies and challenges to the identification of functional SNPs 
 
Functional SNPs underlying human health conditions can be identified in two 
ways: (1) identification of relevant functional SNPs by demonstrating their biological 
functions and associating these SNPs to the possible conditions related to such 
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biological plausibility; or (2) lineage mapping/genetic association followed by 
functional testing of the SNPs to potentially explain the biological effect. 
The first approach is usually employed when there is extensive prior 
knowledge to support the function of the SNP as well as the gene. This approach was 
employed for the MDM2 study discussed previously, where the promoter SNP in the 
MDM2 gene was demonstrated to enhance SP1 binding to the MDM2 promoter and 
later found to be associated with earlier tumour onset (Bond, Hu et al. 2005). By 
comparison, when prior knowledge is weak or new biological plausibility is required, 
the second approach is used. “Linkage mapping” or genetic association studies are 
first carried out to find the regions or SNPs likely to be responsible for the condition. 
This is later followed by functional testing of the SNPs for possible biological 
plausibility to explain the observed association. This approach led to the discovery of 
the SNP in the α-globin cluster associated with α-thalassemia (De Gobbi, Viprakasit 
et al. 2006). The region containing the SNP was first found to be associated with the 
disease in the Melanesian population. The SNP was later found to create a promoter 
and suppresses the expression of α-globin by competing with the native promoter. 
Between the two approaches, the latter reveals new biological mechanisms (Li 2006) 
because it is less restricted by prior knowledge. The drop in sequencing and 
large-scale genotyping costs also makes this approach more popular in recent years. 
This is evidenced by the wide adoption of the “hypothesis-free” genome-wide 
association studies (GWAS) for various human health conditions. 
The successful application of both approaches requires a complete list of all 
possible functional SNPs to be known, such that no important SNPs are omitted. 
Further, limiting this list to only the most important SNPs would be more time- and 
cost-effective, and introduce less noise into the association analysis. Unfortunately, no 
Potentially Functional Single Nucleotide Polymorphisms (pfSNPs) in the Human Genome and their Potential Applications 
8 
such list is readily available. The next section briefly discusses some of the 
computational resources that I employed to help derive such a list. 
 
1.1.4 Computational methods and resources to facilitate the identification of 
functional SNPs 
 
1.1.4.1 SNP cataloguing projects to reveal SNP architecture in gene and genome 
 
To facilitate the identification of functional SNPs, a catalogue that contains a 
complete list of SNPs is required. This is particularly important in cases where more 
than one SNP function together to cause the phenotype and an incomplete list that 
does not contain one of these SNPs will not be helpful. A complete list of SNPs is 
also useful in GWAS studies to get a better view of the linkage disequilibrium profile 
of the population and subsequently to facilitate the selection of more appropriate 
tagging SNPs. Table 1.2 tabulates some of these recent efforts to catalogue SNPs. 
 
Table 1.2: Some of the SNP cataloguing efforts. 
Database Name Scope Information Provided 
LSDB 
(e.g. IARC TP53 
database) 
Single gene 1. Literature reported function 













HapMap Whole genome 
 
1. Allele frequency in different world 
population for common SNP (MAF >5) 
2. LD and haplotype information 
1000 Genome Project Whole genome 
 
1. Allele frequency in different world 
population for all SNP 
2. LD and haplotype information 
NCBI dbSNP Whole genome 1. Allele frequency by voluntary reporting 
from individual researchers, as well as 
large scale studies 
2. Gene and genome context 
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Small scale catalogues in the format of a locus specific database (LSDB) were 
the first to be introduced (Claustres, Horaitis et al. 2002). These databases catalogue 
SNPs in one or few gene loci and serve as encyclopaedias for SNPs in the gene of 
interest because detailed phenotype relation/molecular function of the SNPs are 
included as a result of expert manual curating. These databases are generally biased 
towards more well-studied genes (Claustres, Horaitis et al. 2002), such as p53 (Olivier, 
Eeles et al. 2002; Hamroun, Kato et al. 2006). Due to the high popularity of LSDB, 
specific toolkits, such as the Universal Mutation Database (UMD) (Beroud, Hamroun 
et al. 2005) and Leiden Open source sequence Variation Database (LOVD) (Fokkema, 
Taschner et al. 2011) has been developed to facilitate database construction. LSDBs 
continue to be under heavy development and extensive efforts have been made to 
establish standards (Celli, Dalgleish et al. 2012) and provide guidelines for building 
such databases (Cotton, Auerbach et al. 2008; Vihinen, den Dunnen et al. 2012).  
Medium-scale SNP catalogues are useful for genetic association studies that 
focus on more than one gene locus. These catalogues focus on SNPs in genes from a 
particular pathway or related to certain phenotype. One example of such resource is 
the National Institute of Environmental Health Sciences (NIEHS) Environmental 
Genome Project (Rieder, Livingston et al. 2008) 
(http://egp.gs.washington.edu/welcome.html), which houses information about 648 
genes that have been previously reported in the literature to be important in 
gene-environment interactions.  SNPs in these 648 genes are then postulated as 
important in gene-environment interactions. Similarly, SNPs catalogued in the Seattle 
SNPs Project (http://pga.gs.washington.edu/), a database of 319 genes previously 
reported to be involved in inflammation, could also be hypothesized to affect pathways 
involved in inflammation. Beside obtaining genotype information directly from 
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experiments, integrating genotype information into a central repository from scattered 
sources in different LSDBs may be useful (den Dunnen, Sijmons et al. 2009). 
Large-scale projects cataloguing SNPs and targeting genome-wide SNP allele 
frequency information in different human populations are also available. Resources, 
such as ALFRED (Osier, Cheung et al. 2001) and SPSmart (Amigo, Salas et al. 2008), 
constructed SNP catalogues by collecting SNP population specific allele frequency 
information from the literature. A different approach, which is to generate this 
information by genotyping a group of individuals from each population via 
high-throughput methods, was undertaken by collaborative efforts under The 
International HAPMAP Project. In the pilot phase of the project, samples representing 
the four major world populations were genotyped. These included thirty sets of trios 
from a USA Utah population, with Northern and Western European ancestry collected 
by the Centre d‟Etude du Polymorphisme Humain (CEPH); thirty sets of trios from a 
Yoruban population in Ibadan, Nigeria (YRI); 45 unrelated Japanese in Tokyo, Japan 
(JPT); and 45 unrelated Han Chinese in Beijing, China (CHB). The pilot phase 
targeted to genotype 600,000 SNPs spaced at approximately one per 5-kilobase 
intervals. As large-scale genotyping technology was relatively new at the time, and 
the accuracy was of concern, a locus had to have minor allele frequency (MAF) of 
more than 5% in at least one population in order to pass the quality control. Today, 
~4M SNPs have been genotyped in the four populations. The MAF requirement of at 
least 5% has also been removed as the genotyping platforms improved over the years. 
Seven additional populations have been included, with 1.6 million SNPs genotyped in 
each population through Affymetrix or Illumina genotyping Chip assays (Altshuler, 
Gibbs et al. 2010). The number of SNPs covered by HAPMAP is currently restricted 
by the technology used, and the 1000 Genomes Project using whole genome 
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sequencing platforms sought to carry on and identify more than 95% of the variants in 
the human genome from different ancestral populations. These variants in the 1000 
Genomes Project included low frequency and rare variants, whose minor allele 
frequencies were 0.5%-5% and less than 0.5%, respectively, that were previously not 
well-covered (Durbin, Abecasis et al. 2010). Information pertaining to allele 
frequencies, genotype and haplotype of known and unknown variants discovered was 
catalogued, and is available to the public (http://www.1000genomes.org/home). 
By far, the most important and thorough large-scale SNP catalogue is the NCBI 
dbSNP (Sayers, Barrett et al. 2011). The NCBI dbSNP provides SNP allele and 
genotype frequencies reported by HAPMAP and the 1000 Genomes Project, as well as 
those submitted by individual researchers in their population of interest. Information 
submitted by individual researchers may help to cross-validate the information provided 
by HAPMAP and the 1000 Genomes Project, as well as provide allele information in 
populations not covered. It also provides the genomic location and gene context of the 
SNP, which offers some basic functional effect of the SNP (e.g., the SNP is a 
non-synonymous SNP). Therefore, the NCBI dbSNP can act as a useful starting point 
for researchers to mine for SNP-related information. One important observation, 
however, is that the NCBI dbSNP database is very dynamic, due to the ever increasing 
number of entries, as well as constant updating from other data sources on which it 
depends, such as RefSeq and Genome Build. Consequently, changes to information 
provided by the NCBI dbSNP can create confusion, even for users that are familiar with 
it. For instance, the assignment of different reference cluster numbers (rsNo, the unique 
identifier of SNP in dbSNP) to the same genomic location adds confusion. Another 
example would be mapping of a SNP to a different gene location due to different 
genome coordinates assigned in a new Genome Build entry or due to some updates in 
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the gene reference sequence (e.g., change of exon length). Although these types of 
changes are infrequent, they can be problematic if researchers use different builds of the 
human genome at different points in time for their work.  
 
1.1.4.2 Computational methods and resources to facilitate the identification of 
functional SNPs 
 
As the number of SNPs documented in the databases continues to grow, 
finding functional SNPs in the human genome is like trying to “find a needle in a 
haystack”. Fortunately, a number of computational methods and resources have been 
developed recently to help pinpoint the potentially functional SNPs (pfSNP) that are 
likely to be causal due to their known biological plausibility. 
 
1.1.4.2.1 Literature-reported “potentially functional SNPs” 
 
Literature-reported functional SNPs in related or even apparently unrelated 
phenotypes may affect the phenotype to be studied due to a phenomenon called 
“pleiotropy”. This is because the SNP may affect a gene that has multiple molecular 
functions, or alternatively, the single molecular function of the gene may be shared by 
different phenotypes (Becker 2004). Some classical examples of “pleiotropy” can be 
found in immune-related diseases (Zhernakova, van Diemen et al. 2009; Lees, Barrett 
et al. 2011) and a recent report (Sivakumaran, Agakov et al. 2011) provided evidence 
that 233 (16.9%) genes and 77 (4.6%) SNPs causing human disease show pleiotrophic 
effect. 
Therefore, mining literature for previously reported SNPs implicated in related 
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traits or traits that share a common pathway may aid in pinpointing the causal SNP. 
However, this is not a trivial task. Although natural language processing has been 
proposed as a promising way to help the mining process, there are a few obstacles to 
be overcome before this will be successfully implemented. The first is the 
non-standardized nomenclature used for SNP reporting. Since non-synonymous SNPs 
were the primary focus in the past, a SNP in the literature is usually referred to by the 
amino acid change it caused; and citing the reference SNP number (rsNo) assigned by 
NCBI dbSNP was not a common practice until recently. SNPs were also referred to as 
an “allele” of the gene, and extensive domain knowledge is required to translate the 
allele number mentioned in the literature into a corresponding SNP, if possible. 
Furthermore, the nomenclature used in SNP reporting is not standardized, and it is 
very difficult to create an accurate rule to sift through the literature (Xuan, Wang et al. 
2007). Therefore, LSDB and other general purpose databases relying on extensive 
manual compilation, such as MutaGeneSys (Stoyanovich and Pe'er 2008) and the 
Human Gene Mutation Database (HGMD, http://www.hgmd.cf.ac.uk/ac/index.php), 
are still the preferred resources for finding literature reported functional SNPs. 
Manual curation is also used for summarizing GWAS results currently available. The 
Genetic Association Database (GAD) (http://geneticassociationdb.nih.gov/) and the 
NHGRI „A Catalog of Published Genome-Wide Association Studies‟ 
(http://www.genome.gov/gwastudies) are maintained by curators rather than 
automated data integration pipelines. 
 
1.1.4.2.2 Predicted “potentially functional SNPs” 
 
As our knowledge about SNP function accumulates, various methods have 
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been proposed to predict SNP functions. I broadly classified these methods into two 
categories, namely “SNP character-based method” and “Motif-based method”, 
according to the underlying mechanisms used to derive the predictions in each method. 
There are also methods that use both approaches, forming a third “Combined method” 
category. Table 1.3 lists some of the methods commonly found in the literature.  
 













Coding Cause NMD  Nonsense Mediated 
Decay 






Cause aberrant 5' 
site (SD-Score)  
(Sahashi, Masuda 
et al. 2007) 
Motif- Based Promoter Change TF 
Binding sites 
TransFac etc.  
Coding Change ESE/ESS 
Site 
RESCUE-ESE etc.  (Fairbrother, Yeh 
et al. 2002; 
Cartegni, Wang et 
al. 2003; Zhang 
and Chasin 2004; 
Zheng 2004) 




400bps of splicing 
site 
(Yeo, Nostrand et 
al. 2007) 
3UTR Change Mir 
Binding 
MirRanda etc. (Krek, Grun et al. 
2005; Grimson, 
Farh et al. 2007; 







sequence alignment  
(Xie, Lu et al. 
2005) 
Coding Protein Domain / 
Functional Sites 
Interpro Scan (Quevillon, 
Silventoinen et al. 
2005) 
Combined Non-synonymous Change functional 
motif 
NetPhos etc. (Hansen, Lund et 
al. 1998; Blom, 
Gammeltoft et al. 
1999) 
  Non-Synonymous 
SNP function 
based on multiple 
criteria 
Polyphen etc. (Ramensky, Bork 




Yue, Melamud et 
al. 2006) 
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The “SNP character-based method” is based on the character of the SNP, such 
as the amino acid change caused. One example of such methods is the empirical rule 
to identify SNPs leading to the degradation of mRNA (nonsense-mediated decay, 
NMD) by generating a premature stop codon in certain coding region (Nagy and 
Maquat 1998). Another example is the SD score (Sahashi, Masuda et al. 2007), which 
is the precise formula for predicting disruption effects of the SNPs found at the 5‟ 
Intron-Exon boundary. It‟s noteworthy that methods strictly belonging to this 
category are scarce, because SNPs usually function in the context of a “motif”, and, 
consequently, the “Combined method” is usually more useful. This can be illustrated 
by the SNPs causing phosphorylation site changes, where a single SNP changing the 
amino acid would be functional, only if such residue is in a phosphorylation motif. 
Compared to “SNP character-based” methods, “Motif-based” methods are 
more abundant and can be used to find pfSNP in all gene regions. However, most of 
them were not developed to find pfSNP directly and extra efforts are needed to adapt 
them for pfSNP screening. Therefore, this section will cover some of the extension 
efforts and review their strengths and weaknesses. 
Promoter SNPs may change transcription factor binding sites (TF binding 
sites), and their effects on gene expression are well-established (Chorley, Wang et al. 
2008). The methods currently available – TRANSFAC Gene Transcription Factor 
database http://www.biobase-international.com/pages/index.php?id=transfac and 
MatInspector 
http://www.genomatix.de/online_help/help_matinspector/matinspector_help.html – 
largely  focus on predicting transcription factor binding sites in a given DNA 
sequence. These tools scan the input DNA sequence against a library of Positional 
Weight Matrices (PWM) for different transcription factors curated from the literature. 
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A hit will be reported if the similar sequence gets a score above a general or a 
tissue-specific threshold. Since these methods do not predict the effect of the SNP on 
the TF binding site, Kim et al. (Kim, Kim et al. 2008) scanned the entire human 
genome for possible TF binding sites, and regarded all the SNPs residing within such 
sites as important. This method suffers from a few drawbacks. Firstly, it ignores the 
fact that TF binding sites are highly degenerate, and a single nucleotide change may 
have a limited impact on the binding affinity (Chorley, Wang et al. 2008). Second, 
this approach ignores SNPs that create novel TF binding sites. Therefore, there is a 
need to develop a tool to compare and contrast the TF binding site scanning results for 
different SNP alleles. 
The 3‟ UTR SNPs were recently in the limelight because of the newly 
discovered microRNA regulation mechanism implicated in the mRNA translation 
process. Similar to TF binding site prediction, a series of programs, such as MirRanda 
(Betel, Wilson et al. 2008), TargetScanS (Grimson, Farh et al. 2007) and PicTar (Krek, 
Grun et al. 2005) can predict miRNA binding sites in a given nucleotide sequence. 
The Patrocles database (Georges, Clop et al. 2006) used MirRanda to scan for miRNA 
binding sites unique to the original and alternative allele of the SNP and nicely 
summarized the SNPs causing differences to miRNA binding sites. Regions of 
conservation in the 3‟UTR can also be used to identify functional motifs, a number of 
which have been identified by Xie et al. (Xie, Lu et al. 2005). 
Other than the SNPs on the miRNA target sites that would affect the efficacy 
of miRNA, SNPs in the coding region, especially the seeding sequence of miRNA, 
would lead to reduced or even abolished miRNA binding to its designated target. The 
SNP may also lead the miRNA to target sequences which are not supposed to be 
regulated and create an “off target” effect. At the time of the project started, no 
Potentially Functional Single Nucleotide Polymorphisms (pfSNPs) in the Human Genome and their Potential Applications 
17 
database focuses on this group of SNPs, and a SNP mapper to identify these SNPs 
would be highly valuable for this task. 
In addition to these well-established mechanisms and their associated tools, 
differential splicing of mRNA has been recently recognized as the next layer of 
complexity in gene regulation, which may, in part, explain the much smaller human 
gene pool as it was once thought to be. Intron-Exon boundaries were thought to be the 
key motif facilitating exon recognition and the conserved sequences were identified 
(Zhang 1998). It was also proposed that exon sequences hosted other motifs, which 
may enhance or suppress the splicing of the particular exon by exonic splicing 
enhancers (ESE) and exonic splicing silencers (ESS), respectively (Fairbrother, Yeh 
et al. 2002; Cartegni, Wang et al. 2003; Zhang and Chasin 2004; Zheng 2004). Yeo et 
al. (Yeo, Nostrand et al. 2007) later proposed that the 400 base pairs of intron flanking 
the exon-intron junction may also contain motifs that either enhance or silence the 
splicing process, and these motifs were termed intronic splicing regulatory elements 
(ISRE). Similar to the TF binding site prediction tools, a number of tools are available 
for identifying these motifs in a given sequence (Fairbrother, Yeh et al. 2002; 
Cartegni, Wang et al. 2003; Zhang and Chasin 2004; Zheng 2004). However, they are 
not designed to compare and contrast the motif scanning results for different SNP 
alleles. 
The “Combined method” is largely exclusive to non-synonymous SNPs. It can 
be further divided into two sub-categories. The first contains methods, such as 
NetPhos (Blom, Gammeltoft et al. 1999) and NetOGlyc (Hansen, Lund et al. 1998), 
which use relative simpler “SNP character-based” rules to determine the SNP 
functional impact. The second sub-category contains methods using more complex 
rules and can be further divided into two sub-groups. The first tries to predict the 
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deleterious potential of a SNP by looking at a group of criteria, such as (1) whether it 
falls in an annotated active motif or binding site; (2) whether it affects the interaction 
with ligands present in the crystallographic structure; (3) whether it leads to 
hydrophobicity or electrostatic charge changes in a buried site; (4) whether it destroys 
a disulphide bond; (5) whether it affects the protein‟s solubility; (6) whether it inserts 
a proline in an α-helix; or (6) whether it is incompatible with the profile of amino acid 
substitutions observed at this site in the set of homologous proteins. PolyPhen 
(Ramensky, Bork et al. 2002) uses this method, and regards a SNP “deleterious” if it 
satisfies some empirical rules summarized from current knowledge. Later, LS-SNP 
(Karchin, Diekhans et al. 2005) and SNP3D (Yue, Melamud et al. 2006) employed 
machine learning methods to identify the proper threshold from a training data set 
rather than relying on a human-defined threshold. The second sub-group looks for 
SNPs in evolutionarily conserved regions amongst the same protein family members. 
It is used by SIFT (Ng and Henikoff 2003) and Panther SNP (Thomas and Kejariwal 
2004). The difference between these two tools is that SIFT uses sequence similarity 
searches to identify potential family members, while Panther SNP relies on their 
expert-curated database for protein sub-family members. 
 
1.1.4.2.3 Inferred “potentially functional SNPs” 
 
As with SIFT and Panther SNP, which suggest that evolutionary history may 
help to identify non-synonymous SNPs with deleterious effects, other methods using 
the same principle (which is to find a SNP with evolutionary evidence of functionality) 
have been developed for other genic and/or inter-genic regions. Unlike 
non-synonymous SNP, these SNPs usually lack any known biological function, and 
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are therefore termed “inferred functional” SNPs. 
A widely used method is to look for SNPs in the ultra-conserved regions under 
the assumption that these regions are conserved for a reason (Lee and Shatkay 2008). 
The pre-calculated 28-way vertebrate multiple sequence alignment (Miller, 
Rosenbloom et al. 2007) by UCSC genome browser (Rhead, Karolchik et al. 2010) is 
usually used for this purpose. There is also a related concept, accelerated conserved 
non-coding (“ACNC”) region, proposed by several authors (Pollard, Salama et al. 
2006; Prabhakar, Noonan et al. 2006; Kim and Pritchard 2007; Bush and Lahn 2008). 
These regions are conserved among multiple species with the exception of humans, 
and are thought to host elements crucial for human speciation. These papers do not 
list SNPs within such regions; as such, a SNP mapper is also needed here. 
Similarly, evolutionary forces may have left some mark on the human genome. 
Sabati et al. suggests that regions with a signature of recent positive selection should 
be functional. Our lab has extended this method further to identify the SNP with a 
signature of recent positive selection (Tang, Wong et al. 2004; Wang, Wang et al. 
2005). The signature refers to the higher than usual haplotype conservation across a 
relatively long distance. Before we look at how such a signature can be found, we 
would first need to understand a group of related statistics to which such signatures 
are heavily related. They are Haplotype Homozygosity (HH), a derived term called 
Extended Haplotype Homozygosity (EHH) as well as a further derived term called 
Relative Extended Haplotype Homozygosity (rEHH). HH is a statistic to measure the 
likelihood of getting a pair of identical haplotypes randomly drawn from a pool 
(Sabatti and Risch 2002). EHH is the HH for a pool of haplotypes all containing one 
allele of a SNP at a specific distance away from the SNP locus. The rEHH marks a 
comparison of the EHH values between 2 alleles of the SNP, and is obtained simply 
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by dividing the EHH of one allele by the EHH of the alternative allele. 
A signature of recent positive selection in SNPs can be illustrated by this 
example. When a SNP first appears as a new mutation in the genome, a new 
haplotype comprising this mutational allele together with alleles of other existing 
SNPs on the same chromosome is created. Assuming that the new allele is strongly 
selected for, and a large number of copies of this haplotype were passed down intact 
to the next generation because homologous recombination has not happen due to the 
short time frame. If we measure EHH for this mutational allele, we would observe 
that it remains as one throughout the whole chromosome because the haplotype pool 
from which we draw comprises solely the intact copies. On the contrary, the ancestral 
allele has existed on the genome for a long time, and extensive crossing over should 
have occurred. As the likelihood of crossing over increases with length, the EHH for 
the ancestral allele would gradually decrease from 1 to 0 along the chromosome 
length. Therefore, if we observe rEHH values for the mutational allele along the 
chromosome length, we should see that it continue to rise from 1 to infinity. For the 
simplicity of calculation, we usually choose to look at the rEHH value at one specific 
distance, and a high rEHH value for one allele is the signature of recent positive 
selection. Random genetic drift could not produce such signatures because a mutation 
under random genetic drift would take a long time to become a SNP, and crossing 
over should have happened extensively to the mutational allele as well. The rEHH 
value would therefore remain low for both alleles. Recombination hot/cold spot would 
not affect the signature, since such a disturbance would equally affect both of the 
alleles and get cancelled out when rEHH values were calculated. The only factor that 
may produce a similar signature besides the selective force is population demographic 
history. This factor can be accounted for by showing that the SNP of interest 
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demonstrates a significantly higher rEHH value than its simulated counterpart under 
such a scenario. 
Besides conservation-based methods, genotype heterozygosity-based methods 
have also been proposed. Akey et al. (Akey, Zhang et al. 2002) inspired by the 
Wright‟s fixation index F
st
 (a measure of population subdivision) proposed that SNPs 
showing a high F
st
 value should be driven by the selective force exerted during the 
formation of different human races. More specifically, since modern human races all 
come from a common ancestor, the genotype heterozygosity for a SNP should be the 
same when each subpopulation (race) and the entire human population as a whole are 
examined. The authors suggest that any discrepancy from this would signify a 
selection on such a SNP during human race formation. Although the same 
phenomenon may be caused by random genetic drift, the authors argue that such 
events would affect all the SNPs on a genomic scale, and can be ruled out by setting 
an empirical threshold based on the distribution of F
st
 values for all of the SNPs. The 
authors proceeded to calculate the F
st
 values for more than 26,000 SNPs in 
populations of African American, East Asian and European American descents, and 
SNPs with F
st 
values within the top 5
th
 percentile were declared to be functional (Akey, 
Zhang et al. 2002). 
Since Akey et al. published their results, the HapMap project released a more 
densely populated SNP genotype dataset and enabled us to have a closer look at F
st
 
distributions genome-wide. However, a fast F
st
 calculator would be needed for 
handling such data.  
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1.2 Overview of genetic association studies 
 
Since genetic association studies are becoming the preferred starting point for 
functional SNP discovery, this section is designated to review the basics of these 
studies and to highlight the challenges they currently face. 
 
1.2.1 Candidate gene-based and genome-wide association studies (GBAS and 
GWAS) 
 
Candidate gene-based association studies (GBAS) focus on SNP markers in a 
single or a few candidate genes that have been identified from prior knowledge. These 
candidate genes can be those reported to play certain roles in pathways related to a 
certain phenotype, previously implicated in a certain phenotype having similar 
characteristics, or directly linked to the phenotype of interest (e.g., Inflammatory 
Bowel Disease and Colon Cancer). This approach is ideal if the phenotype were a 
Mendelian trait, with extensive prior knowledge. 
In candidate gene-based association studies, a literature review is normally 
carried out to identify the gene of interest together with those previously reported 
associated SNP markers. Currently, there are a number of online knowledge bases that 
can facilitate accomplishing this task, such as PharmGKB (Thorn, Klein et al. 2010). 
PharmGKB is a useful web-based resource for researchers interested in the genetic 
basis of drug response or pharmacogenomics. It is a repository containing previously 
published associations of drug response genes with various drug response phenotypes. 
As the drug response phenotype is the consequence of the pharmacokinetic and 
pharmacodynamic effects of a drug, information about drug response genes in 
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PharmGKB is placed within the context of the pharmacokinetic and 
pharmacodynamic pathways of various drugs. Structuring information according to 
pathways that the drug response gene affects enables researchers to visualize the 
effect of a SNP as well as possible SNP-SNP interactions within a pharmacologically 
and biologically meaningful context. Besides application-specific PharmGKB, the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) (Aoki and Kanehisa 2005), 
Gene Ontology (GO) (Ashburner, Ball et al. 2000) and Molecular Signatures 
Database (mSigDB) C2 gene sets (Liberzon, Subramanian et al. 2011) are the general 
purpose repositories frequently consulted for inferring which genes are related to the 
phenotype of interest. KEGG attempts to classify genes into different functional 
pathways. GO, on the other hand, uses controlled vocabulary – a set of preselected, 
defined, authorized terms – to describe gene function and location. mSigDB C2 gene 
sets use extensive curation to collect gene information from various sources, such as 
online pathway databases, publications in PubMed, and knowledge garnered from 
domain experts. 
If the phenotype is complex and multiple genes in different pathways can 
contribute or there is no prior knowledge existing for the particular phenotype, 
researchers can use genome-wide association studies to discover causal variants 
across the whole genome. To perform a genome wide association study (GWAS), 
there is no need to do a literature search.  If whole genome sequencing were used, all 
the SNPs in the genome would be genotyped and analysed. If SNP genotyping Chips 
were used, researcher would have little, if any, freedom to choose markers to 
genotype, due to the limited availability of genotyping Chip suppliers (McCarthy, 
Abecasis et al. 2008).  
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1.2.2 Linkage disequilibrium and its implications in genetic association studies 
 
One of their ultimate goals for HapMap and 1000 Genomes Project is to 
facilitate genetic association study by identifying the human genome architecture in 
terms of SNP haplotype structure and linkage disequilibrium pattern. This section will 
discuss the impact of linkage disequilibrium on genetic association studies.  
 
1.2.2.1 Linkage disequilibrium 
 
Although “linkage disequilibrium” (LD) seems to be related to “linkage”, the 
terms describe different phenomenon. “Linkage” is used to describe the tendency of 
genes to be inherited together during meiosis due to their proximity. “Linkage 
disequilibrium” is defined as the non-random association of alleles at two or more loci. 
Formally, LD can be measured by two statistics, namely |D’| and r
2
. Both are based 
on the Lewontin‟s D, which is the deviation of the observed frequency of a haplotype 
from the expected. |D’| is obtained by dividing D over Dmax, the maximum D possible 
for a given set of allelic frequencies at any two loci. |D’| ranges from 0 to 1, where 0 
signifies complete linkage equilibrium and 1 represents complete linkage 
disequilibrium (Zondervan and Cardon 2004). When there is no recombination 
between two markers, |D'| will be 1.0. |D’| is sensitive to allele frequencies and can be 
inflated when one SNP in the pair has low minor allele frequency while the other has 
high minor allele frequency (Zondervan and Cardon 2004). Therefore, |D'| is only a 
good measure of recombination rate between two SNPs. However, knowing the 
genotype of one SNP may not enable us to predict the genotype of another SNP with a 
perfect |D'| value. In contrast, r
2
 is a measure of the correlation of alleles at two loci. 
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Like |D'|, it can take a value from 0 to 1. r
2
 = 0 means perfect linkage equilibrium and 
r
2
= 1 stands for perfect linkage disequilibrium. r
2
 will only be 1 when every 
occurrence of an allele at each of the markers perfectly predicts the allele at the other 
locus (Zondervan and Cardon 2004).  
 
1.2.2.2 Linkage disequilibrium in genetic association studies 
 
For a group of SNPs with r
2 
= 1, only one SNP in the group needs to be 
genotyped for association analysis because knowing its genotype is equivalent to 
knowing all the other genotypes across the loci. Even for SNPs with lower r
2 
values, it 
is possible to detect an association between the marker SNP and phenotype by 
increasing the sample size by a factor of 1/r
2
 over the number required when the effect 
of the causative SNP is measured directly (Kruglyak 1999; Pickrell, Clerget-Darpoux 
et al. 2007). Therefore, r
2 
is widely used in association studies to reduce the number 
of markers to be examined. It is worthwhile to note that this strategy would only work 
for common SNPs (MAF >5%) that tend to have a higher r
2
 with other common SNPs. 
Surrogate markers do not adequately represent rare SNPs (MAF<5%) because they 
generally have low r
2
 values with both common and other rare SNPs (Gorlov, 
Gorlova et al. 2008; Li and Leal 2008). Hence, tagging SNP strategy described in the 
next section is applicable only to common SNPs.  
When examining the LD structure among SNPs in the genome, Gabriel et al. 
(Gabriel, Schaffner et al. 2002; Tishkoff and Verrelli 2003) discovered that a large 
portion of the human genome comprised blocks of LD separated by recombination 
hotspots. In each LD block, haplotype diversity was found to be low and a few SNPs 
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could capture most of the diversity. This kind of SNP was thus called haplotype 
tagging SNPs.  
Haplotype-based association studies were first used to define disease-causing 
regions in the human genome. Within the regions that were significantly associated 
with the disease phenotype, sequencing would then be performed to identify the 
disease variant (Kerem, Rommens et al. 1989; Hastbacka, de la Chapelle et al. 1992; 
Edwards, Ritter et al. 2005; Haines, Hauser et al. 2005; Klein, Zeiss et al. 2005). The 
LD block structure of the human genome found by Gabriel allowed haplotype tagging 
SNPs to replace haplotypes for correlating with phenotypes in association studies. 
However, identification of a haplotype tagging SNP would require knowing the 
haplotype composition in the region of interest. This is not directly available by using 
popular genotyping methods and would require a phasing process to generate the most 
probable haplotype pool in the region of interest by looking at the genotype data. 
Currently, phasing is normally done with computational intensive programs which 
implement the Expectation-Maximization algorithm (Excoffier and Slatkin 1995) by 
themselves (Zhang, Qin et al. 2005) or use phased output (Anderson and Novembre 
2003; Avi-Itzhak, Su et al. 2003) from other programs, such as “Phase” (Stephens, 
Smith et al. 2001) or “SNPHap” 
https://www-gene.cimr.cam.ac.uk/staff/clayton/software/snphap.txt. In regions with 
dense markers and relatively low LD, a long time is required to perform such 
procedures, and it is very likely to have a long list of low frequency haplotypes with a 
frequency less than 5% (Crawford, Akey et al. 2005). Moreover, SNPs residing in 
different haplotype blocks may still exhibit high LD (Lai, Bowman et al. 2002). To 
avoid such shortcomings, methods for generating tagging SNPs based primarily on 
pair-wise r
2
 values without resolving the haplotype were also developed (Ke and 
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Cardon 2003; Stram, Haiman et al. 2003; Wang and Xu 2003; Weale, Depondt et al. 
2003; Carlson, Eberle et al. 2004; Halldorsson, Bafna et al. 2004). There are also 
tagging SNP selection strategies that rely on principle component analysis, which is a 
method used to reduce the number of variables (SNPs in this case) by finding 
correlations between them, which is able to reduce the SNP set to a smaller and more 
manageable one (Meng, Zaykin et al. 2003; Lin and Altman 2004). 
Associating tagging SNPs with a phenotype has practical advantages. Testing 
every SNP individually for association with the phenotype-of-interest has its limitations, 
as the causal SNP is often unknown to researchers or not easily genotyped. It is also 
impractical and expensive to genotype all the SNPs in a particular genomic region in 
order to identify the causal SNP. By using tagging SNPs, genotyping costs can be 
reduced, as only the tagging SNP for the group of SNPs in the high LD need to be 
genotyped. Genotyping fewer SNPs also relieves, to a certain extent, the burden of 
having to control for multiple testing (Balding 2006), which is discussed later. In 
association studies using customizable SNP marker panel where the total number of 
SNPs is fixed, researchers could have the benefit to cover more genetic regions of 
interest. For researchers studying populations of highly similar ancestry to those in 
HAPMAP or the 1000 Genomes Project, using the pre-scanned tagging SNPs from the 
reference populations in HAPMAP or the 1000 Genomes Project would save much 
effort. However, using tagging SNPs in areas of low LD as a result of many 
recombination hotspots negates the benefits of using tagging SNPs, as the number of 
SNPs genotyped is unlikely to be substantially reduced. 
Genotyping tagging SNPs only would not necessarily lead to loss of information. 
Genotyping data for the tagging SNPs could be used to “impute” the genotype of 
un-genotyped SNPs to enable tests for association (Marchini, Howie et al. 2007; Scott, 
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Mohlke et al. 2007). HapMap samples can be used to deduce the LD structure between 
genotyped tagging SNPs and the un-genotyped ones, and such information is used to 
impute the genotype at the un-genotyped loci. Although this may seem as 
“sleight-of-hand with no information gained” (Clark and Li 2007), it has been shown 
that better association results can be obtained (Marchini, Howie et al. 2007; Scott, 
Mohlke et al. 2007). 
 
1.2.3 SNP selection strategies 
 
In this section, we will discuss why marker selection is needed, the options 
that are available, how different factors may affect the choice of SNP selection 
strategy, and how SNP selection strategy may, in turn, affect a follow-up study. 
 
1.2.3.1 Rationale for SNP selection: Multiple-testing problem and power 
 
Marker selection is a crucial process not only because fewer markers would 
cost less to genotype but also due to the problem of multiple-testing. Each statistical 
test has a false-positive rate equivalent to the alpha value set. If the alpha-value were 
set to 0.05 for a series of 20 tests to establish an association between different SNP 
markers and one phenotype, and only one of them have a P-value marginally less than 
0.05, we would have difficulty in justifying the validity or significance of the result 
simply because we would expect one false positive out of the 20 simultaneous tests. 
The above-mentioned scenario illustrates the multiple-testing problem. 
One way to solve this problem is Bonferroni correction, the simplest but most 
conservative method. In the Bonferroni correction, the P-value cut-off is set to be the 
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alpha value divided by number of tests carried out. For example, in a small scale 
gene-based association study where 5 SNPs were tested for association with the 
phenotype, a threshold of 0.01 would be needed (assuming alpha to be 0.05). As 
gene-based associations now focus on genes in the whole pathway and a dozen of the 
SNPs in these genes can be tested, it is increasingly difficult to detect markers with 
statistical significance. In the case of GWAS, the gold standard is to set the threshold 
to 5 E-8 (Khoury and Yang 1998; Hoggart, Clark et al. 2008), and this creates a lot of 
debate on whether Bonferroni correction should be used (Zhang, Liu et al. 2007; 
McCarthy, Abecasis et al. 2008). There are other correction methods proposed to 
work by controlling the false discovery rate (FDR); for example, the 
Benjamini-Hochberg Procedure (Benjamini and Hochberg 1995) and Q-value 
(Hoggart, Clark et al. 2008). Benjamini-Hochberg procedure ranks the P-values in 
ascending order and subjects each P-value to a cut-off as the product of the rank 
multiplied by the Bonferroni corrected cut-off. In other words, only the smallest P 
value need to pass the most stringent Bonferroni correction while others would be 
subjected to a less stringent (higher) cut-off proportional to its rank. The Q-value 
method is based on the theory that all P-values should distribute equally from 0 to 1 if 
no association exists, and it declares markers deviating from the theoretical 
distribution as a true association. However, such methods only moderate the dropping 
of the threshold, and it would still be challenging to establish an association when tens 
of thousands of markers are to be tested. 
As can be seen, multiple-testing corrections would inevitably lead to a loss of 
power for an association study. This loss can be compensated for by increasing the 
sample size (McCarthy, Abecasis et al. 2008) and it is now a common practice to 
recruit controls in the thousands for GWAS in order to accommodate the stringent 
Potentially Functional Single Nucleotide Polymorphisms (pfSNPs) in the Human Genome and their Potential Applications 
30 
threshold (5 E-8). This, however, adds extra costs in patient recruitment as well as in 
genotyping, and has become a limiting factor in the wider adoption of association 
studies. 
 
1.2.3.2 SNP selection strategies: Direct association and indirect association 
 
In SNP selection, we have the choice of including the SNPs potentially 
causing such differences in phenotypes or targeting the surrogate SNPs which are in 
LD with the causal ones (Cordell and Clayton 2005). We call the first strategy “direct 
association” and the second “indirect association”. 
 
1.2.3.3 Factors affecting the choice of SNP selection strategy 
 
A number of factors may affect the choice of SNP selection strategy:  
1. Choice of the region covered 
2. The genetic basis of the phenotype  
3. The LD structure in the human genome 
The choice of region covered is an important factor. For gene-based 
association studies, “direct association” by targeting non-synonymous SNPs has been 
the preferred choice. This is because non-synonymous SNPs were thought to be the 
most important ones in affecting gene function and other SNPs were largely ignored. 
In recent years, SNPs affecting gene expression are also getting attention, since gene 
expression level is another key factor determining the overall gene function (Chorley, 
Wang et al. 2008).  
For GWAS, the SNP selection strategy used is further dependent on the other 
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two factors: the genetic basis of the phenotype, and the LD structure in the human 
genome. There are different models regarding the genetic basis of common disease 
and human phenotype in general. The “Common Disease, Common Variant” (CDCV) 
model (Reich and Lander 2001; Wang, Barratt et al. 2005) hypothesizes that common 
disease is caused by the same variants that are widely distributed in the population, 
with limited penetrance. Since the causal SNPs are those common ones which tend to 
have a higher LD with other common and non-functional SNPs (Montgomery 2011), 
targeting any SNP in the LD block other than the causal one would result in limited 
power loss (Pickrell, Clerget-Darpoux et al. 2007). Under the proportionality 
assumption, it is possible to detect an association between the marker SNP and 
phenotype by increasing the sample size by a factor of 1/r
2
 over the number required 
when the effect of the functionally significant SNP is measured directly (Kruglyak 
1999; Pickrell, Clerget-Darpoux et al. 2007). It was proposed that ~500K well-spaced 
markers would sufficiently cover the whole human genome (Collins, Guyer et al. 
1997; Reich and Lander 2001), and this forms the basis of the “indirect association” 
approach, which tries to examine surrogate SNPs that are linked to the causal ones 
(Cordell and Clayton 2005). In current GWAS using DNA Chips, the most popular 
approach is the “indirect association” approach (Jorgenson and Witte 2006). 
Affymetrix and Illumina are the two most popular genotyping technologies for 
GWAS and their latest chips can interrogate ~1,000,000 SNPs concurrently. SNPs on 
the Illumina platform are primarily selected based on tagging SNPs (t-SNPs) that 
exceed a predetermined linkage disequilibrium (LD) threshold specified by the 
International HapMap Consortium (Perkel 2008). On the other hand, SNPs in 
Affymetrix chips are quasi-randomly selected (QR-SNPs) to cover the entire genome, 
although their selection of SNPs are also limited to SNPs that can accommodate 
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sequence constraints imposed by the Affymetrix technology (Perkel 2008).  
However, the proportionality assumption (the possibility to detect an 
association between the marker SNP and phenotype by increasing the sample size by 
a factor of 1/r
2
 over the number required when the effect of the functionally 
significant SNP is measured directly) has been criticized as an over-simplification of 
the many factors influencing the strength of the marker (Terwilliger and Hiekkalinna 
2006). Additionally, the usefulness of tagging SNPs to act as good surrogate markers 
for functional or causal SNPs has been challenged, since the presence of two or more 
susceptibility loci, which is assumed in complex disease genetics, may significantly 
impact the power of tagging SNP-based strategies (Terwilliger and Hiekkalinna 2006; 
Pickrell, Clerget-Darpoux et al. 2007). It has been suggested that, in some situations, 
although a causal SNP can unequivocally be detected when it is directly genotyped, 
marker SNPs in high LD with the causal SNP may never show sufficient evidence of 
disease-association even with infinite sample size (Terwilliger and Hiekkalinna 2006). 
As a result, a trimmed-down version of the “direct association” approach, termed 
“gene-centric” approach, has also been used in the GWAS setting (Keating, Tischfield 
et al. 2008; Webb, Broderick et al. 2009).  These “gene-centric” studies either focus 
on SNPs that are capable of representing variants in genes or focus on the putative 
causal variants directly (Jorgenson and Witte 2006). The advantages of the 
“gene-centric” approach include decreasing the genotyping and Type I error burden, 
since SNPs within genes have a higher likelihood of being functionally important. 
Additionally, as it was reported that SNPs within many genes seem to have a lower 
LD, with SNPs residing outside genes (Smith, Thomas et al. 2005), the “indirect 
association” approach may not provide adequate coverage for genic regions. 
Conversely, the “gene-centric approach” suffers the disadvantage of having less 
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power to detect non-genic causal SNPs as compared with the “indirect approach”. 
The “Common Disease, Rare Variant” (CDRV) model attributes the common 
disease to different variants that are each unique to one of a few patients with high 
penetrance (Gorlov, Gorlova et al. 2008; Li and Leal 2008). In the case of the CDRV 
model, the “direct association” approach fits better because rare SNPs (MAF<5%) are 
generally low in LD with all other SNPs and “indirect association” would be 
insufficient to readily capture them (Pritchard and Cox 2002; Zeggini, Rayner et al. 
2005; Montgomery 2011). The CDRV model is now gaining popularity, as previous 
GWAS studies relying on the CDCV model had difficulty in finding causal markers 
for a number of phenotypes (Montgomery 2011).  
 
1.2.4 Methods of association analysis 
 
Single marker-based association analysis is still the most widely used data 
analysis method in candidate gene-based association studies and GWAS. P-values for 
every marker are calculated as the measurement for strength of association. If no 
assumption about the underlying genetic model is made, genotype-based tests can be 
used with the 2-df Pearson test or Fisher‟s exact test focusing on a 2X3 matrices 
tabulating the count of different genotypes in case and control. If an “additive” model 
is assumed, the allele-based test or the Cochran-Armitage test can be used. The 
allele-based test can take the format of 1-df fisher‟s exact / permutation test, with 
assumption of HWE in the case and control population as a whole. Cochran-Armitage 
test has the advantage of independence on the assumption of HWE. The 1-df 
permutation test would be more advantageous by being less conservative as compared 
with the Cochran-Armitage test. Currently, single marker-based analysis methods 
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suffer from the stringent cut-off set to tackle the multiple testing problems caused by 
the ever-growing number of markers tested. The stringent cut-off makes it difficult to 
find markers with moderate-effect size. Moreover, even if such markers would 
survive after the weeding process, the custom to focus on a few top scoring ones 
would still leave them out for further analysis. 
One way to enhance the power of detecting a moderate-effect size marker is to 
look at the combined effects of multiple SNPs. Haplotype-based association analyses 
can help to capture the combined effects of tightly linked cis-acting SNPs. It is only 
applicable to “direct association” studies, because “indirect association” studies 
normally use tagging SNPs with low pair-wise LD between each other (Balding 2006). 
“Indirect association” studies use regression-based methods to measure the combined 
effects, and these methods have the advantage of looking at multiple SNPs, even if 
they are not on the same chromosome. Furthermore, they have the added advantage of 
being able to take other clinical parameters into consideration together with SNPs. 
Such regression-based methods can also be used by “direct association” with one 
extra step of finding tagging SNPs, since too many correlated parameters would 
render the regression less effective (Balding 2006). 
However, even combined effects may not have enough power, since the 
addictive effect may not be strong enough to produce a small P-value to endure the 
multiple testing corrections. It has been suggested a gene set-/pathway-based analysis 
may better suit the need to recover more markers with moderate-effect size. The 
principle of these methods is that the group of truly associated genes must show 
consistent yet moderate deviation from chance and such consistent changes would not 
be visible when looking at the SNPs individually. These methods also tackle multiple 
testing problems by looking at gene set/pathway and reduce the number of tests 
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carried out from millions to just a few. 
The deviation from the “no enrichment of associated SNP in a particular gene 
set/pathway” null hypothesis can be detected either by comparing against expected 
values under the null hypothesis, which is called the “self-contained” method, or 
measured against other gene sets or pathways, which form the basis of “competitive” 
methods. For candidate gene-based association studies, the “self-contained” method is 
the better choice, simply because genes outside the pathway of interest are 
inadequately covered (Wang, Li et al. 2010). For GWAS, both methods can be used. 
However, there is no guideline on whether the “competitive” or “self-contained” 
method should be used in terms of performance, and even the “competitive” method 
has several implementations using different statistical methods (Wang, Li et al. 2010). 
The choice of a better fit is still on a trial-and-error basis. 
 
1.3 Aims of the current study  
 
While pfSNPs can be broadly classified as “literature-reported functional” 
(p12) , “predicted functional” (p13) and “inferred functional” (p18) based on the 
computational methods and resources used to identify them, the methods available to 
identify them were quite limited to the “predicted functional” category and new 
methods to identify pfSNPs from the other two categories were needed. Integrating 
results from these diverse methods via a semi-automated pipeline is required so that a 
pfSNP database at the genome scale can be made possible. Once such a database is 
built, a web portal will need to be established to facilitate the scientific community to tap 
into the pfSNP dataset for various applications. In the meantime, the usefulness of the 
pfSNP dataset and the web portal in finding real causal SNPs will be validated. Formally, 
Potentially Functional Single Nucleotide Polymorphisms (pfSNPs) in the Human Genome and their Potential Applications 
36 
the three major aims for the current study can be summarized as below: 
 
Aim 1: Identification and characterization of pfSNPs in the human genome. 
Aim 2: Development of a pfSNP web-resource. 
Aim 3: Validating the usefulness of pfSNPs in association study 
 
This thesis aims to meet each of the above mentioned aims sequentially, and 
the thesis is structured accordingly. This section will briefly describe each of the aims 
together with the specific aims/deliverables to give an overview of the content of the 
thesis, and the following chapters will present the deliverables achieved for each aim 
together with detailed materials and methods. 
 
1.3.1 Aim 1: Identification and characterization of pfSNPs in the human genome 
 
Chapter Two will be devoted to the process of identification and 
characterization of pfSNPs in the human genome. I will first review the gaps in the 
existing tools and the proposed solutions to these gaps including some new methods 
proposed by me. I will then define the general workflow of the pfSNP identification 
process, the architecture of the pfSNP data warehouse, as well as the design of three 
specific tools needed to build a semi-automated pipeline to facilitate the extraction, 
transformation and loading of the pfSNP dataset into this data warehouse. Storing the 
genome-scale pfSNP dataset into a database can be beneficial in several ways. First, it 
would enable the integration of all our knowledge for such SNPs and facilitate 
analysis of the distribution and characteristics of such SNPs. Second, it would enable 
the easy retrieval of a subset of such pfSNPs for various needs by using customizable 
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criteria. Finally, it would facilitate the easy extension of the collection when a new 
resource or tool becomes available.  
Once the database has been built, I will characterize the pfSNP dataset in 
terms of genomic coverage and MAF spectrum etc. and compare these attributes 
against the SNP marker sets from popular genotyping platforms like Illumina Bead 
Chip 1M Duo and Affymetrix SNP Chip 6.0. As our knowledge about the human 
genome is still far from complete, it is acknowledged that the pfSNP set may not 
thoroughly cover all functional SNPs, and the possibility of using pfSNP as tagging 
SNPs to cover other common functional variants will thus be explored. 
 
1.3.2 Aim 2: Development of a pfSNP web-resource 
 
Once the pfSNP data set has been collected and characterized, a sophisticated 
web portal will be required for the scientific community to tap into the 
information-rich content and various potential applications the pfSNP dataset can 
offer. Therefore, Chapter Three will be devoted to the design and implementation 
issues related to the web portal. Specifically, the pfSNP web portal need features to 
serve the following purposes: 
 
1. Designing experiments to address the predicted functionality of SNPs. This 
web-resource needs to be able to inform the scientist about the predicted 
functionality of the SNP-of-interest so that appropriate experiments may be 
designed. It must also provide information of other previous reports that have 
examined the SNP-of-interest. 
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2. Candidate gene-based association studies. This web-resource will facilitate 
the selection of potentially functional SNPs in candidate genes for genetic 
association studies. Significantly, this resource will enable the selection of a 
subset of pfSNPs in genes within a certain chromosome region, expressed in 
specific tissues, and/or has been associated with a certain 
disease/phenotype/drug response/pathway. It should also facilitate the 
selection of pfSNPs that occur at/above a specific threshold frequency in 
specific populations or pfSNPs residing only in exons or promoter regions or 
at 5‟/3‟ UTRs, etc. 
 
3. Whole-genome association studies (GWAS). As discussed earlier, this resource 
should be made useful to current GWAS scientists, as it will provide 
information with regard to the distance as well as the LD measured by r
2
 of a 
close by HapMap genotyped pfSNP (SNP predicted to be potentially 
functional) that is at the highest LD to the genotyped SNP-of interest. 
Importantly, the integration of gene/pathway level information into the result 
interface with text clouds highlighting enriched terms in each category will be 
useful to these researchers who have a list of SNPs that are associated with a 
phenotype and wish to formulate hypotheses about their findings. 
 
With these applications in mind, I will explain, in detail, how the web portal is 
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1.3.3 Aim 3: Validating the usefulness of pfSNPs in association study 
 
In Chapter Four, I aim to demonstrate the usefulness of the pfSNP dataset and 
the web-resource by showing their value in helping to pinpoint the real functional 
SNPs causing differential response in colorectal cancer patients. I will carry out a 
gene based association study using pfSNPs. The web resource will be used to choose 
the pfSNP markers suitable for the phenotype of interest. pfSNPs will be genotyped 
and tested for any association with the difference in patients‟ drug response.  
In the meantime, it will be interesting to test if tagging SNPs will be able to 
capture the pfSNPs associated with the differential drug response. Although the 
“indirect approach” using tagging SNPs are claimed to be able to capture other SNPs 
adequately via LD, it is still largely based on simulation results focusing on a few 
genetic regions, and evidence that it would hold true in all regions is still wanting. 
The lack of power for the “indirect approach” may be more severe in candidate 
gene-based association studies in which sample sizes are normally small. Previous 
studies using this strategy tend to fail, and it is still unclear if such failure is caused by 
the “indirect approach” used. This study will thus provide a first-hand measure of the 
loss of power by looking at the efficiency of tagging SNPs in capturing the 
association signals shown by pfSNPs.  
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CHAPTER 2: IDENTIFICATION AND CHARACTERIZATION 




2.1.1 The gaps present in the methods to identify pfSNP at genome scale and the 
solutions proposed 
 
As mentioned in Chapter One, pfSNPs can be broadly classified as 
“literature-reported functional”, “predicted functional” and “inferred functional” 
based on the methods used to identify them. However, identification of pfSNPs at 
genome scale was still limited by one or both of the following gaps: 
1. The SNP coverage was not genome scale.  
2. Some of the methods used to identify pfSNPs were not accurate and need 
further enhancement. 
Table 2.1 lists the gaps in the methods for each of the pfSNP categories and 
the solutions proposed by me. 
For the “literature-reported functional” category, resources like OMIM and 
HGMD are largely restricted to gene coding region SNPs. As genome wide 
association study (GWAS) is getting popular and a large portion of the current GWAS 
found their association signals outside the gene region (Hindorff, Sethupathy et al. 
2009), I proposed including SNPs identified from ever-growing GWAS as pfSNP 
which may help to extend the SNP coverage of the “literature-reported functional” 
category outside of the coding region. NCBI dbGaP (Mailman, Feolo et al. 2007), 
which was introduced in 2007 as a central depot for large scale GWAS studies carried 
out by NIH institutes, can be a source of well-powered GWAS studies. Since focusing 
only at the strongest signal in current GWAS may miss markers with moderate effect  
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Table 2.1: Gaps present in the tools and methods to identify pfSNP at genome 





Gap Detail Proposed Solution Publications 
Using this Idea 
Reported SNP coverage 
is not genome 
scale 
OMIM and HGMD 
are limited to gene 
region SNPs 
 
Collect pfSNPs with 
P<0.01 from GWAS 
studies in NCBI 
dbGaP project 
(Li, Wang et al. 
2012) 
Inferred SNP coverage 
is not genome 
scale 
The genome-wide 
scan for SNPs with 
high Fst was limited 
to 26K SNPs 
Scan 4 Million SNPs 
genotyped by 
HapMap for high Fst 
SNPs 
(Duan, Zhang et 
al. 2008) 
It is unknown if 
signature of recent 
positive selection can 
be used to identify 
pfSNPs at genome 
scale 
Show SNPs with 
such signatures are 
wide-spread and can 
be found outside of 





The validity of the 
claim that “SNPs in 




Proposed that SNPs 
in the accelerated 
conserved 
non-coding 
(“ACNC”) region are 
important 
 
Predicted SNP coverage 
is not genome 
scale 
Existing tools are 
limited to SNPs that 
are non-synonymous 








 Inaccuracy in 
existing 
methods 
Declare all SNPs 
reside in motifs 
important without 
proper evaluation of 
motif disruption and 
creation caused by 
SNP 





A single tool may not 
cover all the pfSNPs 
due to limited 
training dataset 
Combine results from 
different algorithms 
for predicting SNPs 
affecting same 
function 
(Liu, Jian et al. 
2011) 
 
size, I further proposed to use a less stringent P value cut off (1E-2) which may help 
to salvage SNPs with weaker association signals. The cut-off of 1E-2 is arbitrary and I 
propose to use it as a clue to guide further experimental validation. This idea was later 
supported by Li et al (Li, Wang et al. 2012) and their GWASdb used a similar P value 
cut-off of 1E-3 to identify important SNPs from dbGaP. 
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For “inferred functional” pfSNPs, existing methods also suffer from limited 
genome coverage. The genome scan for high Fst SNPs carried out by Akey et al 
(Akey, Zhang et al. 2002) is limited to 26K SNPs available at that time. I proposed to 
search for high Fst SNPs amongst the 4 Million SNPs genotyped by HapMap which is 
150 times denser than Akey‟s study. This scan may reveal a more thorough picture of 
high Fst SNPs in the human genome. Duan et al (Duan, Zhang et al. 2008) carried out 
such scan and compiled the results into a database. The possibility of using signature 
of recent positive selection as an indicator of pfSNP at genome scale was still unclear 
because prior work had only shown that it could be found in a few genes with limited 
evidence supporting SNP with such signature is functional (Tang, Wong et al. 2004; 
Wang, Wang et al. 2005). We used HapMap genotype data to show that such 
signatures are widespread in the ABC transporter family and can be readily found 
outside of the gene coding region (Wang, Wang et al. 2007). We also provided more 
evidence that the SNPs with such signature are functional. 
One method proposed to identify “inferred functional” pfSNPs may not be 
valid. SNPs in the ultra-conserved regions were considered important in causing 
disease (Lee and Shatkay 2008). I argue that the SNPs found in these regions should 
be functionally neutral rather than deleterious. In theory, these ultra-conserved regions 
should be under strong purification selection and any deleterious mutation in such 
regions should have been eliminated. Only functionally neutral mutation in these 
regions could escape from the purifying selection and become SNP. I proposed 
another method to identify pfSNPs using conservation related information which is to 
look for SNPs in the accelerated conserved non-coding (“ACNC”) region. It has been 
shown that there are regions conserved amongst multiple species with the exception 
of humans, and are thought to host elements crucial for human speciation (Pollard, 
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Salama et al. 2006; Prabhakar, Noonan et al. 2006; Kim and Pritchard 2007; Bush and 
Lahn 2008). Unlike ultra-conserved regions, these ACNC regions should be subjected 
to strong positive selection and any SNP found in these regions might be a result of 
such selection force. To date, there is no other paper implementing this idea yet and 
the pfSNPs belonging to this category can only be found in our pfSNP resource. 
The coverage of “predicted functional” SNPs is also limited to 
non-synonymous SNPs in coding region. The tools available (e.g. Polyphen and SIFT) 
were applicable to non-synonymous SNPs only. To extend the coverage, I proposed to 
identify “predicted functional” pfSNPs that may affect new gene regulatory 
mechanisms, such as non-sense mediated mRNA decay (Nagy and Maquat 1998), 
intronic SNPs regulating gene differential splicing (Yeo, Nostrand et al. 2007) as well 
as synonymous SNPs causing high codon usage difference (Kimchi-Sarfaty, Oh et al. 
2007). To date, pfSNP is the only resource providing “predicted functional” SNPs 
with such functions. 
It is convenient to claim the SNPs mapped into certain DNA motifs (e.g. 
Transcription factor binding site) are important (Kim, Kim et al. 2008). However, 
such claim is inaccurate because the SNP may not be changing the motif due to the 
high degeneracy of the motif. I proposed to compare the motif scan results for each of 
the alleles and only those SNPs whose alleles leading to a change in motif will be 
included as pfSNP. 
There are also different methods available to identify pfSNPs belonging to the 
same function category. Because the methods use different information and are based 
on different training data (e.g: Both PolyPhen (Ramensky, Bork et al. 2002) and SIFT 
(Ng and Henikoff 2003) are tools trying to identify non-synonymous SNPs with 
deleterious effect. PolyPhen is mainly based on whether the SNP will change the 
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biochemical property of the protein motif while SIFT is based on whether the SNP is 
conserved.), combining the results of these methods may ensure a more thorough 
coverage. I proposed to use five tools, namely Polyphen (Ramensky, Bork et al. 2002), 
SIFT (Ng and Henikoff 2003), SNP3D (Yue, Melamud et al. 2006), LS-SNP (Karchin, 
Diekhans et al. 2005) and PantherSNP (Thomas and Kejariwal 2004), for predicting 
deleterious non-synonymous SNPs. A recent resource dbNSNP (Liu, Jian et al. 2011) 
which tried to identify all the deleterious non-synonymous SNPs used the same idea 
despite different tools were used. 
 
2.1.2 Challenges in building genome scale pfSNP database 
 
With my proposed solutions to existing gaps, a genome-scale pfSNP database 
would be made possible. The pfSNP database would be beneficial in three ways. First, 
it would enable integration of all pfSNP knowledge and facilitate the analysis of their 
distribution and characteristics. Second, through the use of customizable criteria, it 
would enable the easy retrieval of a certain subset of pfSNPs. Third, it would be 
expandable when new resources or tools are available. 
Table 2.2 lists the tools that can be used for pfSNP identification. However, 
there were still technical challenges that stop us from tapping into them. The technical 
challenges can be broadly classified into three categories, namely: 
1. Lack of suitable tools for information integration. 
2. Heterogeneous tools with complex input data requirement. 
3. No cross referencing and cross checking of information available and 
possible erroneous information provided. 
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2.1.2.1 Lack of suitable tools for information integration 
 
In Table 2.2, a number of methods are listed without a URL or tool name. 
These are the methods with no proper implementation, and they require special effort 
to tap into them. Furthermore, some tools (e.g. ESE finder (Cartegni, Wang et al. 
2003)) only provide a web-based interface, which is not suitable for scanning 
large-scale data, and for which scalable local implementation is still required. Further, 
a number of tools are not designed for SNPs (e.g. ESE finder), and post-processing is 
required to identify SNPs with alleles causing a difference in the results (e.g., only 
SNPs that cause a change in the ESE motif will be interesting).  
 
2.1.2.2 Heterogeneous tools with complex input data requirement 
 
Although some tools only require the rs number (rsNo) as an input field, most 
tools require additional information, such as a SNP flanking sequence or even a 
corresponding gene or amino acid  (AA) sequence (Table 2.2 with „*‟ and „#‟ in the 
“Input Requirement” column). For example, PantherSNP (Thomas and Kejariwal 
2004) requires input of the AA sequence change caused by the SNP together with the 
AA sequence of the corresponding splicing variants of the protein. Preparing such 
information requires the use of extra tools and data sources.  
 
2.1.2.3 No cross referencing and cross checking of information available and possible 
erroneous information provided 
 
There are often inconsistencies in the information provided, such as the SNP 
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allele reported and the actual allele found on the mRNA, because SNP allele reporting 
is not required to be on the same strand of mRNA. Furthermore, the SNP allele may 
not correspond to the amino acid change reported for non-synonymous SNPs. Such 
inconsistencies may create unnecessary confusion in interpreting the biological 
impact of the SNP.  
 
2.1.3 Tools needed for the semi automated pipeline 
 
In light of the aforementioned gaps in the available tools, three tools were 
deemed necessary to semi-automate a pfSNP collection pipeline: 1) a multi-purpose 
SNP mapper; 2) a general-purpose motif scanner; and 3) a SNP statistics generator for 
large-scale data sources. 
 
1. A multi-purpose SNP mapper: 
 
Why it‟s needed: The primary goal of the mapper is to obtain the gene 
context of the SNP (e.g., which exon it is in and which codon it is in). The 
mapper will use this information further in two ways. First, it will apply 
location based rules to tell if a SNP is a pfSNP. For example, it can pinpoint 
non-sense SNPs causing mRNA nonsense-mediated decay (NMD), because 
only non-sense SNPs located more than 50 bps from the last intron-exon 
boundary will lead to NMD (Nagy and Maquat 1998). It will also help 
determine whether a SNP is likely to affect miRNA targeting, because SNPs 
in the seed sequence of miRNA are more important than SNPs in other regions. 
Second, it will deduce new information from related information and check for 
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inconsistency automatically. For example, the difference in synonymous SNP 
codon usage can be deduced by retrieving the codon from the corresponding 
mRNA sequence using the gene context of the SNP. A check can be carried 
out to see if the reported allele of the SNP is consistent with the nucleotide 
found on the mRNA at the same location. Furthermore, the SNP allele change 
reported and the amino acid change caused by the non-synonymous SNPs may 
also not tally. For example, if a SNP were reported to have an allele change of 
A/G and an amino acid change of Arg/Ala, it may appear as if the A allele 
corresponds to an Arg residue; there is no guarantee for such correspondence. 
Such inconsistencies may create unnecessary confusion in interpreting the 
biological impact of the SNP. By using the mapper, the amino acid change can 
be deduced from the codon sequence retrieved from the mRNA sequence, 
helping to guarantee consistency between allele change and amino acid 
change. 
 
Special considerations: Although the input data of the mapper will be 
primarily from NCBI, it should work with other data sources as well. 
Therefore, minimal information should be needed, and any information that 
can be derived from known ones should not be required. (e.g. AA change 
caused by a non-synonymous SNP is redundant once the alleles and mRNA 
sequence are known)  
 
2. A general-purpose motif scanner. 
 
Why it‟s needed: A general-purpose motif scanner is beneficial in two ways. 
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First, because a number of papers simply report the important motifs found, 
without describing the tool to screen for such a motif. Second, there is no 
facility to compare and contrast the output for different alleles of a SNP, 
which is the key to pinpointing those SNPs whose alleles would cause a 
change in motif. 
 
Special considerations: Although the motifs that currently need to be 
screened are only DNA motifs, the need to scan for the protein motif in the 
future is likely, and therefore the scanner should be able to handle protein 
sequences as well. 
 
3. A SNP statistics generator for large-scale data sources (such as 
HapMap).  
 
Why it‟s needed: The main purpose for developing a SNP statistics generator 
for large-scale data sources is to be able to calculate pair-wise comparisons 
and overall Fst amongst different HapMap populations. In the meantime, other 
descriptive statistics, such as minor allele frequency and HWE P values, are 
also calculated.  
 
Special considerations: Since the statistics generator may be handy for other 
applications, such as analysing our own genotyping results, building the 
generator as a Microsoft Excel-based tool is highly desirable.  
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2.2 Materials and methods 
  
 Table 2.3 shows the input, output and algorithms/methods to be included into 
the three tools. 
 
Table 2.3: The input, output and algorithms/methods to be included into the 
three tools. 
Tool Input Output Algorithms/methods 
Multi-purpose 
SNP Mapper 
1. SNP genome location 
and allele information. 
2. Gene exon and UTR 
genome coordinates for 
each splicing variants 
3. mRNA sequence 
containing the sequence 
for the splicing variants 
of each gene 
1. SNP mRNA location 






SNP flanking sequences 
with each allele 
embedded 
The motif created and 
disrupted by the allele 
change 
1. ISRE motif 
2. TF binding sites 
3. ESE/ESS motif 





1. HWE P value 
2. Genotype frequency 
3. Allele frequency 





3. Fisher‟s exact test 
 
For the three tools mentioned, I chose to implement them using the Microsoft 
Visual Basic (VB) family of languages. This is mainly because the VB family of 
language is widely used in Microsoft Excel and ASP.NET web framework, and the 
tools can thus be easily built as Microsoft Excel-based desktop applications as well as 
web-based applications with shared core program components and libraries.   
Specifically, the general-purpose SNP mapper was developed as a Microsoft 
Excel macro-based application using Microsoft Visual Basic for Application (VBA). 
Although this mapper is Microsoft Excel-bound, it only uses Microsoft Excel as a 
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running host, and the input and output are all channelled from and to Open Database 
Connectivity (ODBC) compatible databases via Microsoft Excel ActiveX Data 
Objects for the genome scale mapping purpose. To satisfy the “minimal information 
required” requirement, only three pieces of information is needed for the mapper as 
input. The first is a “SNP” table containing genome location and allele information for 
all SNPs. The second is a “Gene” table containing the exon and UTR genome 
coordinates for each splicing variants of every gene. The third is an “mRNA 
sequence” table containing the sequence for the splicing variants of each gene. This 
architecture also makes it easy to adapt the mapper to be used with low-throughput 
data, if needed. Source data in the right format can be read directly from Microsoft 
Excel worksheets and output can be saved as a Microsoft Excel workbook. All 
processes are facilitated by the familiar user interface provided by Microsoft Excel.  
The general-purpose motif scanner was developed in Visual Basic .NET 
(VB.NET). It has two components. The first component is a wrapper to feed the two 
flanking sequences containing each allele of a SNP into respective motif-scanning 
packages. The “PS Scan tool” (ftp://ftp.expasy.org/databases/prosite/tools/ps_scan) 
was selected as a tool to scan for ESE/ESS motifs (Fairbrother, Yeh et al. 2002; Wang, 
Rolish et al. 2004; Zhang and Chasin 2004; Zheng 2004), ISRE motifs (Yeo, 
Nostrand et al. 2007) and 3‟ UTR conserved sites (Xie, Lu et al. 2005) in a 
DNA/RNA sequence. The DNA motif signatures from the abovementioned 
publications were compiled into a Prosite-compatible format by our Microsoft Excel 
macro. Although the “PS Scan tool” was originally designed to screen motifs in AA 
sequences, it can be used to screen for motifs in DNA sequences because the four 
nucleotide code for DNA is within the AA code collection. The Match program from 
TransFac (Matys, Fricke et al. 2003) is used for TF site screening. The second 
Potentially Functional Single Nucleotide Polymorphisms (pfSNPs) in the Human Genome and their Potential Applications 
52 
component is a post processor to screen through the motif scan results and determine 
if any of the altered motifs can be found by comparing the outputs of the two SNP 
alleles. This was implemented by VB.NET. Using VB.NET also enabled the addition 
of a web front for this general-purpose scanner with ease, which has been made 
available at http://pfs.nus.edu.sg/seqmotifscan/. A sequence uploading facility was 
built with the help of a Perl script utilizing the BioPerl sequence manipulation 
package to provide functionalities of taking different input formats and screening for 
reverse complementary sequences. 
The SNP statistic generator was also developed as a Microsoft Excel-bound 
macro-based tool for the same reasons. It can take in genotype in HapMap format 
either from the database connection or from selected Microsoft Excel worksheets, and 
output to a database or a Microsoft Excel workbook, accordingly.  
The three tools form the backbone of a semi-automated pipeline to facilitate 
the pfSNP data warehousing (Figure 2.1). 






















































































































































The workflow begins with retrieving relevant NCBI information (dbSNP and 
Entrez RefSeq (ftp://ftp.ncbi.nih.gov/refseq/) (Figure 2.1 A; more detail in Figure 2.1 
B), and the SNP mapper will be utilized to generate SNP-gene mapping and summary 
reports (e.g., which gene and splicing variant the SNP maps into, which region the 
SNP maps into, what function the SNP has, etc.). Input information for the motif 
scanner will be prepared and fed into the “Predict SNP function” step. SNPs that 















Potentially Functional Single Nucleotide Polymorphisms (pfSNPs) in the Human Genome and their Potential Applications 
55 
will follow to generate SNP function summaries by combining the dynamic prediction 
results with static results, such as that garnered from previous literature function 
reports and other static functional predictions and inferences. Further down the 
pipeline, a gene level summary will be generated by integrating the SNP level 
summary together with gene level information; for example, PharmGKB pathway 
information.  
Besides the three tools developed, which would run primarily in Microsoft 
Windows environment, the database would need to be able to incorporate data from 
Linux-specific programs or internet-based application servers. Figure 2.2 outlines the 
overall architecture of the hardware and software components of the semi-automated 
pfSNP collection pipeline. The pfSNP database will be held in the Background Data 
Integration Server (BDIS) in the format of a relational database. Since flexible 
database architecture would be needed to enable querying from one or all layers of the 
SNP-Gene-Pathway hierarchy, a star schema centred on a SNP-Gene mapping table 
generated by the multi-purpose mapper was used. Dimension tables link to the central 
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To characterize the pfSNP dataset, the numbers of pfSNPs satisfying various 
criteria were obtained by SQL queries carried out in the pfSNP database. The 
chromosome coverage diagrams were generated by a Microsoft Excel-based tool 
developed in-house. The list of markers in the tagging SNP (t-SNP) and quasi-random 
SNP (QR-SNP) sets were obtained from Illumina 1M Duo Bead Chip and Affymetrix 
SNP Array 6.0, respectively. The list of SNPs in HapMap Release 23, their genotypes 
and minor allele frequencies in the four HapMap populations were obtained from 
HapMap FTP server (ftp://ftp.ncbi.nlm.nih.gov/hapmap/). The population names are: 
Beijing Chinese (CHB), Tokyo Japanese (JPT), U.S. residents with northern and 
western European ancestry (CEU) and the Yoruba people of Ibadan, Nigeria (YRI). 
HapMap Release 23 data was used because this is the release Illumina used to 
benchmark the genome coverage of the t-SNP set. The Tagger program in Haploview 
(Barrett, Fry et al. 2005) was used to check the tagging efficiency of pfSNP and also 
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the list of tagging SNPs needed to cover all the SNPs in HapMap Release 23. 
 
2.3 Results and discussion 
 
2.3.1 The multi-purpose SNP mapper 
 
The output of the mapper is a single multi-column table with one SNP per row. 
Figure 2.3 shows a few sample outputs. For the ease of reading, columns are grouped 
as “RNA-related” (Figure 2.3A) and “Protein-related” (Figure 2.3B). The “rsNo” 
and “GeneID” are duplicated in each for easy reference. 
 
Figure 2.3: The structure of SNP-Gene mapping table and sample output. A 








In the “RNA-related” columns, the “RNAAccession” field records the specific 
splicing variant the mapping refers to. The three following “Feature” columns record 
the gene feature (5‟ upstream region, exon, intron or 3‟ UTR), the serial number 
(which exon or intron) and the exact location of the mapping. For example, rs1800372 
in Figure 2.3A, row 3, has “E”, “6” and “369” in the three columns, respectively. It 
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means the SNP is in exon 6 of the gene and 369 bps after the translational start site. 
It is noteworthy that the naming convention is different for different regions 
and the logic for handling such naming conventions has been built into the mapper. 
For example, rs1784410 in Figure 2.3A, row 1, is in the 5‟ upstream region and 
“-1017” refers to 1017 bps upstream of the transcription start site instead of 
translational start site, which is for 5‟UTR and coding region SNPs, as with 
previously mentioned rs1800372. The mapper correctly handles SNPs in different 
regions and chooses naming conventions accordingly.  
The “Allele” column refers to the allele reported by the “SNP” table, while the 
“CorrectedAllele” records the mRNA corrected allele by checking the nucleotide 
found on the mRNA at the position of the SNP. This is to see if the reported allele is 
of the same strand of the particular mRNA. For example, rs1800372 has a reported 
allele change of “T/C”, but the mRNA sequence at this particular position has an A; 
so, the “CorrectedAllele” reports an “A/G” change, which reflects the strand 
difference. Altogether, 54% (115336/214390) UTR or coding SNPs were observed to 
contain strand inconsistency. This was expected, since SNP allele assignment can be 
on either strand of DNA and are done without taking into consideration the mRNA in 
which it may reside. Intronic and 5‟ upstream SNPs cannot be checked, due to the 
lack of reference mRNA sequences.  
I defined the putative promoter as 5000 bps and 500 bps up- and down-stream 
of the transcription start site, respectively. The “InPutativePromoter” column informs 
if a 5‟ UTR and exonic SNP are in the promoter region. For example, rs17884410 in 
Figure 2.3A, row 1, is a promoter SNP in the 5‟UTR region. 
The “EUpBps” and “EDnBps” columns show the distance of the coding SNP 
from the upstream and downstream intron-exon boundary, respectively, which would 
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be helpful to determine if a SNP falls into the conserved motif within the boundary. 
Combining information from “EDnBps” and “InLastExon” would further indicate if a 
stop codon created by the SNP would lead to NMD of the mRNA by predefined rules 
(Nagy and Maquat 1998).  
Figure 2.3B contains columns recording protein level information for the SNP. 
It‟s noteworthy that since we required minimal input information, most of the protein 
level information is derived on the fly, based on the previous mRNA mapping 
information. “CodonChange” information is obtained directly from the actual mRNA 
sequence with the help of previous mRNA mapping information, together with the 
“CorrectedAllele”. The “CodonChange” information further helps to derive the 
“AAChange”, and the status of synonymous or non-synonymous is also generated on 
the fly. “CodonChange” is further used to deduce the “CodonUseDiff”, which is 
obtained by comparing the codon frequency as reported in the codon usage database 
(http://www.kazusa.or.jp/codon/). Synonymous SNPs with top 5% codon usage 
difference were declared as pfSNP. 
 
2.3.2 The general-purpose motif scanner 
 
The general-purpose motif scanner, with built-in compare and contrast facility, 
was developed and has been made accessible at http://pfs.nus.edu.sg/seqmotifscan/. 
Figure 2.4A shows a screen shot of the typical output screen. It is currently capable 
of screening for transcription factor binding sites, exonic splicing enhancers/exonic 
splicing silencers (ESE/ESS), intronic splicing regulatory elements (ISRE), as well as 
3‟UTR conserved sequences. Results for each category of motif are presented in 
different tabs, each with four sub-tabs. The sub-tabs contain the raw scan outputs 
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from the two input files, as well as the unique motif found in each input. The 
sequence upload facility is shown in Figure 2.4B. 
 
Figure 2.4: The general purpose motif scanner. A. Sample output of the motif scanner. B. 








2.3.3 The SNP stats calculator 
The sample output of the SNP stats calculator is shown in Figure 2.5. The 
SNP stats calculator helps to calculate the overall Fst for all input populations as well 
as pairwise Fst for each population pair; there are four populations in this case, but 
more populations can be handled. It also calculates pairwise Fisher‟s exact P values 
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for allele frequency as another measure of population difference. Genotype and allele 
frequencies, together with HWE P values, are also given for easy checking of possible 
genotyping error, if any. The calculator can take input data in HapMap format directly 
from Microsoft Excel and output easy to read summary tables, as shown in Figure 2.5. 
It can also handle large scale data from database and store output into databases 
directly (not shown). 
Figure 2.5: Sample output of the SNP stats calculator in Microsoft Excel. 
 
S NP  ID 
G e ne  
Loca tion P opula tion n
HW E 
P -V a lue Fst 
A A A G G G A G CHB JP T CE U Y RI CHB JP T CE U Y RI
CHB 45 0.46 53.33 42.22 4.44 74.44 25.56 0.06 1.18E -05 1.18E -14 0.33 0.04 0.16 0.67
JP T 45 0.17 31.11 57.78 11.11 60.00 40.00 0.03 1.14E -14 0.04 0.52
CE U 60 0.05 13.33 61.67 25.00 44.17 55.83 2.27E -12 0.32
Y RI 60 0.63 0.00 11.67 88.33 5.83 94.17
G e notype  
fre que ncy (%)
Alle le  
fre que ncy (%)
P a irw ise  d iffe re nce s 
F ishe r's e x a ct P -va lue P a irw ise  Fst V a lue




2.3.4 The semi-automated pfSNP collection pipeline 
In addition to the three major tools developed, a collection of auxiliary scripts 
were written with Bio Perl library to facilitate sequence manipulation and looping 
through a collection of inputs for Linux-based programs. The number of pfSNPs 
identified by each method is listed in Table 2.4. 
Efforts are currently underway to facilitate the continuous update of the pfSNP 
resource in an automated fashion so that this resource can remain useful for a long 
time. As shown in Figure 2.2 previously, pfSNP resource will comprise three servers, 
namely, the Backend Data Integration Server (BDIS), the Windows Application 
Server (WAS) and the Linux Application Server (LAS). The BDIS will monitor 
various Internet Data Sources (IDS) by SQL Server Integration Service for any new 
updates, as well as obtain SNP function prediction results from various application 
servers, including the Internet Application Server (IAS) , the WAS and the LAS. The  
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SNP Cat. Function Cat. Method Short Description No. pfSNP 
Identified 
mRNA  Promoter Change TFBS TransFac 176550 
Coding Region 
SNP 




Detect enrichment compared to 
5UTR and Intronless exons 
Hex mer liberary screening 
Experimentally validated ESE/ESS 
Intronic SNP Change ISRE sites Conserved intronic sequence within 
400bps of splicing site 
134674 
Reside on Splice Site Cause abberant 5' site (SD-Score)  379 
Change 3' Consensus sequence 603 
3‟UTR SNPs Change Mir Binding MiRanda to predict binding change 
and also functional validation 
344 
PolymiRTS Database 10682 
Patrocles Database 11732 
In 3UTR Conserved 
Region 
Functional region predicted multiple 
species sequence alignment  
5035 
Change TFBS TransFac 39920 
5Kb 
Downstream 




Change TFBS TransFac 7407 
Reside on miRNA 
seed, etc region 
NCBI and miRBase 167 
Patrocles Database 117 
Protein Coding Region 
SNP 
Protein Domain / 
Functional Sites 
Interpro Scan 34461 
Tm HMM (Transmembrane domain) 1207 
NetOGlyc (O Glycosylation site) 439 
NetNGlyc (N Glycosylation site) 93 







All Non-Synonymous SNP 49733 
Synonymous SNP Codon usage differences falling in 
top and last 5% 
2933 
SNP All SNP Disease/Function 
Related 
OMIM reported SNPs 67 
PubMed Reported SNPs 531 
NCBI dbGaP Reported SNPs  
(Cut off 0.01) 
22308 
HGMD for Reported SNPs 2043 
Positively Selected mLRH (modified LRH) 82 
WGLRH  
(Whole Genome LRH based on 
LRH) 
4110 
LDD (LD Decay) 24596 
"iHs"  
(Integrated Haplotype Score) 
264040 
Fst  183 
Fst_HM 15368 
abnormal CNC Regions  788 
"Human Accelerated Region" 115 
Accelerated Human CNC Region 680 
Accelerated Human CNC Region  565 
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WAS and LAS will execute SNP function prediction software locally and the 
standardized web-interface wrapper will be implemented to facilitate a unified 
client-server mode of communication between the BDIS and the Application Servers. 
New algorithms/applications can then be easily included manually through a simple 
customization of the standardized web-interface wrapper. 
Minor updates affecting only a single satellite table (e.g., table for dbGAP, 
which is linked to the main table through rsNo) will be downloaded automatically, 
and pre-defined data processing will be carried out by BDIS, which will then update 
the corresponding tables in the BDIS. For major changes, in which the main 
SNP-Gene mapping table has to be altered (e.g., new SNPs are identified through 
ultra-high throughput sequencing or new release of dbSNP database), the database 
will be updated in an incremental manner, where new SNP entries will be identified 
by the BDIS, and various Application Servers will evaluate the potential functionality 
of the new SNP entries. BDIS will then compile a new release of PFS database. 
 
2.3.5 The pfSNP database 
 
The pfSNP database was established in Microsoft SQL Server 2005 as a 
relational database with star schema centred on the SNP-Gene mapping table. Table 
2.5 lists the major tables in the pfSNP database providing SNP- and gene-related 
information. Specifically, Table 2.5 lists how the major tables are linked to the central 
table and the information content provided. The number of tables in Table 2.5 is less 
than the methods and tools used in Table 2.4 because results from the methods of a 
similar purpose are aggregated into one table to facilitate downstream analysis and 
filtering. For example, there are four papers identifying different ESE/ESS motifs in  
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Purpose Information Content Link to 
SNP-Gene 
mapping table 
1 The SNP-Gene Mapping Table rs No., GeneID, mRNA Location 
summary in all the splicing variants, 
mRNA Location Count, AAChange, SNP 
location summary (5' UR,5' UTR, 
Promoter, Coding, NonSyn, Syn, Intron, 
3UTR, 3'DR) 
N.A 
2 SNP chromosome location and 
selection summary 
SNP chromosome location, whether it 
shows RPS signature or in ACNC regions 
rs No. 
3 SNP showing high Fst value Fst value rs No. 
4 SNP minor allele frequency SNP minor allele frequency in all 
HapMap populations 
rs No. 
5 SNP changing Transcription 
Factor binding site in gene 
promoter 
Summary of TF binding site altered by 
the SNP 
rs No. 
6 Non-synonymous SNP 
deleterious effect prediction 
Polyphen, SIFT, SNP 3D, LS-SNP, 
Panther SNP  
rs No, GeneID 
7 Protein domain in which the 
non-synonymous SNP reside 
InterPro Scan results, Transmembrane 
domain by TMHMM, O- and 
N-glycosilation site, Phosphorylation site. 
rs No., GeneID 
8 SNP changing ESE/ESS site ESE/ESS site altered by the SNP rs No. 
9 Synonymous SNP with high 
codon usage difference  
Codon usage difference rs No., GeneID 
10 SNP causing NMD SNP causing NMD in respective gene rs No., GeneID 
11 SNP causing abberant 5' splicing 
site 
SNP causing abberant 5' splicing site rs No. 
12 SNP causing abberant 3' splicing 
site 
SNP causing abberant 3' splicing site rs No. 
13 SNP changing ISRE site ISRE site altered by the SNP rs No. 
14 SNP changing 3' UTR conserved 
motif 
3' UTR conserved motif altered by SNP rs No. 
15 SNP changing 3' UTR miRNA 
binding site 
miRNA whose binding site got altered by 
SNP 
rs No. 
16 SNP reported to be associated 
with phenotype by NCBI dbGaP 
Phenotype associated, P value rs No. 
17 SNP reported by HGMD Phenotype associated and related 
information if any 
rs No. 
18 SNP reported to be associated 
with phenotype by MedLine 
Search 
Phenotype associated and related 
information if any 
rs No. 
19 SNP reported in OMIM OMIM disease relation information rs No. 
20 Gene Information Collection GO term, KEGG path, mSigDB path, 
tissue expression, Pharm GKB knowledge 
and Genetic Assocaiton Database 
information.  
GeneID 
21 Gene reported by OMIM OMIM disease in which the gene 
implicated 
GeneID 
22 SNP changing Transcription 
factor binding site in miRNA 
promoter 
Summary of TF binding sites altered by 
the SNP 
rs No. 
23 SNP mapped into miRNA 
coding and related regions 
The miRNA and region the SNP maps 
into 
rs No. 
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Table 2.4, but their motifs are combined in the scanning process and there is only one 
final table (Table No.8 in Table 2.5) to summarize pfSNPs changing ESE/ESS 
motifs. 
Other than these major tables, the pfSNP database also holds auxiliary tables 
which contain supplementary information to the tables in the core star schema (e.g., a 
table for the ESE/ESS motif reporting their origin and the validation status) as well as 
those tables to facilitate query of the database (e.g., a SNP may have multiple rs No. 
given to it on different occasions, and a table to record such aliases is used in the 
query process so that querying any of the rs No will return the same result). Since 
they are not the focus of the pfSNP database, I will not go into any further detail.  
There are multiple SNP annotation projects similar to pfSNP in recent years 
(Table 2.6). In terms of SNP function coverage, a number of them only cover the 
“predicted” pfSNP or “reported” pfSNP category. Only SNPNexus (Chelala, Khan et 
al. 2009) collects SNPs with reported and predicted functions but it does not compare 
and contrast the motifs that are created or disrupted by different alleles. It also does 
not contain SNPs with inferred functionalities. In contrast, pfSNP also provides 
auxiliary information, such as Linkage Disequilibrium (LD) data to help identify 
causal SNPs when a non-functional SNP is searched. 
Full automation of the whole pipeline is desirable, but daunting. Recently, 
Goodswen et al. proposed an R-based fully automated data integration pipeline 
(Goodswen, Gondro et al. 2010). However, the number of tools tapped into is small 
(namely dbSNP, GO, KEGG, UniProt, QTLdb, OMIA and HomoloGene) and 
restricted to ready-to-use tools with little or no downstream processing required. To 
date, there has yet to be a fully automated pipeline capable of handling complex data 
processing comparable to pfSNP. 
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Other than the data warehousing approach, which stores data locally, federated 
data integration is offered by selected resources, such as FastSNP (Yuan, Chiou et al. 
2006) and SNPit (Shen, Carlson et al. 2009) as lightweight alternatives in term of 
storage space. However, federated data integration sacrifices performance for the 
benefit of storage efficiency and the need for information to be regularly updated. As 
Figure 2.6 shows, querying 137 SNPs will take 45 minutes as compared to less than a 
minute on data warehousing based solutions. The need to process information on the 
fly may also burden the server and the scalability may quickly become a concern. 
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2.3.6 Characterization of the pfSNP data set 
Out of >14,000,000 SNPs in the dbSNP129 database, a total of 972,673 SNPs 
were found to be of potential functional significance (list of SNPs can be downloaded 
from the pfSNP web-resource http://pfs.nus.edu.sg/PickGwas_V2_3.aspx). As shown 
in Figure 2.7A, only <0.2% of the unique and non-redundant dbSNP129 SNPs were 
previously reported to be functional or associated with a disease/phenotype, based on 
information of SNPs culled from the NCBI dbGAP and HGMD databases and from 
two publications that performed literature mining from PubMed (Xuan, Wang et al. 
2007) or OMIM (Stoyanovich and Pe'er 2008). Another ~2% of the SNPs in the 
dbSNP129 database were “inferred” to be functional because they are under selective 
pressure, while only 0.001% were found to reside within miRNA coding regions. 
The percentage of dbSNP129 SNPs residing in the various genomic regions 
predicted to be potentially functional (pfSNPs) was investigated and the results are 
shown in Figure 2.7B.  Greater than 63% of promoter SNPs in dbSNP129 was 
predicted to be potentially important, affecting transcription factor binding sites 
(TFBS). Of the coding dbSNP129 SNPs, 1% were predicted to result in 
nonsense-mediated decay (NMD) while 67.4% were predicted to alter 
exon-splice-enhancer (ESE)/exon-splice-silencer (ESS) sites at the transcript level. At 
the protein level, 11% of coding dbSNP129 SNPs were predicted to reside in 
functionally important domains or alter phosphorylation/glycosylation sites, while 
25.8% were predicted to result in deleterious amino acid changes. Within the introns, 
5.6% of SNPs were predicted to be functionally significant, primarily due to their 
effects on intron splice regulatory element (ISRE) sites, and only 0.3% of dbSNP129 
intronic SNPs were predicted to alter splice sites.  At the 3‟UTR regions, >32% of  
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Figure 2.7: Characterization of potentially functional SNPs (pfSNPs) in 
dbSNP129 database. A. Graph showing the percentage of total SNPs in the dbSNP129 database 
that is reported to be associated with function/disease (left bar), show evidence of natural selection 
(middle bar), or reside within miRNA coding regions (right bar). B. Graph showing the percentage of 
regional (i.e. promoter, coding region, intron or 3‟UTR) SNPs in the dbSNP129 database that is 
predicted to be potentially functional, including affecting transcription factor binding sites (TFBS) in 
the promoter; affecting non-sense mediated decay (NMD) or exon-splice enhancer (ESE)/exon-splice 
silencer (ESS) in coding region at the mRNA level; residing in important domains (e.g. p53 
tetramerization domain) (Domain) or predicted to result in a deleterious amino acid changes 
(deleterious aa) within the coding region at the protein level; affecting intron splicing regulatory 
elements (ISRE) or splice sites (Splice Site) within introns, as well as affecting miRNA binding sites 
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dbSNP129 SNPs were predicted to have potential functional importance, including 
17.1% that affect miR binding sites and 7.2% that reside within highly conserved 
regions. Due to our lack of understanding of the functional significance of inter-genic 
regions, there is a paucity of algorithms to predict the potential functionality of SNPs 
in this region. Hence, only 2.1% of inter-genic SNPs in dbSNP129 were predicted to 
have potential functional significance. These inter-genic pfSNPs are primarily those 
that are reported to be associated with disease/phenotype through genome-wide 
association studies or those under selective pressure. 
As the total number of pfSNPs (972,673) was similar to the number of 
QR-SNPs used in the Affymetrix SNP Array 6.0 (934,968) and the t-SNPs in the 
Illumina Human 1M-Duo DNA-Analysis Beadchip (1,072,820), the characteristics of 
these three SNP sets were compared. 
The extent of similarity amongst the SNPs selected from the three different 
SNP-selection platforms is depicted as a Venn diagram in Figure 2.8.  Only 58,267 
SNPs (<7%) in each SNP set are shared amongst all three. Greater than 21% of the 
SNPs are common between QR-SNPs/pfSNPs. The least sharing of SNPs (<15%) was 
between the pfSNP and QR-SNP sets. An additional ~11% and 13% of Illumina and 




The gross chromosome coverage of the three different SNP-selection datasets 
was then examined. As evident in Figure 2.9, the SNP coverage for pfSNPs (red), 
t-SNPs (green) and QR-SNPs (blue) are similar and even across all chromosomes, 
except for the sex chromosomes. The coverage and distribution of pfSNPs in the X 
and Y chromosomes are slightly reduced as compared with the t-SNPs/QR-SNP sets, 
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which is probably due to the reduced density of validated genes in these 
chromosomes. 
 
Figure 2.8: Venn diagram showing the number of common SNPs amongst the 
three different SNP-selection platforms. The three SNP selection platforms are the currently 
reported putatively functional SNPs (pfSNPs), the Illumina tag-SNPs (t-SNPs) and the Affymetrix 
quasi-random SNPs (QR-SNPs). 
 
 
Since SNPs within the pfSNP set were selected from the dbSNP129 database 
without any consideration for the allele frequency of the SNPs, it is not surprising that 
nearly 50% of the pfSNPs have not been genotyped in the HapMap (Table 2.7). Of 
the non-monomorphic genotyped SNPs, the distribution of MAF amongst the three 
SNP sets was quite similar, except that more pfSNPs have a slightly lower MAF 
(Figure 2.10). 
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Table 2.7: The percentage of SNPs from the three different SNP-selection 
platforms that were not genotyped in the four HapMap populations.  
 
 
Figure 2.10: Box-and-whisker plot showing the lowest, lower quartile, median, 
mean (diamond), upper quartile, and highest MAF in the 4 different populations 
from the three different SNP-selection platforms. pfSNP is in red, t-SNP is in green and 
QR-SNP is in blue. 
 
 
The genomic distribution of the SNPs in the 3 SNP sets was then compared 
(Figure 2.11). Unlike the t-SNP and QR-SNP sets, the majority of the pfSNPs (>75%) 
were found in the genic region. Within the genic regions, pfSNPs (10.36%) were 
more enriched in coding regions as compared with t-SNPs (6.27%) or QR-SNPs 
(2.43%). Moreover, a greater percentage of coding pfSNPs (67.26%) was 
non-synonymous as compared with coding t-SNPs (57.59%) or coding QR-SNPs 
(50%). In the genic non-coding regions, a greater percentage of pfSNPs was localized 
in the promoter (27.81%) and 3‟UTR (7.32%) regions as compared with t-SNPs 
(11.07% and 4.57%) and QR-SNPs (7.22% and 2%). Hence, both commercial SNP 
sets, especially the t-SNP set, appear to reflect the relative distribution of all SNPs in 
the human genome, while pfSNPs are more enriched in regions of potential functional 
significance like promoter and 3‟UTR. Of the two commercial SNP sets, the t-SNP 
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set appears more enriched in regions of potential functional significance compared 
with the QR-SNP selection strategy. 
 
Figure 2.11: Distribution of SNPs in the various genomic regions from the 
pfSNP, t-SNP and QR-SNP datasets. Pie-chart shows the proportion of SNPs in the 
inter-genic (yellow) versus genic (maroon) regions. Within the genic region, the proportion of SNPs in 
the coding (peach) and non-coding (blue) regions is indicated as colored bars. The proportion of genic 
synonymous (pink) and non-synonymous (red) coding SNPs are shown as pie-charts above the coding 
SNP bar. The proportion of intronic (dark blue), promoter (light blue) and 3‟UTR (green) SNPs are 




The proportion of potentially functional SNPs (pfSNPs) that are represented in 
the t-SNP and QR-SNP sets was then investigated (Figure 2.12).  Except for SNPs 
predicted to potentially alter splice sites which are represented at >50% in the two 
platforms, all the other potentially functional SNPs are represented at <40% in both 
the t-SNP and QR-SNP platforms. SNPs that are predicted to have potential 
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functional significance seem to be better represented in the t-SNP set (10-38%) 
compared with the QR-SNP set (<10%). 
 
Figure 2.12: Proportion of potentially functional SNPs (pfSNPs) represented in 
the t-SNP and QR-SNP selection platforms. The proportion of putatively functional SNPs 
(pfSNPs) within the various regions (promoter, coding, intron, 3‟UTR and miRNA) predicted to affect 
the specified function (e.g. TFBS, NMD, etc.) that are represented in the t-SNP (green) and QR-SNP 
(blue) selection platforms are shown. 
 
 
Due to the limited knowledge of SNP function and the availability of 
algorithms used to identify pfSNPs, there might be more pfSNPs yet to be discovered. 
Therefore, it would be interesting to test if the SNPs in the current pfSNP collection 
would be good tagging SNPs so that they would cover other pfSNPs yet to be 
identified. Table 2.8 shows the tagging efficiency of the polymorphic pfSNP markers 
in different HapMap populations. Tagging efficiency is measured as the average 
number of SNPs covered per marker. Table 2.8 shows that the tagging efficiency of 
pfSNP is generally comparable to t-SNP set except for the YRI population. 
 
 
Potentially Functional Single Nucleotide Polymorphisms (pfSNPs) in the Human Genome and their Potential Applications 
75 
Table 2.8: The tagging efficiency of pfSNP in different HapMap populations 




Since the tagging efficiency of pfSNP is good and there were less than 0.5M 
polymorphic pfSNPs in each HapMap population (Table 2.8), it may be possible to 
add additional tagging SNPs outside the 0.5M pfSNP set to cover the whole genome. 
In later sections, this tagging method is called “pfSNP-centric tagging”. Figure 2.13 
shows the number of “pfSNP-centric tagging” markers needed to cover all the SNPs 
in the HapMap Release 23, with different minimal r
2
 values. Around 1M SNPs would 
be able to cover all HapMap Release 23 SNPs with an r
2
 more than 0.6 in the YRI 
population. Although r
2
 of 0.6 would be considered low in practice (Pe'er, de Bakker 
et al. 2006), this is still better than the t-SNP set, which would only cover all the SNPs 
in the YRI population at a much lower r
2
 value of 0.1 (Figure 2.14). For the CEU and 
ASN populations, 1M “pfSNP-centric tagging” SNPs would cover all the HapMap 
Release 23 SNPs at high r
2
 value of 0.8 and 0.9 (Figure 2.13), respectively. This is 
much better than the t-SNP set, which covers all the SNPs only at an r
2
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Figure 2.13: The number of “pfSNP-centric tagging” SNPs needed to cover all of 
the HapMap Release 23 SNPs at different minimal r
2




Figure 2.14: The genomic coverage of Illumina t-SNP set. 
 
Min R2 




To enable accurately identifying pfSNP at genome scale, I proposed a few 
new methods to extend the pfSNP coverage outside of the gene coding region or to 
enhance the accuracy of existing methods. A semi-automated pipeline for collecting 
pfSNP from various resources was established with three major tools developed in the 
Visual Basic family of languages and a collection of Perl scripts to facilitate data 
processing. The tools are designed with an emphasis on flexibility and extensibility in 
terms of incorporating new functionalities easily. 
A database for storing and querying the pfSNP collection was established as a 
relational database with star schema. This database currently holds more than 30 GB 
of data and uses Microsoft SQL Server 2005 as the relational database management 
system. It can be easily queried by using criteria from one or all layers of the 
SNP-gene-pathway hierarchy. Compared with other SNP functional data integration 
projects and pipelines, this semi-automated pipeline targets more data sources and has 
greater data processing capability. The data warehousing solution is also seen as a 
better alternative to the federated option for data integration in term of query 
performance. 
Through the integration of various databases and resources, >900,000 SNPs out 
of >14 million unique non-redundant SNPs in the dbSNP129 database were of potential 
functional significance (pfSNPs). Due to the current paucity of information and 
algorithms to predict functionality in the non-genic regions, >75% of pfSNPs reside in 
genic regions with significant enrichment pfSNPs in the promoter, coding, and 3‟UTR 
regions of genes, but not in introns or inter-genic regions. Interestingly, a very high 
percentage of dbSNP129 promoter and coding SNPs (>60%) were predicted to affect 
Potentially Functional Single Nucleotide Polymorphisms (pfSNPs) in the Human Genome and their Potential Applications 
78 
TFBS and ESE/ESS, while a very low percentage of coding and intronic SNPs (≤1%) 
were predicted to affect NMD or splice sites. 
A comparison of the pfSNP set with the popular commercially available t-SNP 
(Illumina) and QR-SNP (Affymetrix) sets revealed that the three SNP sets were unique 
with less than 7% of SNPs common amongst the 3 platforms. Nonetheless, the gross 
chromosome coverage of the three different SNP sets was similar. Due to the strategy 
of selection, the pfSNP set has the greatest proportion of SNPs (~50%) that were not 
genotyped in HapMap Release 23 compared with the other sets (<5%). Of the 
genotyped SNPs, the pfSNP set also contained the greatest percentage of monomorphic 
SNPs (15-27%) compared with the t-SNP (7-18%) and the QR-SNP (5-21%) sets. 
Nevertheless, the current pfSNP set may act as good tagging SNPs with comparable 
tagging efficiency compared to Illumina t-SNP set. With additional tagging SNPs 
picked outside of the pfSNP set, the “pfSNP-centric tagging” SNP set would cover all 
the SNPs in HapMap Release 23 with higher r
2
 value compared to Illumina t-SNP set.  
As the adoption of next generation sequencing technique has grown drastically 
along the years, more and more SNPs have been identified. Currently, the number of 
SNP in each gene region has increased to be more than 3 times compared to dbSNP 129 
from which I generated the list of pfSNPs (Figure 2.15). Noticeably, more SNPs in the 
coding region which include non-synonymous SNP and synonymous SNP have been 
reported compared to other regions. In the current release of pfSNP collection, pfSNP 
identified by any method would be called a pfSNP. To minimize the false positive rate 
for pfSNP identification, it is possible to choose those predicted by more than one 
algorithm.   
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Figure 2.15: The fold change of SNP numbers in each gene region in dbSNP 137 
compared to  dbSNP 129. 
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CHAPTER 3: DEVELOPMENT OF A PFSNP WEB-RESOURCE 
(Adapted from “pfSNP: An integrated potentially functional SNP resource that facilitates 




As of 2010, a few web-resources had been developed that attempted to 
integrate SNP function information and facilitate a better annotation of the 
functionality of SNPs in the human genome.  For example, one of the earliest 
resources is the SNPselector (Xu, Gregory et al. 2005), which integrates only a few 
resources to prioritize a list of SNPs based on their linkage disequilibrium (LD) 
tagging potential, allele frequencies, source, function, regulatory potential and repeat 
status. However, the resource has been retired from public service as of 2010. One of 
the more comprehensive tools is the F-SNP (Lee and Shatkay 2008); this tool 
integrates 16 bioinformatic resources to annotate the functionality of ~500,000 SNPs 
in ~18,000 genes associated with 85 major human diseases from OMIM. SNPLogic 
(Pico, Smirnov et al. 2009) is another web-resource that combines <15 bioinformatic 
tools to annotate potentially functional SNPs. The user can construct lists of SNPs 
based either on genes, chromosome region or pathways (including OMIM, Biocarta, 
GO, Biocyc, Wikipathway, etc). Another SNP integration tool, SNPit (Shen, Carlson 
et al. 2009) employs less than five bioinformatic tools to annotate the functionality of 
SNPs, based on functional impact of non-synonymous coding SNPs, evolutionary 
conservation of non-coding regions as well as positive selection. Yet another tool, the 
GWAS Analyzer (Fong, Ko et al. 2010), links statistical results from association 
studies, HapMap data, known genes (UCSC Genome Bioinformatics), microRNA 
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(Sanger miRBase), splice sites, and expression data from microarray experiments 
(GENEVAR project).   
Nonetheless, there is still a need for a single comprehensive, integrated SNP 
web-resource that will facilitate hypotheses generation through knowledge synthesis 
mediated by better data integration and a biologist-friendly web interface. Ideally, this 
resource should provide all the pertinent information about the SNPs in the human 
genome, including allele frequency and LD information of SNPs. Furthermore, this 
resource should comprehensively integrate all the available resources that predict the 
potential functionality of SNPs based not only on predicted functionality due to 
sequence motifs but also inferred functionality from a genetic approach and reported 
functionality and disease association from published reports or association studies or 
expression data. To facilitate hypotheses generation through knowledge syntheses, the 
query interface should be biologist-friendly and highly customizable to facilitate 
several combinations of queries. Additionally, the query results interface should be 
similarly user-friendly and also integrate tissue distribution as well as pathway 
information where enriched tissues/pathways are highlighted, and detailed related 
information of the query results are provided. 
I have thus developed the pfSNP web-resource to address the 
above-mentioned need. The pfSNP resource builds on the pfSNP database mentioned 
in the previous chapter. Significantly, to facilitate hypotheses generation through 
knowledge syntheses, the pfSNP resource has a biologist-friendly, highly 
customizable query interface as well as a user-friendly results interface that integrates 
gene, pathway and tissue distribution information with text clouds highlighting the 
enriched tissues/pathways. Hyperlinks providing detailed related information about 
specific results in the result interface are also given. It is anticipated that this pfSNP 
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resource will be useful to most researchers interested in SNPs, including those 
interested in association studies and those focusing on designing experiments to 
address SNP functionality in association with a phenotype.  
 
3.2 Materials and methods 
 
pfSNP web-resource (http://pfs.nus.edu.sg/) integrates >40 different 
algorithms/resource to evaluate the potential functionality of SNPs from the dbSNP 
database (http://www.ncbi.nlm.nih.gov/projects/SNP/), based on previous published 
reports, inferred potential functionality from genetics approaches, and predicted 
potential functionality based on sequence motifs (Table 3.1). 
The design of pfSNP web-resource is based on the snowflake relational 
database schema centered on a SNP-Gene (rs number and Gene ID) mapping table to 
which various other data tables are linked either via the rs number or the Gene ID or 
both (Figure 3.1).  This schema has the advantage of facilitating queries or 
combinations of queries based on different SNPs (including genomic, mRNA or 
protein location) and/or Gene (tissue of expression, biological pathways, etc) 
information. It also ensures appropriate SNP annotation, even when the same SNP is 
found to reside in two different location/genes.  For example, the pfSNP resource 
will inform the user that SNP rs1048913 actually resides in two different genes and 
the effect of that SNP in each gene will be given.  Additionally, new algorithms for 
potential functionality can readily be included as new data tables linked to the same 
SNP-Gene mapping table as they are discovered. 
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Table 3.1: The data sources used in pfSNP web-resource 
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Figure 3.1: The hardware and software architecture of the pfSNP web-resource  
Internet Data Sources 
























The pfSNP web portal is implemented as a 3-tier web application using 
ASP.NET 3.5 with extensive AJAX (Asynchronous Javascript and XML) 
functionality. The 3-tier architecture ensures clear separation of query logic and web 
site presentation, which not only eases the maintenance of the site but is also crucial 
to the functionality of the web portal. In this web portal, various new queries focusing 
on a subgroup of original query results (e.g., the queried SNPs may belong to multiple 
genes and user wants to focus on SNPs in a specific gene) or providing extensive 
supporting information (e.g. view pfSNPs in high LD with the SNPs queried for) may 
be formed naturally as the user navigates through the query results. The separation of 
query logic will facilitate the initiation of a new query without losing track of the 
original query results. AJAX not only enables users to re-arrange their query criteria 
visually (which is the key functionality of the web portal) but also ensures a rich user 
experience, which will be discussed in detail later. 
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3.3 Results 
3.3.1 Biologist-Friendly Features of the pfSNP Web-Resource 
 
The web interface was designed to provide features that are biologist-friendly 
using ASP.NET 3.5 with AJAX (Asynchronous Javascript and XML) for an enriched 
user experience. 
1. Auto-Complete Prompt-As-You-Type feature in the Query Interface.  The 
pfSNP database integrates information from a variety of resources that 
have different terminologies for the same phrase (e.g. Parkinson‟s Disease 
versus Parkinson Disease).  As the list of the terms can be very long, it is 
cumbersome to provide a drop-down list for the user to select. This 
Auto-Complete Prompt-As-You-Type feature in the query interface relies 
on ASP.NET 3.5 web-service to provide the user with a list of query terms 
contained within the various data sources as the user begins to type so that 
the user can rapidly select the appropriate term from the list that is most 
meaningful to him/her (Figure 3.2, an online demonstration of this feature 
as a flash movie can be found at 
http://pfs.nus.edu.sg/demo_src/supp_info_s1.html).  This feature not only 
helps the user to quickly type their term of interest, but prevents the user 
from typing a specific term that is not the exact term found in the query 
database; this may lead to no results for his/her query.  
2. Retrieved all related terms to query. It is also possible to retrieve and 
query a number of related terms containing or beginning with a keyword 
(Figure 3.3A, an online demonstration of this feature as a flash movie can 
be found at http://pfs.nus.edu.sg/demo_src/supp_info_s1.html). A list of 
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related terms will be displayed so that the user can select several or all of 
the relevant related terms for the query (Figure 3.3B). 
 
Figure 3.2: Auto-Complete Prompt-As-You-Type feature in the Query 
Interface. Related term will be retrieved as user key in the query term. 
 
 
Figure 3.3: Retrieve all related terms to query. A. User can retrieve related 









3. Auto Retrieval of SNP ID.  Another useful feature is that the exact SNP 
ID (i.e. rs number) need not be known as this web-resource is capable of 
providing the rs number for any SNP within any gene region so long as 
pertinent information with regards to the SNP is known. This feature 
would be very useful, as most publications (except for more recent ones) 
reporting functionally important SNPs, especially those in the coding 
region, often provide only the amino acid residue changes (e.g. R273H 
polymorphism in p53). For example, to convert amino acid residue change 
to rs number, the SNP ID (rs number) tab can be selected and on the right 
panel, there will be an option to “Search for rs No. by its gene location”.  
As one begins to type the name of the gene, the Auto-Complete 
Prompt-As-You-Type feature will provide a pull-down list of gene names 
and the user can then select the gene name that is the most relevant 
(Figure 3.4A, a step-by-step demonstration of this feature can be found at 
http://pfs.nus.edu.sg/demo_src/supp_info_s2.html). Thereafter, the user 
can select the appropriate gene region that the SNP resides in 
(Figure.3.4B). If the SNP resides in the coding region and the amino acid 
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position is known, the user then provides the amino acid position (Figure 
3.4C) and the rs number will be automatically retrieved and added to the 
list of rs numbers on the SNP ID panel. 
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4. Excel-Like Result Presentation with In-Depth Resource Reference.  The 
results of queries from this web-resource are presented in a familiar 
excel-like format.  This excel-like presentation has customizable freezing 
of headers and columns to facilitate reading and referencing. Most of the 
predicted functions are hyperlinked to either to the original resource itself 
or a summary of important features of the prediction, including 
information of the original resource. The query results are also 
downloadable in a fully hyperlinked well-formatted Excel file.  
 
3.3.2 Features in pfSNP resource that facilitate Hypotheses Generation 
 
The pfSNP web-resource contains the following features that will facilitate 
hypotheses generation: 
1. Ambiguity in SNP information appropriately addressed.  Unlike other 
SNPs tools, all ambiguity in SNP information is appropriately addressed in 
the pfSNP resource. A single SNP (with a unique rs number) may map to 
different splice variants or different genes at the same chromosome 
location (overlapping genes) or to different genes on different 
chromosome locations. A SNP with a unique rs number, but mapping to 
different chromosome locations, could merely represent artifactual single 
nucleotide differences (SNDs) that are caused by the erroneous 
comparison of two or more duplicated (paralogous) sequences  (Day, 
2010; Musumeci, et al., 2010). This web-resource will inform the user if a 
particular SNP is likely to be a SND (Figure 3.5A) or if it represents a 
genuine SNP, mapping to different splice variants/genes at the same 
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chromosomal location.  Detailed information about that SNP in the 
different splicing variant/gene context will be provided (Figure 3.5B). 
 
Figure 3.5: Ambiguity in SNP information appropriately addressed.  
A. User will be warned if the SNP is SND. B. Detailed information matching gene 




2. Linkage Disequilibrium information of genotyped SNPs provided.  Many 
current researchers interested in Genome Wide Association Studies 
(GWAS) have utilized either the Affymetrix or the Illumina SNP chips, 
which select SNPs quasi-randomly or based on „tag‟ SNPs, respectively.  
Many of the SNPs on these chips shown to be associated with a phenotype 
during GWAS may not be predicted to be functional.  This is because the 
SNPs examined in the chips may only serve as surrogate SNPs in strong 
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LD with a causative/functional SNP.  One useful feature of this resource 
is that for any SNP in the human genome that has been genotyped by 
HapMap, it will inform the user of the distance as well as the LD measured 
by r
2
 between the SNP-of-interest and the closest pfSNP. Details of the 
potential functionality of that particular pfSNP will also be given. LD 
information of the nearby genotyped pfSNPs is available for greater than 
75% of Illumina and Affymetrix SNPs.  This will thus guide current 
GWAS scientists to make an informed decision about the potential 
functionality of SNPs in LD with their SNP-of-interest and design 
appropriate experiments to address them. 
 
3. Highly Customizable Query Interface. Biologists often formulate 
hypotheses about the unknown based on currently known information. For 
example, to design a gene-based study to associate SNPs with Parkinson‟s 
Disease (PD) in Asians, one may wish to identify SNPs in genes that were 
previously reported to be associated with the disease.  On the query 
interface page, the user can choose the „Gene Function/Disease‟ tab and 
type „Parkinson Disease‟ (Figure 3.6A). This web-resource utilizes 
information from previous GWAS studies, HGMD as well as limited 
information from OMIM and PubMed to inform the user of the genes (and 
their associated pfSNPs) that may be associated with PD.  It may also be 
possible to limit the focus to SNPs in genes associated with PD that are 
expressed in only a specific organ, such as the brain, or those that are 
found in a specific chromosome region or belonging to a specific pathway. 
This can be done by selecting the „Gene‟ and „Expressed in‟ Tab. A list of 
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tissue options will be available and the user can then select the tissue of 
interest; e.g., Brain (Figure 3.6A, a step-by-step demonstration of this 
feature can be found at http://pfs.nus.edu.sg/demo_src/supp_info_s4.html). 
This web-resource utilizes information from Gene Expression Atlas to 
enable the user to limit the search to only genes that are expressed in a 
specific tissue.  The user may further limit the search to the genes in a 
particular pathway. pfSNP web-resource provides  a choice of either GO 
terms, KEGG pathway or mSigDB C2 pathway or a combination of any of 
these terms. 
Another unique feature of this web-resource is that users would be 
able to arrange their query criteria as they wish by “dragging and 
dropping” the different tabs containing their query criteria and different 
logic operators to form a highly customized query (Figure 3.6B, a 
step-by-step demonstration of this feature can be found at 
http://pfs.nus.edu.sg/Demo_Src/ArrangeCriteria.html). 
Using this web-resource, it is also possible to further limit the 
search to SNPs that occur in Asians above a specific threshold minor 
allele frequency (Figure 3.6C). One can also just look at pfSNPs that are 
located in coding regions, promoters, 5‟UTR, 3‟UTR, introns or a 
combination of different regions or all regions. Hence, the query interface 
of this pfSNP resource is not only user-friendly but highly customizable 
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Figure 3.6: Highly Customizable Query Interface. A. Multiple query criteria can be 
provided in the query interface. B. User can re-arrange the criteria provided and adding appropriate 
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4. Integration of Gene/Pathway Level Information into the Results Interface.  
To facilitate better hypotheses generation, the pfSNP resource integrates 
gene/pathway level information into the Result interface.  This feature 
would be particularly useful for researchers who have identified a list of 
SNPs that may be associated with a particular disease/phenotype from, for 
instance, GWAS and want to know if this list of associated SNPs is 
enriched in any particular pathway so as to generate some testable 
hypotheses. A step-by-step demonstration of this feature can be found at 
http://pfs.nus.edu.sg/Demo_Src/ supp_info_s5.html. When this list of 
SNPs are queried in the pfSNP database, not only is the potential 
functionality of the SNP given, the genes associated with these SNPs as 
well as the tissue distribution of the genes and the pathway/GO term to 
which these genes belong are also given. Importantly, text clouds are 
generated to highlight the enriched terms in each category. As an 
illustration, a list of 16 SNPs that were previously associated with prostate 
cancer were queried in the pfSNP resource (Figure 3.7A). The 
web-resource highlighted that six of these SNPs are inter-genic while the 
other 10 SNPs reside in seven genes (Figure 3.7B). The Query Result 
showed information regarding the seven genes and a summary of the 
properties of the seven genes can be obtained by moving the cursor over 
the various headers. For example, the text clouds under the header, „Tissue 
Expression‟ and „mSigDB Pathway‟ inform the user that majority of these 
seven genes are expressed in the testis as well as prostate and are in the 
pathway of hematopoietic stem cell progenitors (HSC_Early Progenitors), 
since these terms are written in larger fonts compared to the other terms 
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(Figure 3.7C). Such integration of information will help scientists to better 
formulate hypotheses of their findings and focus their efforts on designing 
appropriate experiments. 
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5. Detailed Related Information of the Query Result Provided.  To facilitate a 
better understanding of the results, as well as to aid in the generation of 
hypotheses, detailed related information is also given on the query result. A 
step-by-step demonstration of this feature can be found at 
http://pfs.nus.edu.sg/Demo_Src/ supp_info_s6.html. For example, from the list 
of 16 SNPs associated with prostate cancer, two were predicted to affect 
particular transcription factor (TF) binding sites (Figure 3.8A). The user has 
the option to click on the hyperlink to that TF to better understand the role of 
each one. A new page providing information regarding the tissue expression, 
GO, KEGG pathway, PharmGKB drug association, mSigDB Pathway, OMIM 
or GAD reports of that TF will be shown.  Alternatively, the list of TFs can 
also be queried using the pfSNP web-resource and the general properties of 
the TFs affected by the two SNPs can be inferred by placing the mouse cursor 
over the various headers. Text clouds under the header, „Tissue Expression‟ 
and „mSigDB Pathway‟ reveal that the TFs affected by these two SNPs are 
expressed reasonably significantly in the prostate and are primarily human 
CD34-enriched transcription factors (Figure 3.8B).  This is consistent with 
the tissue distribution and pathway of the list of SNPs associated with prostate 
cancer. The researcher could then perhaps make the hypotheses that the 
polymorphisms in the promoter of these genes created binding sites for stem 
cell-promoting transcription factors that are expressed in the prostate, which, 
in turn, will activate early progenitor genes in the prostate.  The scientist can 
then design appropriate experiments to test this hypothesis. Such information 
may be useful for the researcher to prioritize particular SNP(s) from a list of 
SNPs for functional validation. Additionally, in that TF page, there is another 
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option for the user to click and view all the pfSNPs for that TF. This 
functionality of the pfSNP web-resource will facilitate a better and more 
complete understanding of the potential functionality of the SNP. 
 









The pfSNP web resource aims to provide researchers interested in SNPs with a 
comprehensive and integrated resource that not only annotates the potential 
functionality of all SNPs in the dbSNP database, but also facilitates hypotheses 
generation through knowledge syntheses mediated by better data integration and a 
biologist-friendly web-interface.  The comprehensiveness of this resource is 
achieved through the integration of numerous and diverse algorithms/resources to 
identify potentially functional SNPs not only based on predicted sequence motifs, but 
also based on previously reported functionally significant SNPs and inferred potential 
functionality from genetics approaches. 
With the abovementioned features, I believe that the pfSNP resource will be 
useful for various groups of researchers focusing on SNPs, including those interested 
in: 
1. Designing experiments to address the functionality of specific SNPs.  
This web-resource will inform the scientist about the predicted potential 
functionality of the SNP-of-interest so that appropriate experiments may 
be designed, and provide information from previous reports that have 
examined the SNP-of-interest. 
 
2. Gene-based association studies (GBAS).  This web-resource will 
facilitate the selection of potentially functional SNPs in any 
gene-of-interest for studies associating a particular gene with a phenotype.  
Significantly, this resource has the potential to select subset of pfSNPs in 
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genes within a certain chromosome region; expressed in specific tissues; 
and/or has been associated with a certain disease/phenotype/drug 
response/pathway. It is also possible to select pfSNPs that occur at/above 
specific threshold frequencies in specific populations or pfSNPs residing 
only in exons or promoter or 5‟/3‟ UTRs, etc. 
 
3. Genome-wide association studies (GWAS). As discussed earlier, this 
resource will be useful to current GWAS scientists, as it provides 
information with regards to the distance as well as the LD measured by r
2
 
of a nearby HapMap genotyped pfSNP that is at the highest LD to the 
genotyped SNP-of interest. Importantly, the integration of gene/pathway 
level information into the Results interface with text clouds highlighting 
enriched terms in each category will be useful to those researchers who 
have a list of SNPs associated with a phenotype and would like to 
formulate testable hypotheses about their findings. 
 
When compared against other similar resources (Table 3.2), few other 
resources would be suitable to handle the GBAS- and/or GWAS-related applications 
either due to limited data content or web portal functionality.  
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The inclusion of all publicly available information about the functionality of 
SNPs proved challenging and not all published information about SNPs associated 
with function/disease/drug response has been captured in this database. I have 
attempted to be as comprehensive as possible by culling data from the NCBI dbGAP, 
GAD and HGMD databases, as well as that from two previous publications that 
performed literature mining from PubMed (Xuan, Wang et al. 2007) or OMIM 
(Stoyanovich and Pe'er 2008).  Data from dbGAP, GAD and HGMD databases can 
be updated periodically. However, the two publications which mined either PubMed 
(Xuan, Wang et al. 2007) or OMIM (Stoyanovich and Pe'er 2008) database does not 
seem complete nor updatable as some of the well-known previously reported, 
functionally significant SNPs were not captured in these two publications due to 
algorithm constraints in the PubMed literature mining and imperfection in manual 
curation of the OMIM database. Since many different nomenclatures have been used 
to describe the same SNP in previous published literature, there is no single 
comprehensive algorithm that can completely mine the PubMed literature databases 
for SNPs associated with function or disease/drug response. 
Therefore, the pfSNP web-resource also provides ways for the user to deposit 
and share published information not found on the website. There are two ways to 
deposit published information with regards to a particular SNP. The first is within the 
Results page of the query interface.  In the column titled „Reported‟, there will be a 
phrase “Report New Function” which is hyperlinked to a page for the user to input the 
association of that SNP with disease/function. This feature will be useful for users 
who have previously published on that SNP being associated with disease/function, 
but realized that the previously published association was not reflected in this 
web-resource.  An alternative way to input published information for a 
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SNP-of-interest is by clicking the “Submit Published SNP Info” button found on the 
home page after the login page.   
The webpage to submit published SNP information is simple and contains 
several user-friendly features.  The user will first have to submit the reference of the 
publication that reports the association of the SNP with function/disease/drug 
response.  Although the PubMed ID is required, for users who do not know the 
PubMed ID, the button „Search for PubMed ID‟ (Figure. 3.9A) can be used and 
requires only one or preferably more information with regards to the first author, 
journal, volume, and page number of the publication (Figure. 3.9B). From this, a list 
of titles from PubMed that fits this description will appear for selection. The user then 
inputs the SNP-of-interest as the rs number.  However, if the rs number is not known, 
the user can merely provide other information with regards to the SNP-of-interest by 
clicking the „Search for rs number by its gene location‟ tab (Figure 3.9C and D) and 
the web-resource will then help match the rs number with the information provided.  
The user then provides information about the reported functional significance of the 
SNP – whether the SNP affects function (e.g. disrupt protein function or cause mRNA 
destabilization, etc) or is associated with drug response or disease risk (Figure 3.9E).  
Here, again, the Auto-Complete Prompt-As-You-Type feature for the „drug‟ and 
„disease‟ will facilitate the user to select the most appropriate drug or disease, and if 
none of the drugs/diseases in the database matches what the user has in mind, a new 
drug/disease can also be input. The user is then given an opportunity to elaborate (up 
to a maximum of 200 characters) about the associated functional significance of the 
SNP (Figure 3.9F). When all the information has been provided, the user clicks on 
the „Submit the Literature Reference‟, and the information will then be associated 
with that particular SNP and presented in the Results page when that SNP is queried, 
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with acknowledgement to the individual who submitted the information. With support 
from the scientific community, this pfSNP resource can then be kept comprehensive 
and current.  




Nonetheless, because our current understanding of the functional 
consequences of the sequences in the human genome remains incomplete, there 
remains many yet-to-be discovered pfSNPs.  As our understanding about the 
functional importance of various regions/sequences in the human genome improves, 
more new pfSNPs will be identified and these new pfSNPs can then be updated in 
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later versions of our resource. Our aim is for this pfSNP web-resource to remain 
relevant even as many more new SNPs are identified through whole-genome 
sequencing strategies.  Through automation, we hope that these novel SNPs can be 
input or automatically captured into the pfSNP resource to be evaluated for potential 
functionality. Structural variation, including copy-number variation, represents 
another important source of genetic variation associated with complex 
disease/phenotypes. As our understanding of the role of these structural variants in 
diseases advances, and as algorithms are developed to better predict the potential 
functionality of these variants, such potentially functional variants could also be 
included in later versions of the pfSNP resource. 
 
3.5 Summary 
 A comprehensive, well-annotated, integrated pfSNP Web Resource 
(http://pfs.nus.edu.sg/) which is aimed to facilitate better hypothesis generation 
through knowledge syntheses mediated by better data integration and a user-friendly 
web interface was developed. Its query-interface has the user-friendly „auto-complete, 
prompt-as-you-type‟ feature and is highly customizable facilitating different 
combination of queries using Boolean-logic. Additionally, to facilitate better 
understanding of the results and aid hypotheses generation, gene/pathway-level 
information with text-clouds highlighting enriched tissues/pathways as well as 
detailed related information are also provided on the results page.Hence, this pfSNP 
resource will be of great interest to scientists focusing on association studies as well 
as those interested to experimentally address the functionality of SNPs. 
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Every year, more than one million individuals worldwide will develop 
colorectal cancer (Cunningham, Atkin et al. 2010), accounting for 10% of the global 
cancer burden. Colorectal cancer (CRC) is the most frequently diagnosed cancer in 
Singapore (7,909 new cases between 2005-2009) (SC 2011). More than half of CRC 
patients develop metastatic disease (stage 4) either at diagnosis or at relapse following 
initial curative intent therapy. This means that a substantial proportion of patients may 
need treatment for the metastasis or relapse of colorectal cancer.  
The efficacy of anti-cancer drug treatment for CRC can be measured by either 
tumor response or patient survival. Tumor response is usually used in the 
neo-adjuvant setting where shrinkage of tumor is the primary focus. Response 
Evaluation Criteria In Solid Tumours (RECIST)(Sohaib 2012) is usually used to 
determine tumor response. According to the RECIST criteria, patient responses are 
classified into four categories, namely Complete Response (CR, disappearance of all 
target lesions), Partial Response (PR, at least a 30% decrease in the target lesions), 
Progressive Disease (PD, at least a 20% increase in the target lesions or new lesions) 
and Stable Disease (SD, neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD). Patient survival is used in the adjuvant setting and 
multiple clinical endpoints, such as Overall Survival (OS) and Relapse-Free Survival 
(RFS) can be used to measure patient survival. OS is an endpoint to capture all causes 
of mortality and therefore is a composite measurement of both drug efficacy and 
adverse effects. RFS is defined as the time to the first relapse or death from any cause 
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excluding second primaries or other cancers. It is perhaps the endpoint most sensitive 
to a treatment effect while still accounting for any imbalance in adverse event-related 
deaths (Chua, Sargent et al. 2005). Toxicity of anti-cancer drug treatment is usually 
measured by the severity of adverse effects, specific to the drug used. 
5-fluorouracil (5-FU) and its pro-drug, Capecitabine, are widely used to treat 
CRC. It has been proposed that there are two distinct modes of action for 5-FU. First, 
it acts as anti-metabolite whereby its active form, FdUMP, produced by Thymidine 
Phosphorylase (TYMP), inhibits Thymidylate Synthase (TYMS). Second, it can 
induce cell death, whereby incorporation of its active products FUTP and FdUTP into 
RNA and DNA, respectively, leads to subsequent cell apoptosis (Sobrero, Aschele et 
al. 1997). Uridine Monophosphate Synthetase (UMPS, also known as OPRT) is 
responsible for converting 5-FU to FUMP, which is the first step of producing FUTP 
and FdUTP. It was previously thought that the “anti-metabolite” pathway was more 
important than the “cell toxicity” route. However, the two pathways may overlap, 
because the intermediate product in the “cell toxicity” pathway, FUDP, may also be 
converted to FdUDP and subsequently FdUMP and participate in the 
“anti-metabolite” pathway. 5-FU is catabolized into the inactive form of DHFU by 
Dihydropyrimidine Dehydrogenase (DPYD), and DPYD is the rate-limiting enzyme 
in degrading 5-FU.  
The expression level of the abovementioned genes, namely TYMP, UMPS, 
DPYD and TYMS, have long been suggested to affect 5-FU pharmacokinetics and 
pharmacodynamics and thus determine the efficacy and toxicity of 5-FU. Various 
studies have demonstrated that the expression levels of TYMP, UMPS, DPYD and 
TYMS genes would be markers for predicting CRC patient survival (Koopman, 
Venderbosch et al. 2009). However, such reports remain controversial and not readily 
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replicable possibly due to the inaccuracy of the Immunohistochemistry method used 
for measuring the protein abundance in tissue samples. 
SNPs and other genetic markers in these genes have thus been tested as 
possibly representing better markers for predicting efficacy or toxicity of 5-FU in 
CRC patients (Gosens, Moerland et al. 2008). Table 4.1 shows the variants in either 
“5-FU PD”- or “5-FU PK”-related genes found to be associated with 5-FU efficacy or 
toxicity in CRC patients. The most studied variant is the 28 bp-tandem repeat (Table 
4.1 A, rs34743033, either 2 or 3 repeats and denoted 2R and 3R allele) in the 5‟UTR 
region of the TYMS gene, together with an embedded SNP (rs2853542, E/1/G-58C). 
Patients with genotype 2R/2R, 2R/3C (3C denotes a haplotype comprising 3R allele 
for the tandem repeat and the C allele of the SNP), and 3C/3C were shown to have 
lower expressions of the gene and were associated with a better response to 5-FU, as 
evidenced by longer patient survival (Kawakami and Watanabe 2003). This VNTR 
and SNP have also been shown to be associated with tumor response (Graziano, 
Ruzzo et al. 2008). In the 3‟ UTR region of the TYMS gene, there is also one 6 bp 
indel (rs16430) associated with tumor response (Salgado, Zabalegui et al. 2007). Two 
SNPs in the MTHFR genes (Table 4.1 A), rs1801133 (E/5/G677A, A222V) and 
rs1801131 (E/8/T1298G, E429A), have been associated with patient survival in 
various cancers individually (De Mattia and Toffoli 2009) and a model combining these 
SNPs with TYMS polymorphism/status was proposed to predict the response better 
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Table 4.1: List of variants reported in previous association studies for 5-FU 
efficacy or toxicity in CRC patients.  
A Variants in the 5-FU PD pathways genes 
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B Variants in the 5-FU PK pathway genes 












Efficacy (TR) -- (Farina-Sarasquet
a, van 
Lijnschoten et al. 
2010) 
DPYD rs1801265 E/2/G85A, 
C29R 











Toxicity (Zhang, Li et 
al. 2007) 
-- 
Efficacy (TR) -- (Farina-Sarasquet
a, van 
Lijnschoten et al. 
2010) 
rs3918290 I/14/G1T Toxicity (Schwab, 
Zanger et al. 
2008) 
-- 
Note: “Efficacy (TR)” highlights that “Tumor Response” is used as the measurement of efficacy. 
“Efficacy” means patient survival is used as measurement of efficacy. 
 
Thus far, only variants in the “5-FU PD” genes were reported to be 
significantly associated with efficacy in some studies. The more commonly studied 
SNPs in the “5-FU PD” genes (namely rs2853542 / rs34743033 and rs16430 in the 
UMPS gene) that have reported association with 5-FU are mainly non-coding, 
suggesting that non-coding SNPs may play an important role in determining 5-FU 
efficacy. There may also be locus heterogeneity in 5-FU response since different 
SNPs in different genes were reported to be associated. Unfortunately, replication of 
such reported association between “5-FU PD” gene variants and response remains 
challenging (Cohen, Panet-Raymond et al. 2003; Tsuji, Hidaka et al. 2003; Etienne, 
Formento et al. 2004; Marcuello, Altes et al. 2006; Ruzzo, Graziano et al. 2007; 
Graziano, Ruzzo et al. 2008; Farina-Sarasqueta, van Lijnschoten et al. 2010; Vignoli, 
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Nobili et al. 2011), suggesting the possible presence of other loci in determining 5-FU 
efficacy. 
It was interesting to note that the variants in the “5-FU PK” genes were mainly 
investigated for their association with 5-FU toxicity, not efficacy (Table 4.1 B), 
despite the expression levels of these genes having been previously associated with 
5-FU efficacy (Koopman, Venderbosch et al. 2009). Only one report 
(Farina-Sarasqueta, van Lijnschoten et al. 2010) tried to explore the possible 
association for efficacy, but failed. However, this study might have been 
underpowered to detect such an association, in that it also failed to replicate the 
association for the VNTR and SNP (Table 4.1 A) in the TYMS gene.  
In summary, existing evidence suggests there can be more SNPs in both the 
“5-FU PD” and the “5-FU PK” pathway genes that can determine the efficacy of 
5-FU. The function of such SNPs may also vary and may not be restricted as 
non-synonymous. The aim of this study was to explore as many potentially functional 
SNPs (pfSNPs) in both “5-FU PD” and “5-FU PK” pathway genes for possible 
association with 5-FU efficacy, as measured by tumor response. pfSNPs were 
determined to be good candidates for this study since SNPs with various functions are 
all covered. 
This study will also explore the suitability of using pfSNPs for pathway level, 
candidate gene-based association studies as compared with the traditional, 
non-synonymous SNP-centric approach. The 5-FU response is a good phenotype to 
examine, because it is known that expression levels of the genes involved are 
important in determining the phenotype. This study may reveal more 
expression-related SNPs due to locus heterogeneity, and evaluate the limitation of the 
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non-synonymous SNP-centric approach. Further, this study also aims to compare the 
tagging SNP-based approach versus the direct pfSNP approach.  
 
4.2 Materials and Methods: 
 
The workflow of the study is shown in Figure 4.1.  
 




4.2.1 Patient samples and clinical parameters 
The shrinkage of liver metastatic tumors was used as the clinical endpoint for 
measuring treatment efficacy. Response Evaluation Criteria In Solid Tumours 
(RECIST) (Sohaib 2012) is used to determine tumor response. According to the 
RECIST criteria, patient responses are classified into four categories, namely 
Complete Response (CR, disappearance of all target lesions), Partial Response (PR, at 
least a 30% decrease in the target lesions), Progressive Disease (PD, at least a 20% 
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increase in the target lesions or new lesions) and Stable Disease (SD, neither 
sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD). In our 
patient cohorts, there was no patient belonging to the „Complete Response‟ category. 
Patients with „Partial Response‟ were deemed as „Responders‟ and patients with 
„Progressive Disease‟ or „Stable Disease‟ were classified as „Non-Responders‟ in the 
association analysis. 
There are two batches of unrelated Chinese metastatic CRC patients recruited 
for this study. The recruitment of both batches has been approved by Singhealth 
ethical reviewing committee. They are referred to as “Cohort 1” and “Cohort 2” 
respectively in the following text. All patients had liver metastasis and were given 
neo-adjuvant chemotherapy prior to operation for the liver lesion. Table 4.2 A shows 
the characteristics of the two cohorts. Table 4.2 B shows the age and gender 
distribution in responder and non-responder sub-groups. 
“Cohort 1” comprised 27 unrelated Chinese liver metastatic CRC patients who 
were treated with 5-FU (a few had Capecitabine) alone (a few) or with oxaliplatin 
regime (most) as their neo-adjuvant chemotherapy. Some of these patients had also 
been previously exposed to these drugs. Of these 27 patients, 12 had partial response, 
seven had stable disease, and eight had progressive disease. Hence, the response rate 
was ~40-45%, which is typical for patients undergoing 2-drug combination therapy. 
Two-thirds of these patients are males, and Cohort 1 had a median age of 62 years. 
Age and gender were shown not to be confounding factors in this cohort (Table 4.2 
B).  
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Table 4.2: The demographic characteristics of the two patient cohorts recruited. 
A. The demographic characteristics in two cohorts. B. The age and gender distribution in responder and 
non-responders in each cohorts. 
A 
  Cohort 1 Cohort 2 
Number of Patients  27 75 
Ages (Median)  42-86 (62) 36-78 (59) 
Males (Females)  18(9) 60(15) 
Prior Drug Exposure   
  5-FU alone 2 0 
  Capecitabine alone 3 0 
  5-FU + oxaliplatin 2 0 
  Capecitabine + oxaliplatin 0 0 
  5-FU + Radio Therapy 2 0 
Drugs Treated      
  5-FU alone 2 0 
  Capecitabine alone 1 75 
  5-FU + oxaliplatin 15 0 
  Capecitabine + oxaliplatin 8 0 
  5-FU + Irinotecan 1 0 
Response      
  Partial response 12 13 
  Stable disease 7 31 
  Progressive disease 8 18 
B 
   Responder Non-Responder P Value 
Cohort 1 Ages (Mean) 62.3 63.5 0.30 
Males(Females) 8(4) 10(5) 0.39 
Cohort 2 Ages (Mean) 65.7 59.0 0.03 
Males(Females) 5(8) 43(6) 0.0007 
 
“Cohort 2” comprised 75 unrelated Stage IV CRC Chinese patients. These 
patients were treated with only Capecitabine and they have never been previously 
exposed to this drug. Of these 75 patients, 13 had partial response, 31 had stable 
disease, and 18 had progressive disease.  The response of the remaining 13 patients 
remains unknown. Hence, the response rate of this group of patients is only ~17%, 
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which is typical for single-agent treatment. In “Cohort 2”, ~80% of the patients were 
male, and the median age of the cohort was 59 years. Age and gender were shown to 
be confounding factors in “Cohort 2” (Table 4.2 B). 
 
4.2.2 Selection of potentially functional SNPs (pfSNPs) for association study 
 
I queried our pfSNP resource, as previously described (Wang, Ronaghi et al. 
2011), for genes related to 5-FU/Capecitabine, oxaliplatin as well as colorectal cancer. 
A total of 214 genes and ~2800 pfSNPs were found to be associated with these drug 
pathways or CRC. As only 1,536 SNPs can be genotyped within a single customized 
GoldenGate Genotyping Array (Illumina, Inc), the following criteria were employed 
to select a subset of these 2800 pfSNPs: all SNPs within the promoter, coding, 5‟/3‟ 
un-translated regions with has a GoldenGate Score (GGS: measure of assay quality by 
their platform) of greater than 0.5 were selected. For the introns, pfSNP with a 
GGS>0.7 were selected and monomorphic ones reported in HapMap CHB population 
were excluded, except for those previously reported as functional. For any adjacent 
SNPs that may interfere with each other in the assay, I selected the SNP according to 
the following order: “Previously reported  Non-Synonymous  Synonymous  
UTR  Intron”. A list of all of the SNPs included on the GoldenGate array is 
available as Supplementary Table 1. 
Among the markers that were unsuitable to be genotyped by GoldenGate 
assay, I picked 14 important markers in 5-FU response prediction to be genotyped by 
other methods (listed in Supplementary Table 2). The 14 markers include the 
previously well studied VNTR with embedded SNP as well as the 6bps 3‟ UTR indel 
Potentially Functional Single Nucleotide Polymorphisms (pfSNPs) in the Human Genome and their Potential Applications 
116 
in the TYMS gene (Table 4.1 A) because GoldenGate technology could only 
genotype SNPs. Other markers are SNPs with low GoldenGate scores in the TYMS, 
TYMP and DPYD genes. A customized Sequenom MassARRAY® panel was used to 
genotype 11 of the 14 SNPs and 1 SNP was genotyped by ABI TaqMan. In addition, I 
developed a novel method to genotype the VNTR (rs2853542) and embedded SNP 
(rs34743033) in the TYMS gene. This VNTR can have either 2 or 3 repeats, and the 
SNP can occur in both the second and third repeat (Kawakami and Watanabe 2003). 
Previous papers used Restriction Fragment Length Polymorphism method to genotype 
them (Kawakami and Watanabe 2003), but the star activity of the restriction enzyme 
may make the results less reliable.  I developed a robust method using Sanger 
Sequencing for this purpose. A fragment of 486 bp was amplified using the primers 
(F- CTGCTGGCTTAGAGAAGGCG and R- AGCGGAGGATGTGTTGGATC) and 
the amplicon was sequenced in both directions using the forward and reverse primers. 
Different genotypes would yield distinct patterns on the forward and reverse 
sequencing reads (As shown in Figure 4.2), allowing the genotype to be easily 
deduced. 
In summary, there were 1,536 markers (Listed in Supplementary Table 1) 
genotyped with a single customized Illumina GoldenGate SNP genotyping array, 11 
(Listed in Supplementary Table 2) by Sequenom MassARRAY®, 1 (rs11479) by 
ABI TaqMan and the VNTR (rs2853542), with the embedded SNP (rs34743033) 
genotyped by Sanger Sequencing.  
The distribution of the SNPs and genes selected in the three categories (CRC, 
Fluorouracil and Platinum related) is depicted in Figure 4.3. More than half of the 
SNPs (863) are from fluorouracil-related genes and 702 SNPs are from 
platinum-related genes. A considerable portion of the SNPs (656) are from 
Potentially Functional Single Nucleotide Polymorphisms (pfSNPs) in the Human Genome and their Potential Applications 
117 
CRC-related genes, although 40% (32 out of 80) of these genes and 88% (579 out of 
656) of the SNPs are related to fluorouracil and/or platinum as well. Nonetheless, this 
group of SNPs is valuable because they can be used in pathway-based analyses to 
form the background distribution to which a comparison can be made. 
 
Figure 4.2: The different sequencing patterns generated by the different 
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Figure 4.3: The gene and pathway distribution of pfSNPs chosen for genotyping. 
               
 
The numbers of SNPs in each gene region and function category covered in 
this study are shown in Figure 4.4. Each of the four gene regions, namely promoter, 
coding, intron and 3‟ UTR, are adequately covered in general. For promoter and 
3‟UTR, most of the SNPs genotyped are those that change TF binding sites. In the 
coding region, SNPs that change ESE/ESS sites are the most abundant, and 
non-synonymous SNPs that cause deleterious effects are the second most abundant. 
The intron region SNPs are enriched with those with a signature of recent positive 
selection. 
The distribution of SNP minor allele frequency for the intronic versus 
non-intronic region is shown in Figure 4.5. For coding, 3‟UTR, and promoter regions, 
a number of SNPs not previously genotyped by HapMap (designated by question 
mark in the figure) will be genotyped in this study.  I also endeavoured to genotype a 
number of monomorphic SNPs reported by HapMap. For the intron region, since most 
of the SNPs are those with a signature of recent positive selection, they have MAF 
more than 5%.  I did not genotype many monomorphic ones within introns.  
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4.2.3 Single marker association analysis 
 
Hardy-Weinberg equilibrium was analysed using the Microsoft Excel-based 
SNP Statistics Calculator that I previously developed. Single marker association 
analysis was performed using PLINK (Purcell, Neale et al. 2007) . The P value was 
calculated by the permutation-based method without considering age and gender as 
confounding factors, and the Odds Ratio (OR) and corresponding 95% confidence 
interval were determined using regular allele-based association analyses, because the 
permutation-based method does not provide such information. 
Haploview (Barrett, Fry et al. 2005), together with HapMap release 28 
genotype data, were used to analyze the LD profile in genes of interest and to plot the 
pairwise LD diagram. LD diagrams were also generated using an in-house Microsoft 
Excel-based LD analysis tool written in VBA that I previously developed. SNAP 
(Johnson, Handsaker et al. 2008) was used to check for SNPs in LD with the SNP of 
interest in the 1 Mb flanking region. 
 
4.2.4 Gene set analysis 
 
Gene set analysis was performed using GSA-SNP (Nam, Kim et al. 2010) and 
Pathways of Distinction Analysis (PoDA) (Braun and Buetow 2011). The second best 
P value in each gene was used for the Z-score-based “parametric analysis of gene set 
enrichment” (PAGE) method (Kim and Volsky 2005), as it was suggested that using 
the best P value may increase the risk of a spurious result (Nam, Kim et al. 2010). 
PoDA results were obtained using the R package provided in the original paper. 
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The composition and relationship between the gene sets used are depicted in 
Figure 4.6. The detailed list of the genes in each gene set can be found in 
Supplementary Table 3. 
 
 
Figure 4.6: The composition and relationship of gene sets used in the gene set 
analysis. The number in brackets is the number of genes in that gene set. The “5-FU Activator” is a 






Three 5-FU related pathways/gene sets, namely the “5-FU Activator” gene set, 
the “5-FU PK” pathway and the “5-FU PD” pathway, were included for gene set 
analysis. The “5-FU Activator” gene set is a subset of “5-FU PK” pathway and 
comprises 13 genes that code for enzymes converting 5-FU or Capecitabine into their 
active form. DPYD and related genes that catabolize 5-FU were excluded. Because a 
large number of patients in “Cohort 1” were also administered Oxaliplatin, I 
combined all the genes in “5-FU PK”, “5-FU PD” and “Platinum pathway” to form 
the “5-FU and Platinum Pathway” set so that I could test if the genes in this set would 
show a higher association signal since they all may contribute to the final outcome of 
this cohort. 
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4.3 Results and Discussion: 
 
4.3.1 Genotyping results 
 
Most of the genotyped SNPs in the customized GoldenGate array were either 
monomorphic (36%) or had high minor allele frequency (MAF≥0.1, 46%) (Figure 
4.7). When the MAF of our genotyping results were compared against the HapMap 
results, a high concordance (R
2
=0.9494) was observed (Figure 4.8), which reassures 
the quality of our genotyping results. There were 72 SNPs in “Cohort 1” and 66 SNPs 
in “Cohort 2” have a Hardy-Weinberg Equilibrium P value less than 0.05 and these 
SNPs were excluded from further analysis. 
 
Figure 4.7: The MAF distribution of GoldenGate genotyped SNPs. 
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Nine out of eleven SNPs genotyped by Sequenom MassARRAY® were 
successful, with the genotype calling rate ranging from 97% to 100% in all samples. 
The two SNPs genotyped by Sanger Sequencing and TaqMan were both successful. 
Sanger Sequencing successfully genotyped all of the samples while the TaqMan assay 
obtained a calling rate of 96%. All SNPs successfully genotyped by these methods 
passed the Hardy-Weinberg equilibrium.  
 
4.3.2 Single SNP association analysis identified three SNPs in the UMPS gene 
whose minor allele occurs only in non-responders 
 
Thirty-nine SNPs with un-corrected P-values less than 0.05 in “Cohort 1” are 
listed in Table 4.3 and arranged in ascending order according to their P value. As the 
sample size was small (n=27), none of these markers are statistically significant after 
Bonferroni correction. Interestingly, there are four SNPs that had infinite OR because 
one allele is found only in either the Responders/Non-Responders groups (Table 4.3, 
SNP 25 and SNP 28-30). 
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Table 4.3: List of SNPs showing P<0.05 in “Cohort 1” ranked by P value in this 
cohort. 
 
Abbreviations: Reported: previously reported in the literature to be associated with disease/function; ESE/ESS: 
change Exon splice enhancer/silencer; NMD: mRNA nonsense mediated decay; Non-syn: non-synonymous SNP; 
ProteinDomain: residing in important protein domains; miRNA: change miRNA binding site; RPS: show signature 
of recent positive selection; TF: change transcription factor binding site; ISRE: change intron splice regulatory 
element 
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The C allele of the rs1056836 (CYP1B1 E/3/C1294G L432V, Table 4.3 SNP 
25) in CYP1B1 gene has been recently associated with a reduced sensitivity to 
various anti-metabolites, including 5-FU (Laroche-Clary, Le Morvan et al. 2010). 
Specifically, the haplotype containing the C allele was more responsive to 
anti-metabolite treatment by showing a higher -log (IC50) value as compared with 
other haplotypes containing the G allele. This is in concordance with our observation 
that the C allele is uniquely found in the responders.  
The 3 SNPs in the UMPS gene (Table 4.3, SNP 28-30) whose minor allele 
only occurred in non-responders, namely rs2291078 (E/4/T1050A C350*), rs3772809 
(E/6/A1336G H446Y) and rs3772810 (E6/3UTR/A28G), were in a perfect LD block 
within Cohorts 1 and 2. Although there were no published reports about SNPs within 
UMPS gene associated with drug response, the predicted functional significance of 
the SNPs is consistent with the observed association with 5-FU response. The UMPS 
gene is important in determining 5-FU response, as it converts 5-FU into its active 
metabolite, FUMP, which can participate in both the cell toxicity pathway as well as 
in the “anti-metabolite” pathway. In the cell toxicity pathway, FUMP can be further 
converted into FUTP and FdUTP and get incorporated into RNA and DNA 
respectively. In the “anti-metabolite” pathway, FUMP can be converted into FdUMP 
and inhibits TYMS. The molecular functions of the three alleles unique to the 
non-responders are all associated with the disruption of the UMPS gene function and 
support their unique presence in the non-responders. The A allele of rs2291078 
(UMPS E/4/T1050A C350*) creates a stop codon in exon 4, likely resulting in 
non-sense mediated decay since the stop codon occur more than 50 bps from the last 
exon-exon junction would lead to a decrease in UMPS mRNA abundance. At the 
same time, translation from mRNA containing this allele may be further attenuated by 
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the G allele of the 3‟UTR SNP rs3772810 (UMPS E6/3UTR/A28G). The G allele is 
predicted to create binding sites for miRNA 23a, 23b and 130a*. The miRNA 23a is 
shown to be up-regulated under hypoxic conditions (Kulshreshtha, Ferracin et al. 
2007), which is common in tumors, and hence may possibly suppress the expression 
of UMPS mRNA containing the G allele. In addition to suppressing the expression 
level of the gene, the non-synonymous SNP in the LD block, rs3772809 (UMPS 
E/6/A1336G H446Y), may further enhance the suppression of gene function by 
disrupting the function of the protein product. It is predicted to reside in an important 
domain of the protein (Ribulose-phosphate binding barrel (superfamily SSF51366), 
pyrF: orotidine 5‟-phosphate decarboxylase (HMMTigr TIGR01740)) even though it 
is not explicitly predicted to be deleterious by Polyphen and other tools. 
In HapMap release 28, these non-responder specific alleles of the SNPs occur 
at ~5% in the CHB and JPT populations, 0.5% in the CEU and 0% in the YRI. This 
low frequency of these alleles especially in the CEU and YRI populations suggests 
that they may be under negative selection consistent with the predicted deleterious 
nature of these alleles. 
In “Cohort 2”, the three SNPs in the UMPS gene again showed the same allele 
carried uniquely by non-responders, even though the P values were still not 
statistically significant (Table 4.4). The observation that out of a total of 102 patients 
when both cohorts combined, no responders were found to carry this allele suggests 
that this allele is a “causal” allele for determining the response to 5-FU. The non- 
statistical significant data obtained suggests that this may not be the only “causal” 
alleles for 5-FU response and there are likely other alleles that also play a role in 5-FU 
response suggesting “locus heterogeneity” of response to 5-FU 
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4.3.3 The three SNPs in the UMPS gene reside in a region of low LD and will not 
be “tagged” by “tagging SNP” of r2>0.8 
 
Since most current GWAS studies employ tagging SNP to identify SNPs 
associated with disease or drug response, it is worthwhile to examine if these three 
SNPs that I found to be associated with response to 5-FU/oxaliplatin can be “tagged” 
using pairwise tagging. 
Only two of the three SNPs are genotyped (framed in red in Figure 4.9) in the 
HapMap CHB population (Release 27). The pairwise r
2
 value between these SNPs 
and all the other 18 SNPs in the UMPS gene and even when the region is extended to 
1Mb is very low. Within the gene, the best r
2
 of 0.09 was obtained by a common SNP 
rs10934683 (MAF=0.44, framed in yellow in Figure 4.9), which was genotyped in 
our genotyping panel. This SNP is not associated with 5-FU response in any of the 
cohorts (P = 0.30 in “Cohort 1”, P = 0.32 in “Cohort 2” and P = 0.27 when the two 
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Figure 4.9: The LD diagram for the SNPs in the UMPS gene region. The SNPs 
framed in red are the SNPs showing one allele unique to the non-responders. A. LD plot showing 








 in the UMPS gene 
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4.3.4 Other interesting SNPs affecting 5-FU/Oxaliplatin drug response  
 
In addition to the abovementioned SNPs that occur only in non-responders, 
several other interesting SNPs with lower P-values were also found to be associated 
with drug response in our patients before multiple test correction in Cohort 1.  The 
VNTR (rs34743033) polymorphism containing the embedded SNP (rs2853542) was 
found to be significantly associated with drug response in our study with a P value of 
0.015 and OR of 7.6 (Table 4.3, SNP 12).  These 2 polymorphisms has been 
previously reported to be associated with 5-FU efficacy measured by tumor response 
(Table 4.1) which alludes to the robustness of our method without multiple test 
correction for identifying previously reported associated SNPs.  
Another noteworthy observation from Cohort 1 is that the 39 SNPs that were 
associated with drug response before multiple test correction belong to only 14 genes 
suggesting that several SNPs within the same gene were found to have significant 
association. For example, 14 different SNPs within ABCC4 were found to be 
associated with drug response including SNP, rs4148485 (Table 4.3, SNP 1), within 
the intron 9 of the ABCC4 gene which showed signatures of recent positive selection 
and has the lowest P-value of 1.98x10-3 and a strong OR of 6.57. ABCC4 is a 
membrane transporter that resides at both the apical and luminal surface of the 
hepatocyte (Keppler 2005).Unlike ABCG2, another member of the ABC family of 
transporter, which localizes at one side of the cell, ABCC4 may plays roles in both in 
and out flux of 5-FU and may potentially have a more significant role in 5-FU 
pharmacokinetics (PK). 
A total of 38 SNP in 13 genes in Cohort 2 are associated with drug response 
(Table 4.5). Interestingly, the SNP rs1801019 (Table 4.5, SNP 8) in the UMPS gene  
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Table 4.5: List of SNPs showing P<0.05 in “Cohort 2” ranked by P value in this 
cohort. 
 
Abbreviations: Reported: previously reported in the literature to be associated with disease/function; ESE/ESS: 
change Exon splice enhancer/silencer; NMD: mRNA nonsense mediated decay; Non-syn: non-synonymous SNP; 
ProteinDomain: residing in important protein domains; miRNA: change miRNA binding site; RPS: show signature 
of recent positive selection; TF: change transcription factor binding site; ISRE: change intron splice regulatory 
element 
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which was significantly associated with capecitabine response in Cohort 2 was 
previously reported to be associated with UMPS mRNA level, UMPS enzyme activity 
and 5-FU toxicity (Ichikawa, Takahashi et al. 2006). Note that UMPS is the gene 
containing the 3 SNPs in both cohorts with infinite Odds Ratios mentioned preciously. 
Another noteworthy gene enriched with SNPs associated with drug response in 
Cohort 2 is the RRM1 gene where 8 SNPs in 3 LD blocks were associated with drug 
response. A 5‟UTR SNP (5UTR/C-37A) in the RRM1 gene was reported to be 
associated with the transcription level of RRM1 (Dong, Guo et al. 2010; Rodriguez, 
Boni et al. 2011)  and may determine the treatment outcome of gemcitabine, a 
nucleotide analogue like 5-FU, in metastatic CRC patients (Rodriguez, Boni et al. 
2011) and other cancer patients (Dong, Guo et al. 2010).  This SNP was not 
deposited into the dbSNP database and hence was not interrogated in this study. 
Nonetheless, similar to the reported promoter SNP, all three LD blocks in the RRM1 
have at least one SNP associated with capecitabine response also localized to the 
promoter region. Curiously, SNPs associated with drug response in Cohort 1 is 
different from those in Cohort 2 (Table 4.4 and Table 4.5).  This is not surprising 
because these 2 cohorts comprise patients that have different drugs administered.  
Cohort 1 patients received 5-FU and oxaliplatin whereas Cohort 2 patients received 
only Capecitabine, precursor of 5-FU. Nonetheless, 4 genes, ABCC4, UMPS, ABCB1 
and SMARCA2, albeit with different SNPs were associated with drug response in 
both cohorts.  Three (ABCC4, UMPS, ABCB1) of these 4 genes are involved in the 
pharmacokinetics of 5-FU.  This data suggests that although different SNPs are 
involved in drug response in the 2 cohorts, SNPs within the same 4 genes, 3 of which 
are in the 5-FU PK pathway, are associated with drug response in both cohorts.  
Additionally, a significant proportion (38-46%) of the genes that were associated with 
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drug response in Cohort1 as well as Cohort 2 is in the 5-FU PK pathway.  Hence, it 
may be worthwhile to explore a Gene Set or pathway based approach to evaluate 
association with drug response in these patients. 
 
4.3.5 Gene Set Analyses highlights the importance of the „5-FU PK‟ pathway  
 
While single marker analyses has thus far been the most popular method to 
identify association of SNPs with disease, one limitation of this conventional 
approach for complex disease association studies is that there may not be sufficient 
statistical power to identify a true positive when many SNPs are interrogated 
simultaneously.  Alternative complementary approaches have recently been 
developed to address the power limitations of single marker approaches including 
association analyses using haplotype based method or regression-based methods 
(Balding 2006) as well as the most recent pathway-based association approaches 
(Wang, Li et al. 2010). 
In this study, although I observed several potentially functional SNPs that 
have potentially interesting association with drug response, none of these remained 
significant after multiple test correction since the sample size is small.  These 
interesting SNPs include 3 SNPs within UMPS gene that has infinite odds ratio since 
the minor allele only occurs in the non-responders and a few SNPs that confirms 
previously reported association with the same drug. I thus employed pathway-based 
approach to evaluate if our observed association prior to multiple test corrections of 
multiple SNPs within a group of related genes have consistent but moderate deviation 
from chance suggesting that these genes and mechanisms are involved in drug 
response. 
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Currently there are several algorithms to perform pathway-based association 
analyses and these algorithms can be group into 2 categories, the „competitive‟ and 
„self-contained‟ approach of hypothesis testing.  In the „Competitive‟ approach, the 
statistics of genes in a selected pathway is compared with the statistics of all the other 
pathways to evaluate if the genes of the selected pathway are more associated with the 
disease/drug response. In the „self-contained‟ approach, the test statistics of the 
selected pathway is compared against the expected test statistics generated by random 
sampling, for example. 
I thus selected one „competitive‟ approach, namely GSA-SNP (Nam, Kim et al. 
2010) and a „self-contained‟ approach, namely PODA (Braun and Buetow 2011) to 
further analyse our data. 
Table 4.6 shows the results from the analyses using GSA-SNP (top) and 
PODA (bottom) for Cohort 1. In Cohort 1, ~85% (23 or 27) of the patients were 
treated with 5-FU/Capecitabine with oxaliplatin.  GSA-SNP analyses revealed that 
although the 5-FU PK, platinum as well as the combined 5-FU and Platinum 
pathways were statistically significant before multiple test corrections, only the 
combined 5-FU and Platinum pathway remained statistically significant after multiple 
test correction. This is consistent with the drug treatment of Cohort 1 where majority 
of the patients received the 5-FU and Oxaliplatin combination treatment suggesting 
for this Cohort of patients, genes from both 5-FU as well as platinum pathways play 
roles in their drug response.  These results were confirmed using PODA, a 
self-contained approach which is different from GSA-SNP which is a „competitive‟ 
approach of analyses.  As evident in the lower panel of Table 4.6, the 5-FU PK, 
Platinum as well as combined 5-FU and platinum pathways showed significant 
association with drug response for Cohort 1. 
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Table 4.6: The gene set analysis results for “Cohort 1”. A. Results from GSA-SNP. The 
“Set size” column shows number of genes in the set and “Gene count” column shows the number of 
genes successfully genotyped in each set. The “P-value” column is derived based on the “Z-score” and 
the last column shows if the gene set with significant, the P-value would withstand Bonferroni 
correction. B. Results from PoDA. “DSp” is the distinction score for each gene set and “P-value” 
column shows the permutation-based P-value for DSp.  
A. 




Z-score P-value Pass 
MTC 
5-FU and Platinum 
Pathway 
76 76 2.54 0.006 YES 
5-FU PK 23 23 1.91 0.028 No 
Platinum pathway 45 45 1.88 0.030 No 
Colorectal Cancer 
Associated 
79 80 0.92 0.179 -- 
5-FU Activator 13 13 0.82 0.206 -- 
5-FU PD 10 10 0.51 0.304 -- 
B.  
Set name DSp P-value 
5-FU PK 1.64 0.026 
5-FU and Platinum 
Pathway 
1.37 0.037 




5-FU Activator 0.25 0.457 
5-FU PD -0.37 0.716 
 
Table 4.7 shows the results from the analyses using GSA-SNP (top) and 
PODA (bottom) for Cohort 2. All patients in Cohort 2 only received Capecitabine, a 
precursor of 5-FU. The GSA-SNP analyses revealed 5-FU Activator, 5-FU PK as well 
as combined 5-FU and Platinum pathways as statistically significant even after 
multiple testing corrections.  PODA analyses showed that only the 5-FU activator is 
statistically significant.  It is interesting to note that 5-FU activator is only 
statistically significant in Cohort 2 using both GSA-SNP as well as PoDA analyses 
but is not significant in Cohort 1 which has only very few patients receiving 
Capecitabine which is a precursor of 5-FU and has to be converted to 5-FU by genes 
within the „5-FU activator‟ pathways.  Taken together, these data suggest that when 
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patients are given Capecitabine rather than 5-FU, genes within the 5-FU activation 
pathway will play a more significant role.  Additionally the 5-FU PK pathway 
seemed to be more significant than the 5-FU PD pathway for these 2 Cohorts of 
patients. 
 
Table 4.7: The gene set analysis results for “Cohort 2”. A. Results from GSA-SNP. The 
“Set size” column shows the number of genes in the set, and “Gene count” column shows the number 
of genes successfully genotyped in each set. The “P-value” column is derived based on the “Z-score” 
and the last column shows if the gene set with a significant P-value could withstand Bonferroni 
correction. B. Results from PoDA. “DSp” is the distinction score for each gene set and “P-value” 
column shows the permutation-based P-value for DSp.  
A. 




Z-score P-value Pass 
MTC 
5-FU Activator 13 13 2.96 0.002 YES 
5-FU and Platinum 
Pathway 
76 76 2.92 0.002 YES 
5-FU PK 23 23 2.83 0.002 YES 
5-FU PD 10 10 1.35 0.089 -- 
Platinum pathway 45 45 1.24 0.108 -- 
Colorectal Cancer 
Associated 
79 80 0.58 0.282 -- 
B 
Set name DSp P-value 
5-FU Activator 1.43 0.029 
Platinum pathway 0.49 0.128 






5-FU PD -0.30 0.505 
5-FU PK -0.71 0.602 
 
This represents the first report to highlight the significant role of genes within 








In this study, I found three pfSNPs in the UMPS gene, which is a “5-FU PK” 
gene, consistently showed one allele unique to the non-responders in both cohorts. 
The P values for these three pfSNPs in the LD block were less than 0.05 in “Cohort 1” 
as well as in the combined cohort. Although the P values were not statistical 
significant in “Cohort 2”, this may be explained by the polygenic nature of the drug 
response phenotype, where these SNPs may cause the non-responsiveness; but, they 
only explain a small portion of all the non-responders who may carry other SNPs that 
will cause the non-responsiveness. Nevertheless, it is also possible that the low MAF 
of these SNPs and the small sample size contributed to the absence of such alleles in 
the responders. Follow up studies with larger sample size would be desirable to rule 
out this possibility. 
When LD analysis was carried out, it was seen that the three pfSNPs with one 
allele unique to the non-responders were in perfect LD with each other but were in  
low LD (r
2
<0.09) with other gene region SNPs, as well as SNPs in the 1M bps 
flanking region (r
2
<0.6).  This suggests that these SNPs will not be identified when 
tagging SNP approach is employed and highlights the limitations of the tagging SNP 
approach to identify the real causal pfSNP in association studies.  
Besides these three pfSNPs in the UMPS gene, a number of other pfSNPs 
were also found to be interesting. The VNTR (rs2853542) polymorphism containing 
the embedded SNP (rs34743033) in the TYMS gene, which was previously associated 
with tumor response and patient survival, was found with a P value of 0.015 and OR 
of 7.6 in “Cohort 1”. There were also 14 different SNPs within the ABCC4 gene 
found to be associated with drug response including the SNP (rs4148485) with the 
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lowest P value in cohort 1. The non-synonymous SNP in the UMPS gene (rs1801019, 
E/3/G638C, G213A) previously found to be associated with UMPS mRNA level, 
UMPS enzyme activity and 5-FU toxicity was found to be associated with drug 
response in “Cohort 2” as well as in the combined cohort. Eight SNPs in the RRM1 
gene were found to be associated with drug response and 2 of them were close to the 
SNP (5UTR/C-37A) which had been associated with gemcitabine drug response in 
CRC patients. When gene set analysis was carried out, the “5-FU and Platinum 
pathway” as a whole was shown to be statistically significant by both GSA-SNP and 
PoDA in cohort 1 which is consistent with the drug regime used. In cohort 2, the 
“5-FU Activator” gene set, which is a subset of the “5-FU PK” pathway, was shown 
to be statistically significant by both methods and highlights the significant role of 
this gene set in determining Capcitabine efficacy. 
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CHAPTER 5: CONCLUSION  
 
This thesis began with building a genome-scale potentially functional SNP 
(pfSNP) database, followed by characterization of the collection of pfSNPs in NCBI 
dbSNP129. It has been shown that these pfSNPs do not overlap with the SNP sets 
from the popular genotyping chips, and may also function as good tagging SNP. The 
tagging efficiency of the pfSNPs was comparable to the Illumina t-SNPs. The 
“pfSNP-centric tagging” SNP set, which comprised polymorphic pfSNPs and 
additional tagging SNPs identified from the genome, may cover the human genome 
more efficiently with a higher r
2
 value compared with the existing Illumina t-SNP set. 
A biologist-friendly web-resource was then built to facilitate the pfSNPs to be used 
for different applications. A gene-based association study, using a pfSNP panel, was 
then carried out to identify pfSNPs associated with anti-cancer drug response in 
metastatic colorectal cancer patients. Three pfSNPs (one non-sense, one 
non-synonymous and one 3‟ UTR SNP that changes miRNA binding) in the UMPS 
gene were found, with one allele unique to the non-responders, and the potential 
molecular functions of these pfSNPs supports the association. These SNPs were in 
low LD with other SNPs in the UMPS gene as well as other SNPs in the 1 Mb 
flanking regions. This shows that using pfSNPs directly may enhance the power of a 
study because they may not be well-covered by other tagging SNPs. Pathway-based 
association analysis using pfSNPs also highlighted the relative importance of the 
“5-FU PK” pathway, as well as its subset “5-FU activator” pathway, in determining 
patient response in different treatment regimens used. 
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5.1 Current gaps in association study and using pfSNP dataset as a 
possible solution 
 
With the abovementioned results, I will discuss the current gaps in association 
study and how the pfSNPs resource may be used to fill in these gaps. 
 
5.1.1 Candidate gene-based association studies 
 
Small sample size and an inadequate marker selection strategy that only 
targets non-synonymous SNPs in candidate gene-based association studies often 
result in difficulties in replicating the identified association (Hirschhorn, Lohmueller 
et al. 2002). In candidate gene-based association studies with a limited number of 
genes, the use of pfSNPs would provide coverage for SNPs in non-coding regions, 
which are proven to be important in determining gene functions. On the other hand, in 
candidate gene-based association studies targeting all the genes in one or more 
relevant of the pathways, the use of pfSNPs may help to reduce genotyping cost and 
multiple testing problems due to the elimination of non-functional SNPs in 
“function-rich” regions (e.g., not all promoter SNPs will change a transcription factor 
binding site). Furthermore, a gene set/pathway-based association analysis may be 
carried out with more power by targeting the causal SNPs directly and generating 
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5.1.2 “Common Disease, Common Variants” hypothesis-based genome-wide 
association studies 
 
The current CDCV hypothesis-based GWAS studies are often inundated with 
the problem of “Missing Heritability” (Manolio, Collins et al. 2009; Eichler, Flint et 
al. 2010) where the markers found to be associated with the phenotype only explain 
part of the heritability observed. The cause of the “Missing Heritability” remains 
unclear. 
In my opinion, the problem of “Missing Heritability” may be partly caused by 
inadequate coverage of common functional SNPs by current genotyping platforms 
due to non-optimal marker selection. For the popular tagging SNP-based GWAS (here 
after referred to as “tagging SNP-centric” approach), the efficiency of a tagging SNP 
to represent the real causal one remain unclear since many factors may influence the 
strength of the marker (Terwilliger and Hiekkalinna 2006) and, under certain extreme 
conditions, the marker may never show sufficient evidence of disease association, 
even with infinite sample sizes (Terwilliger and Hiekkalinna 2006) (Please refer to 
Chapter 1 for more detail). Practically, the popular Illumina t-SNP set is capable of 
covering the entire human genome at an r
2
 value of 0.1 to 0.2, which is too low to be 
considered useful (Pe'er, de Bakker et al. 2006) (Please refer to Chapter 2 for more 
detail). 
Using an alternative to the “tagging SNP-centric” approaches in GWAS has 
been proposed by Risch (Risch 2000) in the form of “gene-centric, non-synonymous 
SNP favoured” approach at the beginning of the new millennium. This approach 
directly cover SNPs prioritized mainly according to the gene region in which they 
reside, with special emphasis on non-synonymous SNPs (Risch and Merikangas 
1996). Risch foresees that the priority may need further refinement if new mechanism 
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of gene function/regulation is found. For example, in year 2000, SNPs in the 5‟UTR 
was thought to be more important in influencing phenotype than the 3‟UTR by Risch 
(Risch 2000) because 5‟ UTR SNPs were more conserved (Halushka, Fan et al. 1999). 
However, with the discovery of miRNAs in 2004 which can regulate several mRNAs 
via its binding to the 3‟UTR, SNPs within the 3‟UTR region is now recognized to 
play more important roles in modulating phenotype.  
The “gene-centric, non-synonymous SNP favoured” strategy may need to be 
further enhanced. The emphasis on “non-synonymous SNPs” may no longer hold true, 
in that more than 80% of association signals in current GWAS are present outside of 
the coding region, despite the over-representation of coding SNPs on these chips 
(Hindorff, Sethupathy et al. 2009; Manolio, Collins et al. 2009). Practically, only one 
GWAS study (Webb, Broderick et al. 2009) actually implemented the “gene-centric, 
non-synonymous SNP only” approach, and it failed to produce any meaningful results. 
Furthermore, new discoveries in gene function and regulation also support the 
inclusion of more functional SNPs from other gene regions. Besides promoter SNPs 
and 3‟UTR SNPs, which are now well-known for their importance in determining 
gene transcription and translation efficiency, synonymous SNPs previously thought to 
be “functionally neutral”, and even intronic SNPs outside the mRNA splicing 
donor/receptor sites, are now recognized to be important in affecting splicing variant 
production and thus gene function. Even the inter-genic regions are no longer 
considered to be pure “junk”, and the HAPMAP ENCODE project discovered that 
most of these “junk” regions are transcribed into RNA (Birney, Stamatoyannopoulos 
et al. 2007). All of these findings support the possibility that causal variants may well 
be present in other non-coding regions and extending the coverage outside the coding 
region may be a sound alternative. 
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As an extension to the “gene-centric, non-synonymous SNP favoured” 
approach, I propose a “pfSNP-centric” approach, which directly targets a set of 
pfSNPs anywhere in the human genome. As with the “gene-centric, non-synonymous 
SNP favoured” approach, the “pfSNP-centric” approach is a form of “direct 
association”. However, the “pfSNP-centric” strategy proposed here attempts to cover 
all of the functional SNPs in different gene regions equally, and the coverage extends 
to inter-genic regions. In the meantime, stringent filters are employed where it is 
possible to control the total number of SNPs included. It may benefit GWAS in three 
ways. First, sufficient coverage in both gene and inter-genic regions will be provided 
so it will be more “genome-wide”. Second, excessive genotyping costs and multiple 
testing problems will be avoided due to the elimination of non-functional SNPs in 
“function-rich” regions. Third, a gene set/pathway-based analysis may be carried out 
with more power by targeting the causal SNPs directly and generating stronger 
association signals.  
Despite all these benefits, the “pfSNP-centric” approach proposed here may 
not be thorough enough to cover all the functional SNPs in the human genome in light 
that our current understanding of the human genome is far from complete. Therefore, 
a “pfSNP-centric tagging” approach, which uses the polymorphic pfSNPs as well as 
additional tagging SNPs identified from the genome, may be more practical for now. 
In Chapter 2, I showed that the polymorphic pfSNPs identified thus far can act as 
good tagging SNPs, with a tagging efficiency that is comparable to the Illumina t-SNP 
set. I also showed that the “pfSNP-centric tagging” SNP set would cover the human 
genome with a higher r
2
 value as compared with the Illumina t-SNP set when the 
same number of markers is used. The increased r
2
 value, ranging from 0.6 to 0.9, 
offered by the “pfSNP-centric tagging” SNP set would lead to higher power to 
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discover causal SNPs and thus provide a possible remedy to the “Missing 
Heritability” problem due to inadequate coverage. 
 
5.1.3 “Common Disease, Rare Variants” hypothesis-based genome wide 
association studies 
 
In a recent interview, experts (Eichler, Flint et al. 2010) acknowledged that 
rare SNPs could play a role in addressing the “Missing Heritability” problem for 
GWAS. The current focus of the field should be, therefore, to find new a statistical 
method to better delineate the additive/multiplicative effects of rare SNPs in the 
statistical analysis process.  
A number of such tests have already been proposed (Morgenthaler and Thilly 
2007; Li and Leal 2008; Madsen and Browning 2009; Hoffmann, Marini et al. 2010; 
Liu and Leal 2010; Makowsky, Pajewski et al. 2011; Cardin, Mefford et al. 2012). A 
popular approach is to combine or “collapse” rare variants by different criteria 
(Morgenthaler and Thilly 2007; Li and Leal 2008; Madsen and Browning 2009; 
Hoffmann, Marini et al. 2010; Cardin, Mefford et al. 2012). This approach is sensitive 
to the misclassification problem, where inclusion of non-functionally important SNPs 
and exclusion of functionally important SNPs would both cause a loss of statistical 
power (Li and Leal 2008; Madsen and Browning 2009; Hoffmann, Marini et al. 2010). 
Therefore, filtering for potentially functional SNPs before collapsing is crucial to its 
success. The Cohort Allelic Sums Test (CAST) utilises Human Gene Mutation 
Database (http://www.hgmd.org/), which stores previously identified disease-related 
SNPs; the Combined Multivariate and Collapsing (CMC) method (Li and Leal 2008), 
in comparison, recommends Polyphen or SIFT for this purpose. However, these tools 
all provide a limited SNP coverage. pfSNPs set may enhance the classification of the 
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SNPs by providing a more complete set of reported, predicted as well as inferred 
functional SNPs both inside and outside the coding region. 
 
5.2 Current applications of the pfSNP web-resource and developing 
of the future pfSNP resource 
 
As discussed in Chapter Three, the current pfSNP web-resource may be used 
for three purposes.  The first is to select SNPs to investigate in a candidate 
gene-based association study (GBAS).  The second purpose would be to analyze 
results obtained from a GWAS study. The third would be to predict, in silico, the 
functional consequences of a SNP to guide experimental investigations. Since the 
third function is straight forward, the following section will review the current 
features of the pfSNP web-resource in facilitating the first two applications and 
discuss the future directions of the pfSNP web-resource development to further 
enhance the functionalities. Moreover, as whole genome sequencing is replacing 
SNP-Chip based GWAS, I will discuss the challenges and future direction of pfSNP 
web-resource development to accommodate the analysis requirement of whole 
genome sequencing. 
 
(i) SNP selection for candidate gene-based association studies (GBAS) 
 Selecting SNPs in candidate genes for study in genetic association 
studies is not easy. Selecting too few SNPs for study, whilst easier from a 
logistics perspective, may increase the risk of omitting the causative SNP. 
Conversely, selecting too many SNPs for a GBAS can have its own set of 
problems including increasing in type II error, where biologically significant 
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SNPs are inadvertently omitted from further study due to a more stringent 
threshold of statistical significance post multiple test correction (Balding 
2006). Genotyping too many SNPs can also add to the cost of the study 
without contributing additional information towards the study question. 
One possible solution to the problem of having too many SNPs for 
GBAS is to use the pfSNP web-resource to filter SNPs according to defined 
criteria, such as potential functionality and minor allele frequency. 
Reported functional SNPs from Online Mendelian Inheritance in Man 
(OMIM) and Genetic Association Database (GAD) are provided in the pfSNP 
web-resource so that researchers can be informed if the SNP has been 
previously studied. In addition, the pfSNP web-resource would allow the 
researcher to identify novel areas of SNP research (predicted to be functional 
using the pfSNP resource) that may be relevant but poorly investigated. 
Furthermore, by using population-specific allele frequency data 
integrated into the pfSNP web-resource, researchers can also identify SNP 
allele frequencies in a population that is most closely related to their 
population of interest. This knowledge will allow researchers to plan aspects 
of the GBAS, such as sample size determination and determining the SNPs to 
genotype depending on whether the researcher is interested in rare or common 
variants.  
The second possible solution to the problem of having too many SNPs 
for GBAS is to select tagging SNPs. Genotyping tagging SNPs for GBAS 
serves to reduce the genotyping costs as a result of genotyping fewer SNPs 
whilst minimizing the loss of statistical power (Balding 2006) for the genetic 
association study. The pfSNP web-resource currently provides a function 
Potentially Functional Single Nucleotide Polymorphisms (pfSNPs) in the Human Genome and their Potential Applications 
148 
called “Alternative pfSNP view” (Figure 5.1) to help identifying pfSNPs to 
tag a list of candidate SNPs for GBAS. This function first distinguishes 
pfSNPs and non-pfSNPs from the list of SNPs. The pfSNPs in the list would 
require no further action. For the non-pfSNPs, pfSNPs in highest LD 
measured by r
2 
are sought as tagging SNPs. The final output, therefore, is a 
list of pfSNPs in the original list as well as the pfSNPs that can tag the 
non-pfSNPs in the original list. The limitation of the current function is that 
the non-pfSNP would not be covered if there is no pfSNP in high LD with it. 
 
 
Figure 5.1: The current function provided in pfSNP web-resource to help 





In the future, the pfSNP web-resource may be further developed to 
enhance its utilization in GBAS. The first is to include more reported 
functional SNPs from the literature. Currently, OMIM is still the major source 
providing SNPs with confirmed biological function. As OMIM only includes 
confirmed causal SNPs, SNPs newly reported in the literature with limited 
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evidence of causality would not be covered by OMIM. With new emerging 
text mining tools, the pfSNP web-resource may use them to identify the 
newly reported SNPs from recently published literature. The second is to 
include SNP allele frequency information from resources such as 1000 
Genomes Project to enhance the SNP allele frequency filter currently limited 
to SNPs genotyped by the HapMap project. The third is to enhance the 
identification of tagging SNP functionality to provide “pfSNP-centric 
tagging” SNPs, where SNPs outside the pfSNP set may be picked as tagging 





(ii) Analyses of results from genome wide association studies (GWAS) 
Annotating tagging SNPs showing significant associations in GWAS 
may be misleading. This is because the tagging SNP showing association may 
not be the actual causative SNP but instead is in high LD with the causative 
SNP. To solve this problem, the “Alternative pfSNP view” function (Figure 
5.1) previously mentioned would be useful. It provides the pfSNPs in high LD 
with the tagging SNP showing significant association so that the association 
may be explained by the pfSNP rather than the tagging SNP without an 
apparent biological function. 
Besides annotating the GWAS results, the researcher may face further 
challenges depending on the threshold of statistical significance (alpha value) 
set and the P values of the SNPs tested for the association. The first challenge 
is that an extensive set of SNPs may be deemed statistically significant for the 
association. The second challenge, on the contrary, is that no SNPs are found 
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to be statistically significantly associated with the phenotype due to the 
stringent threshold set to account for multiple test correction. 
With an extensive set of SNPs showing positive association with the 
phenotype, the pfSNP web-resource can be used to prioritize SNPs for further 
study. The pfSNP web-resource currently provides “SNP Function Category 
Analysis” (Figure 5.2), which displays a function summary for each SNP 
(Figure 5.2, framed in yellow). pfSNPs that are more likely to be functional 
(for example, those with predicted function and found to be associated with 
similar phenotypes in previous GWAS) may be easily prioritized by going 
through this summary. It can also facilitate prioritizing SNPs with specific 
function by providing a detailed filtering utility (Figure 5.2, framed in red). 
In the near future, more quantitative analytical features can be built into the 
“SNP Function Category Analysis”. For example, Fisher‟s exact test can be 
used to detect if the SNPs in the list are enriched in a specific function 
category. A 2X2 contingency table can be used to tabulate the number of 
SNPs in four categories, namely (1) “In the SNP list with the specific 
function”, (2) “In the SNP list without the specific function”, (3) “Not in the 
SNP list but with the specific function” and (4) “Not in the SNP list and 
without the specific function”. Fisher‟s exact test can then be applied to the 
contingency table and a P-value less than 0.05 in the Fisher‟s exact test can 
signify the SNPs in the list is enriched in the specific function category. 
In contrast, if there were no SNPs found to be statistically significantly 
associated with the phenotype in a GWAS, the alpha value could be increased 
so as to yield a group of SNPs with small to moderate effect sizes. From this 
group of SNPs, pathway-based prioritization available in specialized web 
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resources, such as GesBaP (Medina, Montaner et al. 2009) or iGSEA4GWAS 
(Zhang, Cui et al. 2010), can be applied to determine if the group of SNPs 
generated after raising the alpha value is enriched in certain pathways and 
therefore the association observed is less likely to be spurious. Currently, the 
pfSNP and similar web-resources do not have any feature to support 
pathway-based prioritization as yet, and such a facility would be desirable in 
the future build. 
 
Figure 5.2: The “SNP function category analysis” can help to prioritize 
SNPs that are more likely to be functional or to filter for SNPs belonging 
to specific function category. Framed in yellow is the link to display the function 
summary for the list of SNPs. Framed in red are the filters that can be applied individually or 
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(iii) Challenges and future directions in analyzing whole genome 
sequencing results 
As whole genome sequencing technology improves, new challenges in 
the development of pfSNP web-resource emerge. These challenges are largely 
related to technical gaps, such as the capacity of the pfSNP web-resource to 
handle large volumes of data, and gaps in the development of tools to analyze 
whole genome sequencing results within a biologically meaningful context. 
With the increasing amount of sequencing data generated, the demand 
for storing, analyzing and sharing SNP genotype data also grows. 
Unfortunately, the pfSNP web-resource and other similar resources are not 
able to handle the raw data without heavy investment in storage capacity. The 
large amount of data, together with the increased complexity of data analysis, 
would also demand a higher computing power to efficiently carry out the data 
analysis. One of the solutions to these problems might be cloud computing, 
which features essentially unlimited online storage and analytical power 
(2010; Stein 2010). Recent tools like “Cloud BioLinux” (Krampis, Booth et al. 
2012) and “CloVR” (Angiuoli, Matalka et al. 2011) are already providing 
cloud enabled, virtual machine based solutions to the raw data handling and 
analysis challenges. I foresee similar solutions can be applicable to pfSNP 
web-resource where a bootable virtual machine image can be distributed in 
the cloud and used on-demand by the user. However, using cloud computing 
to store and analyze SNP data is still in its infancy with a limiting factor in 
slow data transfer rate provided by the current internet. 
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Besides these technical challenges faced by the pfSNP web resource, 
the complexity of the human genome may pose an even bigger challenge to 
the making of a successful SNP analytical resource. 
We have a long way to go in our understanding of SNP architecture in 
the human genome. Many SNPs have yet to be discovered, as reflected in the 
observation that more than 2.7 million new SNPs are reported in the latest 
dbSNP 137 release 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi). 
We also know too little about the human genome in terms of pathways 
and/or regulation mechanisms that have yet to be discovered. Hirschhorn et al. 
(Hirschhorn 2009) pointed out that the real benefits of performing GWAS 
studies has been the illumination of novel pathways. The discovery of micro 
RNAs‟ impact on mRNA level (Zeng, Wagner et al. 2002) in 2002 further 
indicates that there may be other mechanisms affecting gene regulation yet to 
be discovered. However, current SNP function prediction tools were 
developed and trained on the basis of the current knowledge of known 
biological mechanisms. Hence, using current prediction tools may result in 
false negatives; that is, SNPs which have been deemed in silico as 
non-functional but are, in reality, functional in vivo. Therefore, there is a need 
for the pfSNP web-resource that can rapidly keep pace with current 
developments in biology and readily incorporate new tools.  
One stark observation made since the advent of GWAS studies has 
been the relatively little success of GWAS in finding high-risk SNPs that can 
account for a large proportion of phenotypic differences (Moore 2003; Eichler, 
Flint et al. 2010). This observation has been particularly pertinent to complex 
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phenotypes. Current tools for GWAS analysis are not able to adequately 
analyze the genotype-complex phenotype relationships within a holistic 
biologically relevant framework that considers SNP-SNP and gene-gene 
interactions, as well as gene-environmental interactions. This problem is more 
severe in whole genome sequencing results analysis where the possible 
number of interactions is prohibitively large. Future analytical tools should 
consider incorporating prior biological knowledge about the SNP and gene 
pathway in which the SNP lies into the algorithm (Moore, Asselbergs et al. 
2010). 
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Supplementary Table 1: The list of all the SNPs included on the GoldenGate array 
 
# rsNo Gene mRNA Location AA Change 
1 rs10046 CYP19A1 E10/3UTR /G19A -- 
2 rs1010167 GSTM4 E/1/C-285G -- 
3 rs1041983 NAT2 E/2/C282T Y94Y 
4 rs1042522 TP53 E/4/G215C P72R 
5 rs1042636 CASR E/7/A2968G R990G 
6 rs1047840 EXO1 E/12/G1765A E589K 
7 rs1048572 SMARCE1 I/4/A1465G -- 
8 rs10493895 DPYD I/3/A22444C -- 
9 rs10502975 DCC I/20/C1225G -- 
10 rs10508022 ABCC4 I/19/T11361C -- 
11 rs1051266 SLC19A1 E/2/T80C H27R 
12 rs10513348 HLTF I/23/G975A -- 
13 rs10515959 DCC I/15/G-19191T -- 
14 rs1052555 ERCC2 E/22/G2133A D711D 
15 rs1052748 PLD2 E/17/C1730T T577I 
16 rs1056836 CYP1B1 E/3/C1294G -- 
17 rs1057910 CYP2C9 E/7/A1075C I359L 
18 rs1059234 CDKN1A E3/3UTR /C20T -- 
19 rs10875053 DPYD I/20/C21659G -- 
20 rs10903118 RUNX3 5UR//T-3376C -- 
21 rs10934683 UMPS I/1/C-557T -- 
22 rs10947623 CDKN1A 5UR//G-3650A -- 
23 rs11202592 PTEN E/1/C-9G -- 
24 rs1143627 IL1B 5UR//G-30A -- 
25 rs1145231 PMS1 E/9/T1181C M394T 
26 rs11545078 GGH E/5/G452A T151I 
27 rs11549467 HIF1A E/12/G1762A A588T 
28 rs11569017 EGF E/15/A2351T D784V 
29 rs11615 ERCC1 E/3/A354G N118N 
30 rs11664579 WDR7 I/13/A323G -- 
31 rs12052058 SMARCA4 I/30/G7289T -- 
32 rs12052201 SMARCA4 I/30/G6860T -- 
33 rs1208 NAT2 E/2/G803A R268K 
34 rs1234213 PTEN I/3/G-1482A -- 
35 rs12458289 BCL2 3DR//G6601T -- 
36 rs12917 MGMT E/5/C250T L84F 
37 rs12954274 DCC I/14/C-209T -- 
38 rs1314 UPB1 E10/3UTR /T690G -- 
39 rs131794 TYMP 5UR//A-3296C -- 
40 rs13181 ERCC2 E/23/T2251G K751Q 
41 rs1367634 DCC I/14/T-1415G -- 
42 rs1381547 BCL2 3DR//T27848C -- 
43 rs1402001 ABCC5 3DR//A58790G -- 
44 rs16260 CDH1 5UR//C-160A -- 
45 rs1650697 DHFR E/1/A-473G -- 
46 rs1657396 WDR7 E27/3UTR /T1969C -- 
Potentially Functional Single Nucleotide Polymorphisms (pfSNPs) in the Human Genome and their Potential Applications 
168 
 
47 rs1657415 WDR7 I/25/G19951A -- 
48 rs16950632 ABCC4 I/20/G6290A -- 
49 rs17189467 ABCC4 I/4/A-1931T -- 
50 rs17217716 MSH2 E/1/C23T T8M 
51 rs17217772 MSH2 E/3/A380G N127S 
52 rs17224367 MSH2 E/7/C1168T L390F 
53 rs17630758 SMARCB1 I/3/G667A -- 
54 rs17655 ERCC5 E/15/G3310C D1104H 
55 rs17756073 BCL2 3DR//A175404G -- 
56 rs1787479 WDR7 I/25/C-24771G -- 
57 rs1799782 XRCC1 E/6/G580A R194W 
58 rs1799794 XRCC3 E/2/T-315C -- 
59 rs1799930 NAT2 E/2/G590A R197Q 
60 rs1800371 TP53 E/4/G139A P47S 
61 rs1800566 NQO1 E/5/G445A P149S 
62 rs1800734 MLH1 5UR//G-32A -- 
63 rs1800975 XPA E/1/T-4C -- 
64 rs1801126 OGG1 E/1/G-18T -- 
65 rs1801131 MTHFR E/8/T1286G E429A 
66 rs1801133 MTHFR E/5/G665A A222V 
67 rs1801158 DPYD E/13/C1601T S534N 
68 rs1801166 APC E/16/G3949C E1317Q 
69 rs1801265 DPYD E/2/G85A C29R 
70 rs1801268 DPYD E/23/C2983A V995F 
71 rs1801270 CDKN1A E/2/C93A S31R 
72 rs1804197 APC E16/3UTR /C86A -- 
73 rs1810132 ERBB2 I/4/C-61T -- 
74 rs1811086 TK1 I/4/G-1323A -- 
75 rs1860460 PMS2 5UR//G-4548A -- 
76 rs1922242 ABCB1 I/17/A-76T -- 
77 rs1926657 ABCC4 I/4/T11908C -- 
78 rs1950902 MTHFD1 E/6/A401G R134K 
79 rs1979277 SHMT1 E/11/G1303A L435F 
80 rs2020873 MLH1 E/19/C2152T H718Y 
81 rs2020911 MSH6 I/5/A14T -- 
82 rs2020912 MSH6 E/4/T2633C V878A 
83 rs2066109 SMARCA2 I/23/T-1115C -- 
84 rs2066518 SMARCAL1 E/5/G1129C G377R 
85 rs2072671 CDA E/1/A79C K27Q 
86 rs2073390 SMARCB1 I/1/G-373A -- 
87 rs2078486 TP53 I/1/G-3143A -- 
88 rs2083020 WDR7 I/20/A20363G -- 
89 rs2227306 IL8 I/1/C-204T -- 
90 rs2227311 RB1 I/17/A31453G -- 
91 rs2228001 XPC E/16/G2818T L940M 
92 rs2228527 ERCC6 E/18/T3637C R1213G 
93 rs2229080 DCC E/3/C601G R201G 
94 rs2229992 APC E/12/T1458C Y486Y 
95 rs2229995 APC E/16/G7504A G2502S 
96 rs2231142 ABCG2 E/5/G421T Q141K 
97 rs2233919 SMUG1 E/3/G7A Q3* 
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98 rs2234978 FAS E/6/T579C T193T 
99 rs2235035 ABCB1 I/14/G81A -- 
100 rs2236722 CYP19A1 E/2/A115G W39R 
101 rs2243115 IL12A 5UR//T-348G -- 
102 rs2244500 TYMS I/2/A-1141G -- 
103 rs2250889 MMP9 E/10/G1721C R574P 
104 rs2270951 DCC I/21/C127T -- 
105 rs2274976 MTHFR E/12/C1781T R594Q 
106 rs2277448 ATP7B E/1/G-75T -- 
107 rs2278495 WDR7 I/25/G-163A -- 
108 rs2279115 BCL2 5UR//G-223T -- 
109 rs2289310 DLG5 E/23/G4442T P1481Q 
110 rs2299939 PTEN I/2/C3284A -- 
111 rs2302323 PLD2 E/25/G2702A G901D 
112 rs2303428 MSH2 I/12/T-6C -- 
113 rs2308321 MGMT E/7/A427G S143P 
114 rs2308327 MGMT E/7/A533G G178E 
115 rs2355164 UPP2 I/2/C27144T -- 
116 rs2376311 SMARCA2 I/25/G666A -- 
117 rs238406 ERCC2 E/6/T468G R156R 
118 rs240993 REV3L I/18/T-720C -- 
119 rs243865 MMP2 5UR//C-1281T -- 
120 rs2517954 ERBB2 5UR//T-12703C -- 
121 rs2517955 ERBB2 5UR//C-12572T -- 
122 rs2517956 ERBB2 5UR//G-12394A -- 
123 rs25487 XRCC1 E/10/T1196C R399Q 
124 rs25489 XRCC1 E/9/C839T R280H 
125 rs25496 XRCC1 E/3/A215G V72A 
126 rs2660744 PPAT E/11/G1462A Q488* 
127 rs2665797 SMARCD2 5UR//G-2133C -- 
128 rs2735343 PTEN I/5/G-6446C -- 
129 rs28366003 MT2A 5UR//A-19G -- 
130 rs28399504 CYP2C19 E/1/A1G M1V 
131 rs2853741 TYMS 5UR//T-298C -- 
132 rs28756987 MLH3 E/2/G1939A R647C 
133 rs3092856 ATM E/2/C94T H32Y 
134 rs3136367 MSH6 I/8/C-40G -- 
135 rs3136788 POLB I/11/A-2634G -- 
136 rs3136797 POLB E/12/C725G P242R 
137 rs3176734 XPA I/5/G-2522A -- 
138 rs3212931 ERCC1 5UR//G-137T -- 
139 rs3218599 REV3L E/13/C5434G D1812H 
140 rs3219090 PARP1 I/13/T118C -- 
141 rs34035085 UPB1 E/2/C254A A85E 
142 rs34136999 MSH2 E/5/C815T A272V 
143 rs34213726 MLH1 E/12/A1327C K443Q 
144 rs34330 CDKN1B E/1/T-79C -- 
145 rs34374438 MSH6 E/4/A2561T K854M 
146 rs34986638 MSH2 E/14/G2422T E808* 
147 rs35001569 MLH1 E/16/A1852G K618E 
148 rs35032294 MLH1 5UR//C-208G -- 
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149 rs35045067 MLH1 E/17/A1937G Y646C 
150 rs351855 FGFR4 E/9/G1162A G388R 
151 rs35917308 PTEN E/4/C234T P78P 
152 rs3731249 CDKN2A E/2/C442T A148T 
153 rs3732183 MSH2 I/10/G12A -- 
154 rs3738888 BARD1 E/10/G1972A R658C 
155 rs3740066 ABCC2 E/28/C3972T I1324I 
156 rs3744951 BCL2 3DR//T59207C -- 
157 rs3749441 ABCC5 3DR//C40735G -- 
158 rs3755319 UGT1A1 5UR//A-1336C -- 
159 rs3758149 GGH 5UR//G-341A -- 
160 rs3758581 CYP2C19 E/7/G991A I331V 
161 rs3764496 DCC I/15/T-61C -- 
162 rs3789243 ABCB1 I/4/A4196G -- 
163 rs3790674 UCK2 I/5/A1103G -- 
164 rs3792582 ABCC5 3DR//A6939G -- 
165 rs3793784 ERCC6 5UR//G-466C -- 
166 rs3794917 DCC I/16/G-1683T -- 
167 rs3794922 DCC I/16/G1739A -- 
168 rs3803185 ARL11 E/2/T442C C148R 
169 rs3805112 ABCC5 3DR//C55879T -- 
170 rs3808607 CYP7A1 5UR//G-202T -- 
171 rs3817672 TFRC E/4/C424T S142G 
172 rs3918290 DPYD I/14/C1T -- 
173 rs4105144 CYP2A6 5UR//T-2283C -- 
174 rs41294980 MLH1 E/12/G1217A S406N 
175 rs41295278 MSH6 E/9/A3961G R1321G 
176 rs4150001 EXO1 E/14/G2276A G759E 
177 rs4150521 ERCC3 E/14/G2111A S704L 
178 rs41549115 ERCC2 E/2/G72A Y24Y 
179 rs42427 APC E/16/G5034A G1678G 
180 rs4246514 DPYD I/2/C-3979G -- 
181 rs4253038 ERCC6 I/3/A-408G -- 
182 rs4253208 ERCC6 E/18/G3284C P1095R 
183 rs4372296 DPYD I/2/C-26740A -- 
184 rs4379706 DPYD I/2/C26441T -- 
185 rs4421623 DPYD I/2/T-22533G -- 
186 rs4516035 VDR 5UR//T-1011C -- 
187 rs459552 APC E/16/T5465A V1822D 
188 rs4645878 BAX 5UR//A-178G -- 
189 rs465899 APC E/16/G5880A P1960P 
190 rs4673 CYBA E/4/A214G Y72H 
191 rs4773866 ABCC4 I/1/C24169T -- 
192 rs4775936 CYP19A1 I/1/C-875T -- 
193 rs4986783 NAT1 E/3/T640G S214A 
194 rs4986909 CYP3A4 E/11/G1247A P416L 
195 rs4986913 CYP3A4 E/12/G1399A P467S 
196 rs4987188 MSH2 E/6/G965A G322D 
197 rs527912 CDA I/2/G2751A -- 
198 rs532545 CDA 5UR//C-271T -- 
199 rs56131651 ABCC2 E/7/-842- -- 
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200 rs6413420 CYP2E1 5UR//G-37T -- 
201 rs6413438 CYP2C19 E/5/C680T P227L 
202 rs6566846 WDR7 I/21/T-2912G -- 
203 rs6593634 DPYD I/20/A23413C -- 
204 rs6665429 DPYD I/14/C-5602T -- 
205 rs671 ALDH2 E/12/G1510A E504K 
206 rs6759948 UPP2 I/2/A17195G -- 
207 rs689466 PTGS2 5UR//T-1194C -- 
208 rs717620 ABCC2 E/1/C-24T -- 
209 rs7234941 BCL2 3DR//C62336T -- 
210 rs7336051 ABCC4 I/1/C-26424T -- 
211 rs7439366 UGT2B7 E/2/T802C H268Y 
212 rs762551 CYP1A2 I/1/C-154A -- 
213 rs7646621 ABCC5 3DR//G60676T -- 
214 rs7993619 ABCC4 I/19/A698C -- 
215 rs7996205 ABCC4 3DR//G66320A -- 
216 rs8082807 DCC I/25/A-2265C -- 
217 rs8094838 WDR7 I/21/A532G -- 
218 rs8187699 ABCC2 E/27/A3817G T1273A 
219 rs8187710 ABCC2 E/32/G4544A C1515Y 
220 rs861539 XRCC3 E/7/G722A T241M 
221 rs869224 DCC I/23/A766G -- 
222 rs886205 ALDH2 E/1/A-360G -- 
223 rs887829 UGT1A1 5UR//C-348T -- 
224 rs945881 DPYD I/13/G-29513A -- 
225 rs955850 DPYD I/14/T-9744C -- 
226 rs9651118 MTHFR I/2/T724C -- 
227 rs965943 DCC I/14/A-8653G -- 
228 rs9807370 DCC I/21/G719A -- 
229 rs9946253 WDR7 I/18/A-2783C -- 
230 rs9950970 DCC I/14/T-2275C -- 
231 rs10041507 SLCO6A1 I/3/T220C -- 
232 rs10041525 SLCO6A1 I/3/T142C -- 
233 rs1005793 BCL2 3DR//A95027G -- 
234 rs10062613 SLCO6A1 I/11/C702T -- 
235 rs10073892 SLCO6A1 I/10/T-21C -- 
236 rs10081796 SLC31A1 I/1/C16220G -- 
237 rs1011019 ERCC3 I/9/A463G -- 
238 rs10124350 SMARCA2 I/23/A-2552G -- 
239 rs10162199 ABCC4 I/11/C878T -- 
240 rs10186677 UPP2 E/7/A462C A154A 
241 rs10204779 UPP2 I/2/G7261A -- 
242 rs10276036 ABCB1 I/10/C-44T -- 
243 rs1042040 PPAT E11/3UTR /C1220G -- 
244 rs10503079 BCL2 3DR//C72821T -- 
245 rs10505058 DPYS I/7/A4947G -- 
246 rs10513190 SLC31A1 I/1/C9965T -- 
247 rs1062472 ATP7A E23/3UTR /T1960C -- 
248 rs10747486 DPYD I/3/A39932G -- 
249 rs10757122 SMARCA2 I/1/T-4348C -- 
250 rs10757185 SMARCA2 I/26/G1836T -- 
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251 rs10757188 SMARCA2 I/26/T-939C -- 
252 rs10757211 SMARCA2 I/27/T12883G -- 
253 rs10783069 DPYD I/10/G-6470C -- 
254 rs10811481 SMARCA2 I/27/C203T -- 
255 rs10811504 SMARCA2 I/27/T5807C -- 
256 rs10811515 SMARCA2 I/27/T8841C -- 
257 rs10875098 DPYD I/10/T-2194C -- 
258 rs10964466 SMARCA2 I/1/A-45G -- 
259 rs10964500 SMARCA2 I/3/A1359C -- 
260 rs10964921 SMARCA2 I/27/G8243A -- 
261 rs10965088 SMARCA2 I/28/G-9017A -- 
262 rs10981699 SLC31A1 I/1/C11943T -- 
263 rs11097408 SMARCAD1 I/6/T3505C -- 
264 rs11202600 PTEN I/2/G-2437C -- 
265 rs11202607 PTEN E9/3UTR /C2185T -- 
266 rs11241185 APC I/4/G3971A -- 
267 rs1125205 SMARCA2 I/4/A-2508G -- 
268 rs1132776 ABCC5 3DR//A5139G -- 
269 rs11579252 CDA I/2/A2681G -- 
270 rs11665624 WDR7 I/25/G-27842A -- 
271 rs11714840 SMARCC1 I/10/G800C -- 
272 rs11746217 SLCO6A1 I/4/A-9G -- 
273 rs118202 REV3L I/21/G-1558T -- 
274 rs11864810 CES1 5UR//T-2652G -- 
275 rs11872907 WDR7 I/13/C4188T -- 
276 rs11876256 WDR7 I/14/T9751A -- 
277 rs11877604 WDR7 I/12/C-2229T -- 
278 rs11879293 SMARCA4 I/1/G760A -- 
279 rs1202168 ABCB1 I/7/G139A -- 
280 rs12045999 DPYD I/14/C7624T -- 
281 rs12121543 MTHFR I/7/C-76A -- 
282 rs1234224 PTEN I/2/A-9974G -- 
283 rs1234225 PTEN I/2/C-11701T -- 
284 rs12345640 SMARCA2 I/27/T13816C -- 
285 rs12380390 SMARCA2 I/5/A-1218G -- 
286 rs12467193 UPP2 5UR//C-3548T -- 
287 rs12511433 SMARCAD1 I/6/G268A -- 
288 rs12571445 ERCC6 I/5/A-8125G -- 
289 rs12610607 SMARCA4 I/1/A-9803G -- 
290 rs12634398 ABCC5 I/2/A-1234G -- 
291 rs12677953 GGH I/7/C-100A -- 
292 rs12921111 ERCC4 5UR//G-4199A -- 
293 rs13090196 HLTF I/23/C902G -- 
294 rs13190449 SLCO6A1 E/1/G80A A27V 
295 rs1333717 DPYD I/3/G29092A -- 
296 rs13425206 MSH2 I/6/G-2037T -- 
297 rs1370216 WDR7 I/26/G736A -- 
298 rs1383596 BCL2 3DR//C76325A -- 
299 rs1437069 WDR7 I/25/T-14715C -- 
300 rs1437135 NQO1 I/1/A2508G -- 
301 rs1452057 SLCO6A1 I/6/A4781G -- 
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302 rs1476413 MTHFR I/10/C35T -- 
303 rs1520025 PPAT I/1/G1024A -- 
304 rs1542005 WDR7 I/20/G8005A -- 
305 rs1562961 SLCO6A1 I/10/A-2493G -- 
306 rs1617844 ABCC4 I/8/G651A -- 
307 rs1657410 WDR7 I/25/A-20153G -- 
308 rs1657421 WDR7 I/25/C29064T -- 
309 rs16851444 UCK2 I/1/T10643G -- 
310 rs16861365 HLTF E/15/T1506C V502V 
311 rs16930959 SLC31A1 I/1/A-6936G -- 
312 rs16937154 SMARCA2 I/9/T-3581A -- 
313 rs17017854 SMARCA5 I/14/G865C -- 
314 rs17070841 BCL2 3DR//T87993C -- 
315 rs17070861 BCL2 3DR//T78707G -- 
316 rs17086746 PPAT E11/3UTR /C1519T -- 
317 rs17086758 PPAT I/1/T-6672C -- 
318 rs17107001 PTEN I/3/G1195T -- 
319 rs17139614 ATP7A E23/3UTR /G2241C -- 
320 rs17139617 ATP7A I/12/C-882A -- 
321 rs17189481 ABCC4 I/4/C4542T -- 
322 rs17300865 ABCC4 I/4/G4340A -- 
323 rs17431184 PTEN I/7/T-400C -- 
324 rs17471125 DPYD I/21/T-5102C -- 
325 rs1751021 ABCC4 I/8/C-2406T -- 
326 rs1751029 ABCC4 I/8/A728G -- 
327 rs17757541 BCL2 3DR//C105501G -- 
328 rs17775180 ERCC6 I/8/C2846A -- 
329 rs17785248 SMARCC1 I/24/A3765G -- 
330 rs1787462 WDR7 I/25/A-28222G -- 
331 rs1787463 WDR7 I/25/A-28121G -- 
332 rs1787468 WDR7 I/25/C-27977T -- 
333 rs1787475 WDR7 E27/3UTR /A1061G -- 
334 rs1800668 GPX1 E/1/G-46A -- 
335 rs1807999 BCL2 3DR//C83015G -- 
336 rs184026 SMARCAL1 I/14/C642T -- 
337 rs1871446 CDC2 E6/3UTR/A30G -- 
338 rs1886261 SMARCA2 I/28/A-7981G -- 
339 rs1893806 BCL2 3DR//C223A -- 
340 rs1901512 SLCO6A1 I/12/T517C -- 
341 rs1901521 SLCO6A1 I/9/G1986T -- 
342 rs1901522 SLCO6A1 I/9/T5068G -- 
343 rs1914 APC I/8/A-6748T -- 
344 rs1931063 DPYD I/3/C30060T -- 
345 rs1962292 SMARCA2 I/24/A164G -- 
346 rs1962293 SMARCA2 I/24/T327C -- 
347 rs2001776 SMARCA2 I/26/G1290A -- 
348 rs2002042 ABCC2 I/19/C-2133T -- 
349 rs2065943 DPYD I/8/T-10704C -- 
350 rs2066462 MTHFR E/7/G1056A S352S 
351 rs2139512 PPAT I/1/G-2737C -- 
352 rs2214102 ABCB1 E/3/T-1C -- 
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353 rs2233913 SLC31A1 5UR//T-651C -- 
354 rs2235046 ABCB1 I/17/T73C -- 
355 rs2235048 ABCB1 I/27/G80A -- 
356 rs2235074 ABCB1 I/4/G36A -- 
357 rs2270860 SLC22A7 E/7/C1269T S423S 
358 rs2271937 ABCC5 3DR//G18581A -- 
359 rs2273697 ABCC2 E/10/G1249A V417I 
360 rs2280392 ABCC5 3DR//A35799G -- 
361 rs2281793 ERCC6 I/5/C4537T -- 
362 rs2281794 ERCC6 I/5/T3659C -- 
363 rs2282011 UCK1 I/2/G-444A -- 
364 rs2293001 ABCC5 3DR//C1330T -- 
365 rs2299941 PTEN I/5/A-7156G -- 
366 rs2306802 SMARCAD1 E/10/A1479G Q493Q 
367 rs232054 RRM1 I/2/C116G -- 
368 rs2343614 REV3L I/9/G-2511A -- 
369 rs240954 REV3L I/21/G-3009A -- 
370 rs240955 REV3L I/21/G-3830A -- 
371 rs240991 REV3L I/20/C2247G -- 
372 rs240995 REV3L I/18/T1704C -- 
373 rs2431238 APC I/6/T-3774C -- 
374 rs2464803 APC I/7/A3561G -- 
375 rs2464805 APC I/2/C-230A -- 
376 rs2520464 ABCB1 I/5/C-1547T -- 
377 rs2545162 APC I/11/G743A -- 
378 rs2546106 APC I/8/C-5931A -- 
379 rs2546108 APC I/11/C-1336A -- 
380 rs2546110 APC I/11/A-392G -- 
381 rs2576415 WDR7 I/19/T-30795A -- 
382 rs2622604 ABCG2 I/1/T614C -- 
383 rs2661681 TK1 I/5/C-4T -- 
384 rs2707763 APC I/4/T-2461C -- 
385 rs2723877 TDG I/1/T-1570C -- 
386 rs2727280 SMARCD2 I/1/A1737G -- 
387 rs2735691 RRM1 I/1/C1448G -- 
388 rs2786498 DPYD I/8/G-6425A -- 
389 rs284564 SMARCAL1 I/4/T1088A -- 
390 rs2848968 WDR7 I/25/G-20982A -- 
391 rs2854510 XRCC1 I/2/A4850G -- 
392 rs2909787 APC I/14/G-2518C -- 
393 rs2952615 APC I/8/G1808C -- 
394 rs3136748 POLB I/5/C1214T -- 
395 rs3176658 XPA I/2/A-1942G -- 
396 rs3176750 XPA E/6/G754C L252V 
397 rs3212106 XRCC3 I/6/T-292C -- 
398 rs3212121 XRCC3 E10/3UTR /T613C -- 
399 rs3213255 XRCC1 I/2/G1555A -- 
400 rs3213356 XRCC1 I/4/C-404T -- 
401 rs351771 APC E/14/G1635A A545A 
402 rs3740065 ABCC2 I/29/A154G -- 
403 rs3745041 WDR7 I/13/C-199T -- 
Potentially Functional Single Nucleotide Polymorphisms (pfSNPs) in the Human Genome and their Potential Applications 
175 
 
404 rs3749443 ABCC5 3DR//C62218T -- 
405 rs3750417 SMARCA2 I/5/C-188T -- 
406 rs3750748 ERCC6 I/5/C2665T -- 
407 rs3750749 ERCC6 I/12/A33G -- 
408 rs3758395 ABCC2 I/26/T154C -- 
409 rs3774341 MLH1 I/3/A-659C -- 
410 rs3780128 GGH I/3/T-1214C -- 
411 rs3782964 ABCC4 I/4/C-430T -- 
412 rs3785911 ABCC3 I/30/A-1022C -- 
413 rs3786362 TYMS E/3/A381G I127I 
414 rs3789244 ABCB1 I/10/G1228T -- 
415 rs3790661 UCK2 I/4/T2927C -- 
416 rs3792584 ABCC5 3DR//T17631C -- 
417 rs3793499 SMARCA2 I/27/C8053G -- 
418 rs3805109 ABCC5 3DR//G11276A -- 
419 rs3808830 UCK1 5UR//C-1778T -- 
420 rs3810915 SLC31A1 5UR//A-2096G -- 
421 rs3810944 ERCC6 I/19/A236G -- 
422 rs3817403 ABCC5 3DR//A18396G -- 
423 rs3829070 SMARCA2 I/26/T-80C -- 
424 rs3829072 SMARCA2 I/27/G3859A -- 
425 rs3829073 SMARCA2 I/27/T3946C -- 
426 rs3829300 TDG I/2/A12G -- 
427 rs390092 APC I/8/T-4995G -- 
428 rs4135082 TDG I/1/T-1409C -- 
429 rs4135087 TDG I/2/C387T -- 
430 rs4135094 TDG I/2/T-147C -- 
431 rs4148328 UGT1A1 I/4/C574T -- 
432 rs4148432 ABCC4 I/1/C-13075T -- 
433 rs4148469 ABCC4 I/4/A-323G -- 
434 rs4148485 ABCC4 I/9/G-2464A -- 
435 rs4148568 ABCC5 I/2/C9031T -- 
436 rs4148575 ABCC5 E7/3UTR /A447G -- 
437 rs4148580 ABCC5 3DR//T16358C -- 
438 rs4148584 ABCC5 3DR//A24040C -- 
439 rs4148594 ABCC5 3DR//T61157C -- 
440 rs4148738 ABCB1 I/21/C-2236T -- 
441 rs4150402 ERCC3 I/3/T52C -- 
442 rs4150456 ERCC3 E/9/C1485T E495E 
443 rs4150471 ERCC3 I/10/A2210G -- 
444 rs4253055 ERCC6 I/5/A3752G -- 
445 rs4253060 ERCC6 I/5/C4292T -- 
446 rs4253095 ERCC6 I/5/A-1137G -- 
447 rs4253101 ERCC6 I/6/T871G -- 
448 rs4253121 ERCC6 I/7/G1597A -- 
449 rs4253126 ERCC6 I/7/G-892T -- 
450 rs4253138 ERCC6 I/8/C828T -- 
451 rs4253165 ERCC6 I/9/C-128T -- 
452 rs4253166 ERCC6 I/10/T716G -- 
453 rs4303338 ABCC4 I/4/C10763G -- 
454 rs4373572 SMARCA2 I/27/A632G -- 
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455 rs4537601 DPYD I/3/G-27495C -- 
456 rs453776 REV3L I/21/T1665C -- 
457 rs454886 APC I/8/A-5075G -- 
458 rs455645 REV3L E/13/C4485T S1495S 
459 rs455650 REV3L I/13/C2276T -- 
460 rs460594 REV3L I/20/C616G -- 
461 rs461646 REV3L E/13/G3301A L1101L 
462 rs4641140 SLC31A1 I/1/A1629G -- 
463 rs4664236 UPP2 I/2/T17318G -- 
464 rs4664920 UPP2 I/2/G7182A -- 
465 rs4741637 SMARCA2 I/5/C3248G -- 
466 rs4741638 SMARCA2 I/5/A3360T -- 
467 rs4741640 SMARCA2 I/6/A-780C -- 
468 rs4773854 ABCC4 I/4/G7454A -- 
469 rs4940574 BCL2 3DR//G147343C -- 
470 rs4941189 BCL2 3DR//C77260T -- 
471 rs4970728 DPYD I/4/G3787C -- 
472 rs4987770 BCL2 3DR//C80832T -- 
473 rs4987802 BCL2 3DR//C140464G -- 
474 rs562 ABCC5 3DR//T63696C -- 
475 rs614080 GSTP1 5UR//G-3998A -- 
476 rs628959 DPYD I/18/C31955T -- 
477 rs6437129 UPP2 I/2/A-7469G -- 
478 rs6475506 SMARCA2 I/27/G2301A -- 
479 rs6475507 SMARCA2 I/27/A3532T -- 
480 rs6475511 SMARCA2 I/27/T4991G -- 
481 rs6475514 SMARCA2 I/27/G5170C -- 
482 rs6475520 SMARCA2 I/27/A6891G -- 
483 rs6475524 SMARCA2 I/27/A7597G -- 
484 rs6567334 BCL2 3DR//A67807C -- 
485 rs6683957 DPYD I/4/A5229G -- 
486 rs6768699 SMARCC1 I/8/A-450G -- 
487 rs6790814 ABCC5 3DR//C44735G -- 
488 rs6806313 ABCC5 3DR//G59389C -- 
489 rs6854326 PPAT I/1/T-2027C -- 
490 rs6873738 SLCO6A1 I/12/A7020C -- 
491 rs6877722 SLCO6A1 I/12/G-738T -- 
492 rs6884141 SLCO6A1 E/2/G393A G131G 
493 rs6915753 REV3L I/1/T-4004C -- 
494 rs6922226 REV3L I/4/A2189G -- 
495 rs6935759 REV3L I/1/G25233A -- 
496 rs6942129 REV3L I/1/T-25945C -- 
497 rs6949448 ABCB1 I/26/T2733C -- 
498 rs6961665 ABCB1 I/10/C-1264A -- 
499 rs699937 POLH 5UR//G-3018A -- 
500 rs699937 XPO5 I/2/G291A -- 
501 rs7021817 SMARCA2 I/27/A16224G -- 
502 rs7033529 SMARCA2 I/27/A1164G -- 
503 rs7035071 SMARCA2 I/14/T1474C -- 
504 rs7035608 SMARCA2 I/9/C3521T -- 
505 rs7035898 SMARCA2 I/9/C3809T -- 
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506 rs7040174 SMARCA2 I/24/A-1116C -- 
507 rs7040968 SMARCA2 I/27/G-12720A -- 
508 rs7048496 SMARCA2 I/27/C1294A -- 
509 rs7048976 SMARCA2 I/28/G-8275T -- 
510 rs7073830 ERCC6 I/7/G-1932A -- 
511 rs719717 ABCC3 I/1/C-3695G -- 
512 rs720159 UPP2 5UR//G-2886A -- 
513 rs7243516 WDR7 I/12/C-7239T -- 
514 rs726511 BCL2 3DR//A72295T -- 
515 rs731420 XRCC1 I/4/G-137A -- 
516 rs748766 MLH1 I/14/T-885C -- 
517 rs7506986 WDR7 I/14/G5730A -- 
518 rs7618758 SMARCC1 I/6/C-258T -- 
519 rs7654543 PPAT I/1/A-8415C -- 
520 rs7751272 REV3L I/1/A-2596G -- 
521 rs7764543 REV3L I/1/T-6644C -- 
522 rs7766610 REV3L I/9/C1147A -- 
523 rs7847382 SMARCA2 I/27/T4325G -- 
524 rs7851702 SMARCA2 I/23/A-2352G -- 
525 rs7853086 SMARCA2 I/26/A-299T -- 
526 rs7858597 SMARCA2 I/27/C4461G -- 
527 rs7862805 SMARCA2 I/27/T13414A -- 
528 rs7864080 SMARCA2 I/11/A-52T -- 
529 rs7864452 SLC31A1 I/1/C14630T -- 
530 rs7869436 SMARCA2 I/27/A3378G -- 
531 rs7920256 ERCC6 I/7/A-2848G -- 
532 rs7927381 GSTP1 5UR//T-4542C -- 
533 rs8001444 ABCC4 I/1/T1058C -- 
534 rs8060569 MT1A 5UR//T-1437C -- 
535 rs8073898 MPO E12/3UTR /A561T -- 
536 rs8086404 BCL2 3DR//G68063C -- 
537 rs8093133 WDR7 I/12/T-444G -- 
538 rs8096380 BCL2 3DR//G64706A -- 
539 rs8187692 ABCC2 E/25/G3542T R1181L 
540 rs8192729 CYP2A6 I/7/C203T -- 
541 rs861531 XRCC3 I/5/C533A -- 
542 rs869951 ABCC4 5UR//C-522G -- 
543 rs899497 ABCC4 I/4/A-108G -- 
544 rs9400476 REV3L I/1/C19578T -- 
545 rs9472084 POLH I/3/A-1658G -- 
546 rs9487639 REV3L I/1/G-10319A -- 
547 rs9487645 REV3L I/1/T-26593C -- 
548 rs9524856 ABCC4 I/4/T588C -- 
549 rs9524873 ABCC4 I/1/G26109A -- 
550 rs9524885 ABCC4 I/1/T17906C -- 
551 rs9561811 ABCC4 I/4/C3193T -- 
552 rs956275 PPAT I/7/C90T -- 
553 rs9568682 ATP7B I/1/C-15456G -- 
554 rs9590228 ABCC4 I/1/C-23383T -- 
555 rs9634642 ABCC4 I/3/T-1583C -- 
556 rs971667 ERCC6 I/7/G3490A -- 
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557 rs9812777 ABCC5 3DR//C38368T -- 
558 rs981988 SLCO6A1 I/1/T-3843C -- 
559 rs9864549 HLTF I/18/A-1738C -- 
560 rs991791 WDR7 I/25/T-22204C -- 
561 rs9936741 MT1A 5UR//T-4792C -- 
562 rs9972996 BCL2 3DR//A63297G -- 
563 rs2695784 SMARCC2 5UR//T-3166C -- 
564 rs291592 DPYD E23/3UTR /C768T -- 
565 rs2930788 SMARCC2 5UR//T-2971C -- 
566 rs3136717 POLB I/1/C-89T -- 
567 rs4801043 WDR7 5UR//T-1512C -- 
568 rs2071487 GSTM1 E/7/T462C T154T 
569 rs4846049 MTHFR E12/3UTR /T372G -- 
570 rs733590 CDKN1A 5UR//T-1283C -- 
571 rs10075210 ATOX1 5UR//G-771A -- 
572 rs1008767 MT2A 5UR//T-2567C -- 
573 rs10118903 FPGS 5UR//C-106T -- 
574 rs10120113 SMARCA2 5UR//A-2574G -- 
575 rs10121175 SMARCA2 5UR//G-4580A -- 
576 rs1023159 SLC19A1 5UR//G-3828A -- 
577 rs10239964 POLM 5UR//A-2978G -- 
578 rs10252226 ABCB1 5UR//A-4823C -- 
579 rs10261685 ABCB1 5UR//A-1853C -- 
580 rs10265836 POLM 5UR//C-2395A -- 
581 rs10269664 POLM 5UR//C-3062T -- 
582 rs10424731 XRCC1 5UR//T-2582C -- 
583 rs10458900 RRM1 5UR//C-4328G -- 
584 rs1046512 MLH1 5UR//A-2682C -- 
585 rs1057985 SLC29A1 5UR//T-1340C -- 
586 rs10857503 ERCC6 5UR//C-2667T -- 
587 rs10857795 GSTM1 I/1/G-25A -- 
588 rs10929302 UGT1A1 5UR//G-3136A -- 
589 rs10947622 CDKN1A 5UR//C-4084T -- 
590 rs10951974 PMS2 5UR//C-2630T -- 
591 rs10987740 FPGS 5UR//G-2689A -- 
592 rs11101152 ERCC6 5UR//C-1488A -- 
593 rs11111858 TDG 5UR//T-1934A -- 
594 rs11133442 PPAT 5UR//A-4621T -- 
595 rs1114357 SLC22A7 5UR//C-3068T -- 
596 rs1130609 RRM2 E/1/T-6G -- 
597 rs11400410 MSH6 5UR//--3687G -- 
598 rs11445091 UMPS 5UR//--3982T -- 
599 rs11594945 ERCC6 5UR//T-4153C -- 
600 rs11649492 ERCC4 5UR//G-4604C -- 
601 rs11653440 SMARCD2 5UR//T-2821C -- 
602 rs11657432 TK1 5UR//C-3010A -- 
603 rs11665663 FXYD3 5UR//T-4460C -- 
604 rs11671498 XRCC1 5UR//G-4956C -- 
605 rs11673726 UGT1A1 5UR//G-4858T -- 
606 rs11681986 RRM2 5UR//G-1507A -- 
607 rs11705654 GSTT1 5UR//A-2542G -- 
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608 rs11769882 POLM 5UR//G-2000A -- 
609 rs11779233 DPYS 5UR//T-4702A -- 
610 rs11790511 SLC31A1 5UR//C-3396T -- 
611 rs11809445 GPX7 E/1/G-27T -- 
612 rs11816547 ABCC2 5UR//T-3037C -- 
613 rs11846751 XRCC3 5UR//C-2833G -- 
614 rs11846751 ZFYVE21 I/1/C2341G -- 
615 rs11846838 XRCC3 5UR//G-2913A -- 
616 rs11846838 ZFYVE21 I/1/G2421A -- 
617 rs11848956 XRCC3 5UR//G-4444T -- 
618 rs11848956 ZFYVE21 I/1/G3952T -- 
619 rs11865517 MT2A 5UR//G-1835A -- 
620 rs11878644 ERCC2 5UR//T-3137C -- 
621 rs11880627 ERCC1 5UR//G-3793A -- 
622 rs11909852 SOD1 5UR//C-4004T -- 
623 rs11933670 SMARCA5 E/1/G-183A -- 
624 rs11948127 FGFR4 5UR//G-1395A -- 
625 rs11971012 UPP1 5UR//T-3523C -- 
626 rs12068997 GSTM1 E/2/C81T S27S 
627 rs12192827 CDKN1A 5UR//C-3515T -- 
628 rs12199346 CDKN1A 5UR//C-4940A -- 
629 rs12214686 CDKN1A 5UR//A-3935G -- 
630 rs12379987 FPGS 5UR//T-3465C -- 
631 rs12445357 CES1 5UR//T-1752C -- 
632 rs12463451 ERCC3 5UR//C-2130T -- 
633 rs12471171 ERCC3 5UR//G-1851A -- 
634 rs12492095 UMPS 5UR//T-1256A -- 
635 rs12526616 POLH I/1/A16C -- 
636 rs12526616 XPO5 5UR//A-528C -- 
637 rs12536587 POLM 5UR//G-709C -- 
638 rs12597222 MT2A 5UR//T-2922C -- 
639 rs12621805 SMARCAL1 5UR//T-3123C -- 
640 rs12632590 UMPS I/1/C30T -- 
641 rs12659155 ATOX1 5UR//C-1641T -- 
642 rs12806698 RRM1 E/1/C-269A -- 
643 rs12949848 MPO 5UR//A-3770G -- 
644 rs12978764 FXYD3 5UR//C-4585T -- 
645 rs13079924 SMARCC1 5UR//A-1323C -- 
646 rs1319052 ERCC1 5UR//G-4043A -- 
647 rs13206175 CDKN1A 5UR//A-1452T -- 
648 rs13306560 MTHFR 5UR//C-67T -- 
649 rs1331700 HMGB1 5UR//C-1834T -- 
650 rs13330389 CES1 5UR//A-662G -- 
651 rs13401024 UPP2 5UR//C-2098T -- 
652 rs13405649 SMARCAL1 5UR//G-4805T -- 
653 rs13414112 UPP2 I/1/G32C -- 
654 rs1364362 ERCC4 5UR//T-3128C -- 
655 rs1382539 DHFR 5UR//G-1353A -- 
656 rs1382541 DHFR 5UR//T-2683C -- 
657 rs1382542 DHFR 5UR//T-2780C -- 
658 rs140313 GSTT1 I/1/C166T -- 
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659 rs140315 GSTT1 5UR//G-3437A -- 
660 rs140316 GSTT1 5UR//C-4042T -- 
661 rs140317 GSTT1 5UR//A-4410G -- 
662 rs1465952 RRM1 5UR//G-1384A -- 
663 rs1469908 NQO1 5UR//C-3878T -- 
664 rs1473418 BCL2 E/1/C-428G -- 
665 rs1510841 SMARCAL1 I/1/G115A -- 
666 rs1520195 ABCC5 5UR//G-1154A -- 
667 rs1526603 SMARCE1 5UR//C-1164T -- 
668 rs1544105 FPGS 5UR//C-2428T -- 
669 rs1549920 ATOX1 5UR//A-2633T -- 
670 rs1554494 UPP1 5UR//G-165A -- 
671 rs1561876 RRM1 5UR//G-2528A -- 
672 rs1611028 DHFR 5UR//TT-2880- -- 
673 rs1634252 GSTM1 5UR//T-1751C -- 
674 rs1643639 DHFR 5UR//T-1589C -- 
675 rs1662162 RRM1 5UR//T-659C -- 
676 rs1677667 DHFR 5UR//C-1740G -- 
677 rs16835902 UMPS 5UR//C-3448G -- 
678 rs16835912 UMPS 5UR//C-3308A -- 
679 rs16856038 SMARCAL1 5UR//C-3302G -- 
680 rs1688038 FXYD3 5UR//G-1799C -- 
681 rs1688039 FXYD3 5UR//A-1575T -- 
682 rs16896398 SLC22A7 5UR//A-3293T -- 
683 rs16929410 RRM1 5UR//G-382A -- 
684 rs17037425 MTHFR 5UR//G-4267A -- 
685 rs17160359 ABCB1 5UR//G-4254T -- 
686 rs172814 TDG 5UR//T-1802C -- 
687 rs1735068 RRM1 5UR//T-265G -- 
688 rs17510346 REV3L 5UR//G-1937A -- 
689 rs17511525 REV3L E/31/G9045T I3015I 
690 rs1764416 ABCC4 5UR//T-3360C -- 
691 rs1766902 ABCC4 5UR//T-3275C -- 
692 rs17767961 CES2 5UR//G-4155A -- 
693 rs17779585 SMUG1 5UR//C-2175G -- 
694 rs17843768 UMPS 5UR//C-827A -- 
695 rs17880282 TP53 5UR//C-1079T -- 
696 rs17882503 SOD1 5UR//T-649C -- 
697 rs17883184 TP53 5UR//G-636A -- 
698 rs17883908 TP53 I/1/A236G -- 
699 rs17884410 TP53 E/1/T-110C -- 
700 rs17886079 TP53 5UR//C-342T -- 
701 rs1799797 ERCC4 5UR//T-29A -- 
702 rs1811322 MT2A 5UR//A-2805T -- 
703 rs1827211 MT1A 5UR//C-4321T -- 
704 rs1827212 MT1A 5UR//T-2674C -- 
705 rs1827213 MT1A 5UR//G-736A -- 
706 rs184239 XRCC1 5UR//G-4439A -- 
707 rs1862849 MT2A 5UR//G-3016A -- 
708 rs1863332 MSH2 5UR//T-364G -- 
709 rs1863333 MSH2 5UR//T-658C -- 
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710 rs1917800 ERCC6 5UR//G-3844C -- 
711 rs1944423 BCL2 5UR//A-3904G -- 
712 rs1977172 CDKN1A 5UR//A-4732C -- 
713 rs2009115 PMS2 5UR//G-3818A -- 
714 rs2014704 SMARCE1 5UR//T-4145G -- 
715 rs2020872 MLH1 E/1/A94G I32V 
716 rs2066461 MTHFR E/3/G345T T115T 
717 rs2066466 MTHFR E/3/C417T T139T 
718 rs2070473 UPB1 5UR//G-356A -- 
719 rs2070474 UPB1 E/1/C-80G -- 
720 rs2073387 SMARCB1 5UR//T-144G -- 
721 rs2107545 MPO 5UR//A-1821G -- 
722 rs2108811 UPP2 5UR//A-3048G -- 
723 rs2144078 XRCC3 5UR//T-2523C -- 
724 rs2144078 ZFYVE21 I/1/T2031C -- 
725 rs2145851 ABCC2 5UR//C-4676A -- 
726 rs2161737 MT2A 5UR//A-3276G -- 
727 rs2180989 ABCC2 5UR//T-4761G -- 
728 rs219240 SMARCD3 5UR//C-32793T -- 
729 rs2231135 ABCG2 E/1/A-475G -- 
730 rs2232861 UPB1 5UR//G-96A -- 
731 rs2233914 SLC31A1 5UR//G-327A -- 
732 rs2266635 GSTT1 E/1/C61T A21T 
733 rs2270836 MT1A 5UR//C-4963T -- 
734 rs2276665 SMARCAL1 5UR//T-1005G -- 
735 rs2276910 SMARCAD1 I/1/T17C -- 
736 rs2287497 TP53 5UR//G-1862A -- 
737 rs2287498 TP53 5UR//C-1642T -- 
738 rs2287499 TP53 5UR//C-1250G -- 
739 rs2297393 SLC29A1 5UR//T-2522C -- 
740 rs2298840 DPYS E/1/G216A F72F 
741 rs2307160 POLB E/1/A-62G -- 
742 rs2313211 ABCC5 5UR//T-2898A -- 
743 rs2334102 TYMP 5UR//G-1296C -- 
744 rs2395655 CDKN1A 5UR//A-790G -- 
745 rs2429247 SMARCD3 5UR//T-28911C -- 
746 rs244711 FGFR4 5UR//C-4727T -- 
747 rs2448341 CDC2 5UR//C-3953T -- 
748 rs2448342 CDC2 5UR//A-3883G -- 
749 rs2463365 SMARCC2 5UR//C-4298T -- 
750 rs2467573 TK1 5UR//A-286T -- 
751 rs2517953 ERBB2 5UR//G-15042C -- 
752 rs2546095 FGFR4 5UR//T-4336G -- 
753 rs2584618 SMARCD2 5UR//T-3259C -- 
754 rs2584879 RRM1 E/1/G17A R6Q 
755 rs2607997 HLTF 5UR//G-4655T -- 
756 rs2665796 SMARCD2 5UR//G-3364C -- 
757 rs2682585 XRCC1 5UR//A-1572G -- 
758 rs2727326 SMARCD2 5UR//G-2664A -- 
759 rs2727327 SMARCD2 5UR//G-3070A -- 
760 rs2804403 ABCC2 5UR//C-3357T -- 
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761 rs2805832 XPA 5UR//G-3188A -- 
762 rs28372687 POLM 5UR//G-841A -- 
763 rs28381715 ABCB1 5UR//T-334G -- 
764 rs28382572 SMARCB1 5UR//C-3836T -- 
765 rs28382580 SMARCB1 5UR//A-2457- -- 
766 rs28382617 POLM 5UR//T-1584C -- 
767 rs28382618 POLM 5UR//A-1410G -- 
768 rs28382628 POLM 5UR//G-216A -- 
769 rs28382644 POLM E/5/C659G G220A 
770 rs28382812 CES2 E/1/C111T I37I 
771 rs28382815 CES2 E/2/C406T R136* 
772 rs28419190 SMARCAD1 5UR//T-2796C -- 
773 rs2853533 TYMS I/1/G117C -- 
774 rs2853742 TYMS 5UR//T-176C -- 
775 rs2854495 XRCC1 5UR//C-2834A -- 
776 rs28565268 POLB 5UR//T-4791C -- 
777 rs28570299 FPGS 5UR//A-1540T -- 
778 rs28712867 TK1 5UR//C-3689T -- 
779 rs2877173 SMARCB1 5UR//G-3584A -- 
780 rs2892547 HMGB1 5UR//C-3393A -- 
781 rs2917667 NQO1 5UR//A-3244G -- 
782 rs2942570 DPYS 5UR//T-2427C -- 
783 rs2959024 DPYS 5UR//T-493G -- 
784 rs2959025 DPYS 5UR//A-902G -- 
785 rs2959026 DPYS 5UR//A-3374G -- 
786 rs2959027 DPYS 5UR//A-4439G -- 
787 rs2964584 ATOX1 5UR//T-4667C -- 
788 rs2992904 ABCC4 5UR//A-4485C -- 
789 rs304731 XRCC1 5UR//T-3229C -- 
790 rs3057854 SMARCA2 5UR//--745TATTTTT -- 
791 rs3106134 SMARCAD1 5UR//A-1102G -- 
792 rs3118106 SMARCA1 5UR//G-2060C -- 
793 rs3131275 SMARCA1 5UR//A-2539G -- 
794 rs3136038 ERCC4 5UR//C-643T -- 
795 rs3136227 MSH6 5UR//C-613A -- 
796 rs3136716 POLB I/1/C159G -- 
797 rs3172297 MLH1 5UR//T-2608C -- 
798 rs3176320 CDKN1A I/1/A213G -- 
799 rs3176323 CDKN1A I/1/T133C -- 
800 rs3176628 XPA 5UR//G-845A -- 
801 rs3176629 XPA 5UR//G-383A -- 
802 rs3204953 REV3L E/31/C9190T V3064I 
803 rs3212929 ERCC1 5UR//C-450A -- 
804 rs3212935 ERCC1 E/1/T-143C -- 
805 rs3212936 ERCC1 E/1/--78C -- 
806 rs3213138 E2F1 5UR//A-322G -- 
807 rs3213143 E2F1 E/1/G111A S37S 
808 rs3213174 E2F1 E/6/G932T T311N 
809 rs3213177 E2F1 E7/3UTR /C5A -- 
810 rs3213180 E2F1 E7/3UTR /G914C -- 
811 rs3213236 XRCC1 5UR//--1739G -- 
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812 rs3213246 XRCC1 E/1/G-64A -- 
813 rs3218602 REV3L E/31/A9108G Y3036Y 
814 rs3218655 POLM E/1/C102A L34L 
815 rs3218657 POLM E/2/C351T V117V 
816 rs322102 TDG I/1/C94G -- 
817 rs322104 TDG 5UR//G-472A -- 
818 rs330792 MSH6 5UR//A-1646C -- 
819 rs33934538 SMARCA2 5UR//A-2071- -- 
820 rs34009709 TDG 5UR//G-2327A -- 
821 rs34067256 TP53 5UR//C-1455G -- 
822 rs34144509 WDR7 5UR//T-1451C -- 
823 rs34213602 FDXR I/1/C147G -- 
824 rs34248325 SMARCB1 5UR//G-711A -- 
825 rs34428341 CES1 5UR//C-1005T -- 
826 rs34484367 SMARCE1 5UR//C-2083G -- 
827 rs34547608 UGT1A1 5UR//T-90C -- 
828 rs34547779 FDXR 5UR//G-667C -- 
829 rs34800257 MT2A 5UR//T-1478C -- 
830 rs34976170 SMARCB1 5UR//C-482G -- 
831 rs34994762 MTHFR 5UR//A-4163G -- 
832 rs35033646 FDXR E12/3UTR /G139T -- 
833 rs35072974 FDXR E/8/G743A P248L 
834 rs35263175 SLC22A7 E/1/T222C D74D 
835 rs35395489 MT2A 5UR//A-561G -- 
836 rs35448124 ERCC4 5UR//TGTG-4441- -- 
837 rs35466868 ERBB2 5UR//C-13786T -- 
838 rs35634719 FDXR 5UR//TG-1250- -- 
839 rs35665780 UGT1A1 5UR//C-620T -- 
840 rs35880761 FDXR 5UR//A-1824G -- 
841 rs35891829 TP53 5UR//A-2059C -- 
842 rs35960304 RRM1 5UR//C-3341T -- 
843 rs35988004 MT1A 5UR//T-1668-/A -- 
844 rs36010696 FDXR 5UR//A-1108T -- 
845 rs36106739 FDXR I/1/T292C -- 
846 rs36124867 TYMS 5UR//A-4424C -- 
847 rs36204705 FPGS 5UR//G-1011T -- 
848 rs36209093 GSTM1 5UR//C-654T -- 
849 rs36211400 GSTT1 5UR//C-688G -- 
850 rs36230817 SLC19A1 5UR//A-1948G -- 
851 rs36233090 SOD1 5UR//C-1659G -- 
852 rs3734701 SLC29A1 5UR//T-1987C -- 
853 rs3735295 PMS2 I/1/G72A -- 
854 rs3735296 PMS2 5UR//G-66C -- 
855 rs3737965 MTHFR 5UR//G-335A -- 
856 rs3747802 ABCB1 5UR//A-21G -- 
857 rs3750187 DPYS 5UR//G-3197A -- 
858 rs3750747 ERCC6 I/1/G156C -- 
859 rs3750994 RRM1 5UR//T-2453G -- 
860 rs3750996 RRM1 5UR//A-2723G -- 
861 rs3755141 SMARCAL1 5UR//C-1325T -- 
862 rs3755142 SMARCAL1 5UR//T-1647C -- 
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863 rs376184 SMARCD1 5UR//T-4942C -- 
864 rs3763505 UPP1 E/1/G-363A -- 
865 rs3787037 FXYD3 5UR//A-1925G -- 
866 rs3787039 FXYD3 5UR//A-2261G -- 
867 rs3794050 RRM1 5UR//A-4023G -- 
868 rs3806573 SMARCAL1 5UR//A-551G -- 
869 rs3809159 SMUG1 5UR//G-1270C -- 
870 rs3814270 ABCC4 5UR//G-639A -- 
871 rs3826317 FDXR 5UR//C-491T -- 
872 rs3826992 FXYD3 5UR//G-2347C -- 
873 rs3829965 CDKN1A 5UR//A-1976G -- 
874 rs3829967 CDKN1A 5UR//T-1528C -- 
875 rs3831222 SLC29A1 5UR//G-2445- -- 
876 rs406113 GPX6 E/1/A39C F13L 
877 rs4124874 UGT1A1 5UR//T-3259G -- 
878 rs412543 GSTM1 5UR//G-497C -- 
879 rs41275676 SMARCAD1 E/2/A-6G -- 
880 rs41294988 MSH6 E/1/A38C K13T 
881 rs4135036 TDG 5UR//T-562C -- 
882 rs4145763 UCK2 5UR//C-1645T -- 
883 rs4147563 GSTM1 5UR//C-338T -- 
884 rs4147581 GSTP1 I/1/C-20G -- 
885 rs4148727 ABCB1 5UR//A-201G -- 
886 rs4151702 CDKN1A 5UR//G-498C -- 
887 rs423143 FGFR4 5UR//G-4265A -- 
888 rs4253003 ERCC6 5UR//C-137T -- 
889 rs4253006 ERCC6 E/1/C-21T -- 
890 rs4253046 ERCC6 E/5/T1274G D425A 
891 rs4399719 UGT1A1 5UR//T-2457G -- 
892 rs4401102 MPO 5UR//C-2540T -- 
893 rs442767 DHFR 5UR//G-695T -- 
894 rs453544 DHFR 5UR//G-1008A -- 
895 rs45498791 MTHFR 5UR//C-479A -- 
896 rs45546035 MTHFR E/3/G276A D92D 
897 rs45557639 FGFR4 5UR//T-3458C -- 
898 rs45585938 FGFR4 5UR//A-3570G -- 
899 rs4647201 MLH1 5UR//C-1487A -- 
900 rs4647203 MLH1 5UR//G-794A -- 
901 rs4681481 HLTF 5UR//T-2502C -- 
902 rs4711460 CDKN1A 5UR//C-4358A -- 
903 rs4714003 CDKN1A 5UR//C-4226T -- 
904 rs4724280 POLM 5UR//G-2496A -- 
905 rs4741636 SMARCA2 5UR//T-1761C -- 
906 rs4759344 SMUG1 5UR//A-357G -- 
907 rs477415 WDR7 I/1/A292T -- 
908 rs4784701 MT1A 5UR//T-1910G -- 
909 rs4806085 FXYD3 5UR//T-4784C -- 
910 rs4806087 FXYD3 5UR//G-3524A -- 
911 rs4806088 FXYD3 5UR//G-3458A -- 
912 rs4846054 MTHFR 5UR//C-3114T -- 
913 rs485365 WDR7 5UR//G-3183A -- 
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914 rs487140 WDR7 5UR//G-3339A -- 
915 rs492095 FDXR E/1/A-9G -- 
916 rs4987706 BCL2 I/1/T42C -- 
917 rs501415 WDR7 I/1/A35G -- 
918 rs507964 SLC29A1 5UR//T-4905G -- 
919 rs535437 WDR7 5UR//G-1238A -- 
920 rs559998 WDR7 5UR//G-1592T -- 
921 rs561762 WDR7 5UR//C-1764T -- 
922 rs572362 FDXR 5UR//T-870G -- 
923 rs6003880 SMARCB1 5UR//C-219T -- 
924 rs6120343 E2F1 5UR//G-3228A -- 
925 rs613653 WDR7 5UR//T-4204C -- 
926 rs6141997 E2F1 5UR//T-2621C -- 
927 rs6151599 DHFR 5UR//A-231G -- 
928 rs6151600 DHFR 5UR//T-907C -- 
929 rs621018 WDR7 5UR//A-443G -- 
930 rs628047 WDR7 5UR//C-3276G -- 
931 rs632427 WDR7 5UR//C-703T -- 
932 rs6440583 HLTF 5UR//C-857T -- 
933 rs6498485 ERCC4 5UR//G-3028A -- 
934 rs6499786 CES1 5UR//A-2159G -- 
935 rs6499788 CES1 5UR//T-4761A -- 
936 rs6511716 SMARCA4 5UR//A-3770G -- 
937 rs6580978 SMUG1 5UR//A-779G -- 
938 rs662855 WDR7 5UR//G-2907T -- 
939 rs6672420 RUNX3 5UR//A-34239T -- 
940 rs6689902 GSTM1 5UR//A-1643C -- 
941 rs6714634 UGT1A1 5UR//T-4153C -- 
942 rs6798870 ABCC5 5UR//G-4622A -- 
943 rs6830518 PPAT 5UR//C-4949T -- 
944 rs6883528 SLCO6A1 5UR//T-1419C -- 
945 rs688890 WDR7 5UR//G-288A -- 
946 rs689384 WDR7 5UR//T-161C -- 
947 rs689456 NQO1 5UR//C-1029T -- 
948 rs6898458 SLCO6A1 5UR//G-1944A -- 
949 rs690115 FDXR 5UR//C-4912T -- 
950 rs6976251 PMS2 5UR//G-543C -- 
951 rs7040790 SMARCA2 5UR//T-1379G -- 
952 rs717378 UPP2 5UR//G-3222C -- 
953 rs7196890 MT1A 5UR//C-1557A -- 
954 rs7202530 CES2 5UR//T-4928A -- 
955 rs7219483 SMARCE1 5UR//A-3853G -- 
956 rs7277748 SOD1 E/1/A-109G -- 
957 rs7289159 UPB1 5UR//G-901T -- 
958 rs7292735 TYMP 5UR//A-2347G -- 
959 rs7328090 ATP7B 5UR//G-2175T -- 
960 rs7459020 UPP1 5UR//G-149A -- 
961 rs7498748 CES1 5UR//T-163C -- 
962 rs7534738 UCK2 5UR//A-1501C -- 
963 rs7556417 UCK2 5UR//C-2312T -- 
964 rs7582263 RRM2 5UR//C-1246A -- 
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965 rs7619819 ABCC5 5UR//A-3831G -- 
966 rs762623 CDKN1A 5UR//G-1020A -- 
967 rs762624 CDKN1A 5UR//A-898C -- 
968 rs7628248 HLTF 5UR//C-3217A -- 
969 rs7688482 PPAT 5UR//T-2585C -- 
970 rs7753792 SLC29A1 5UR//C-1718A -- 
971 rs7793905 UPP1 5UR//C-1160T -- 
972 rs7927657 GSTP1 5UR//T-4297C -- 
973 rs7934581 RRM1 5UR//C-3890T -- 
974 rs7941648 GSTP1 5UR//C-3690T -- 
975 rs7945035 GSTP1 5UR//A-3123G -- 
976 rs796736 TDG 5UR//T-2448A -- 
977 rs7991067 HMGB1 5UR//C-4553A -- 
978 rs8068725 FDXR 5UR//A-3081G -- 
979 rs8071253 TK1 5UR//G-1181A -- 
980 rs8073029 FDXR 5UR//T-3265C -- 
981 rs812498 TDG 5UR//T-4817C -- 
982 rs8132524 SOD1 5UR//C-2443T -- 
983 rs8137555 SMARCB1 5UR//T-2842C -- 
984 rs8177412 GPX3 E/1/T-129C -- 
985 rs8177413 GPX3 E/1/G39C L13L 
986 rs8191439 GSTP1 E/1/G-18A -- 
987 rs8192443 SMARCD1 5UR//C-3479A -- 
988 rs868853 ABCC4 5UR//C-1388T -- 
989 rs879000 WDR7 5UR//A-4398G -- 
990 rs897761 FXYD3 5UR//T-326A -- 
991 rs903501 ERBB2 5UR//T-16760C -- 
992 rs9311149 MLH1 5UR//C-4803A -- 
993 rs9333500 POLH E/1/G-200T -- 
994 rs9333500 XPO5 5UR//G-316T -- 
995 rs9357436 SLC29A1 5UR//G-4521A -- 
996 rs961077 UMPS 5UR//C-4613T -- 
997 rs9630729 SMARCE1 5UR//T-3757C -- 
998 rs9673491 MT1A 5UR//G-3655T -- 
999 rs9674227 MT1A 5UR//A-3590C -- 
1000 rs9890046 ABCC3 I/1/C369G -- 
1001 rs9927585 CES1 5UR//G-4382A -- 
1002 rs9947507 TYMS 5UR//C-555T -- 
1003 rs17222547 ABCC2 E/22/C2901A Y967* 
1004 rs2066523 SMARCAL1 E/11/G1945A R649* 
1005 rs2291078 UMPS E/4/T1050A C350* 
1006 rs3201997 ABCG2 E/9/C1000A E334* 
1007 rs5023780 CES1 E/3/G310A R104* 
1008 rs596909 TYMS E/4/G470T L157* 
1009 rs1003355 ABCC3 E/12/C1583G A528G 
1010 rs10055840 SLCO6A1 E/12/G1961C T654R 
1011 rs10073333 SLCO6A1 E/9/G1579C P527A 
1012 rs10091081 POLB E/8/G431C G144A 
1013 rs1042709 UGT1A1 E/5/G1531C A511P 
1014 rs1050101 SMARCD3 E/5/G508A P170S 
1015 rs1061017 ABCG2 E/5/G496C Q166E 
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1016 rs1061018 ABCG2 E/6/A623G F208S 
1017 rs10964468 SMARCA2 E/2/G-5A -- 
1018 rs10983315 XPA E/3/C289T V97I 
1019 rs1132543 TK1 E/5/C442T V148M 
1020 rs1138272 GSTP1 E/6/C341T A114V 
1021 rs11553892 GSTP1 E/7/C526A L176M 
1022 rs11555797 SMARCAL1 E/2/G341A T114M 
1023 rs11568587 ABCC3 E/22/-3051- -- 
1024 rs11568591 ABCC3 E/27/G3890A R1297H 
1025 rs11568599 ABCC3 E/15/-1926- -- 
1026 rs11568658 ABCC4 E/5/C559A G187W 
1027 rs11568669 ABCC4 E/11/T1492C K498E 
1028 rs11568705 ABCC4 E/9/G1208A P403L 
1029 rs11656685 ABCC3 E/31/C4538A A1513D 
1030 rs11708427 ABCC5 3DR//C1158G -- 
1031 rs11722476 SMARCAD1 E/7/G740A S247N 
1032 rs11723410 SMARCAD1 E/3/C197T S66F 
1033 rs11954456 FGFR4 E/6/C825G S275R 
1034 rs11971829 UPP1 E/3/C11T T4M 
1035 rs1202183 ABCB1 E/5/T131C N44S 
1036 rs12103928 SMARCE1 E/5/T183G K61N 
1037 rs12367528 TDG E/10/C1136A P379H 
1038 rs12388502 SMARCA1 E/17/C2113G E705Q 
1039 rs12678588 POLB E/7/G410A R137Q 
1040 rs12682945 UCK1 E/7/A785G L262P 
1041 rs12686275 FPGS E/14/T1160A V387D 
1042 rs12808005 RRM1 E/7/A536C H179P 
1043 rs12928616 ERCC4 E/11/C2240T S747F 
1044 rs12928650 ERCC4 E/11/C2303T S768F 
1045 rs13079661 SMARCC1 E/14/T1357A S453C 
1046 rs13091100 HLTF E/3/A248C V83G 
1047 rs13308178 POLM E/10/C1357G G453R 
1048 rs1332018 GSTM3 E/1/G-63T -- 
1049 rs13400205 RRM2 E/4/T320G G107V 
1050 rs1695 GSTP1 E/5/A313G I105V 
1051 rs17150488 SLCO6A1 E/7/T1142C K381R 
1052 rs17216317 ABCC2 E/28/C3872T P1291L 
1053 rs17222674 ABCC2 E/8/A998G D333G 
1054 rs17510963 REV3L E/14/A6225C I2075M 
1055 rs17539588 REV3L E/13/C2885T R962Q 
1056 rs17539616 REV3L E/13/G4015T P1339T 
1057 rs17539692 REV3L E/14/T6044A E2015V 
1058 rs17843776 UMPS E/1/A88G R30W 
1059 rs17843819 UMPS E/3/T859C E287K 
1060 rs17880492 GPX2 E/2/G436A R146C 
1061 rs17882252 TP53 E/10/C1015T E339K 
1062 rs1799792 ERCC2 E/8/G601A H201Y 
1063 rs1799802 ERCC4 E/7/C1135T P379S 
1064 rs1800067 ERCC4 E/8/G1244A R415Q 
1065 rs1800068 ERCC4 E/8/G1727C R576T 
1066 rs1800124 ERCC4 E/11/A2624G E875G 
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1067 rs1800152 MSH2 E/12/T1917G H639Q 
1068 rs1800938 MSH6 E/4/A660C E220D 
1069 rs1801201 ERBB2 E/17/A1960G I654V 
1070 rs1801244 ATP7B E/3/C1366G V456L 
1071 rs1801266 DPYD E/7/G703A R235W 
1072 rs1803687 GSTM3 E/6/C384G K128N 
1073 rs1805318 PMS2 E/11/T1789A T597S 
1074 rs1805322 PMS2 E/8/G830T T277K 
1075 rs1805323 PMS2 E/11/G1454T T485K 
1076 rs1805324 PMS2 E/11/C1866T M622I 
1077 rs1966265 FGFR4 E/1/G28A V10I 
1078 rs2020908 MSH6 E/4/C1186G L396V 
1079 rs2020955 ERCC4 E/10/T1984C S662P 
1080 rs2020956 ERCC4 E/11/G2735A G912E 
1081 rs2020959 ERCC4 E/11/C2169A C723* 
1082 rs2020961 ERCC4 E/3/C503T A168V 
1083 rs2066472 MTHFR E/2/C203T R68Q 
1084 rs2066522 SMARCAL1 E/4/C945G Q315H 
1085 rs2066524 SMARCAL1 E/2/G127A C43R 
1086 rs2227291 ATP7A E/10/G2299C V767L 
1087 rs2227963 GSTM5 E/7/G536A L179P 
1088 rs2228006 PMS2 E/11/T1621C E541K 
1089 rs2228529 ERCC6 E/21/T4238C Q1413R 
1090 rs2229107 ABCB1 E/27/A3421T S1141T 
1091 rs2229361 HLTF E/21/C2456T R819H 
1092 rs2229996 APC E/16/C4487G T1496S 
1093 rs2231137 ABCG2 E/2/C34T V12M 
1094 rs2233915 SLC31A1 E/2/C73G P25A 
1095 rs2233916 SLC31A1 E/4/C365G T122S 
1096 rs2234935 ATP7A E/9/T2006C I669T 
1097 rs2234953 GSTT1 E/4/C517T E173K 
1098 rs2235036 ABCB1 E/16/C1795T A599T 
1099 rs2235039 ABCB1 E/21/C2401T V801M 
1100 rs2266633 GSTT1 E/4/C421T D141N 
1101 rs2271336 SMARCAL1 E/13/C2225T Y742C 
1102 rs2274974 MTHFR E/11/C1697T G566E 
1103 rs2277447 ATP7B E/7/C2029T E677K 
1104 rs2296212 SMARCA2 E/32/C4584G D1528E 
1105 rs2305868 HLTF E/8/T932C N311S 
1106 rs2307167 XRCC1 E/15/C1676T R559Q 
1107 rs2307184 XRCC1 E/13/G1454T S485Y 
1108 rs2307191 XRCC1 E/5/G482A P161L 
1109 rs2307227 CES1 E/5/G609T D203E 
1110 rs2307240 CES1 E/2/C224T S75N 
1111 rs2307456 POLH E/5/G626T G209V 
1112 rs2388544 HMGB1 E/3/G293A P98L 
1113 rs25474 XRCC1 E/14/G1541A P514L 
1114 rs25491 XRCC1 E/9/G925A P309S 
1115 rs2632398 SMARCAD1 E/4/C418T R140C 
1116 rs2682557 XRCC1 E/16/T1726A Y576N 
1117 rs28364274 ABCB1 E/29/C3751T V1251I 
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1118 rs28381801 ABCB1 E/2/T-42C -- 
1119 rs28381902 ABCB1 E/15/C1696T E566K 
1120 rs28381967 ABCB1 E/22/T2506C I836V 
1121 rs28382653 POLM E/6/C736A V246F 
1122 rs28382661 POLM E/11/G1450A L484F 
1123 rs28401798 ABCB1 E/26/G3151C P1051A 
1124 rs28563878 CES1 E/1/A34C S12A 
1125 rs3103135 SMARCAD1 E/14/A1765C N589H 
1126 rs3113842 SMARCAD1 E/12/T1612C Y538H 
1127 rs3116448 ABCG2 E/7/A742G S248P 
1128 rs3136334 MSH6 E/4/C1867G P623A 
1129 rs3136389 SMUG1 E/4/G313A R105W 
1130 rs3188420 ERCC1 E/2/G230T P77H 
1131 rs3212057 XRCC3 E/5/C281T R94H 
1132 rs3212977 ERCC1 E/8/C796T A266T 
1133 rs3213172 E2F1 E/5/C755T R252H 
1134 rs3213173 E2F1 E/5/C826T V276M 
1135 rs3213176 E2F1 E/7/C1177T G393S 
1136 rs3218572 REV3L E/13/T4406G Q1469P 
1137 rs3218578 REV3L E/13/T3850G T1284P 
1138 rs3218579 REV3L E/10/T1190G Q397P 
1139 rs3218582 REV3L E/13/G4727A S1576L 
1140 rs3218585 REV3L E/13/C5137T D1713N 
1141 rs3218592 REV3L E/26/C8285T R2762Q 
1142 rs3218593 REV3L E/13/A2078G M693T 
1143 rs3218595 REV3L E/13/C3927A Q1309H 
1144 rs3218600 REV3L E/13/G3659A S1220L 
1145 rs3218604 REV3L E/14/C5767G G1923R 
1146 rs3218606 REV3L E/14/C5909T R1970H 
1147 rs33974176 APC E/16/C2608T P870S 
1148 rs34110964 UPB1 E/9/C1019A A340D 
1149 rs34138361 FGFR4 E/11/C1652T S551F 
1150 rs34157245 APC E/16/G5645C R1882T 
1151 rs34284947 FGFR4 E/10/G1466A R489Q 
1152 rs34354111 FPGS E/15/G1433C S478T 
1153 rs34447156 NQO1 E/5/C693G Q231H 
1154 rs34622270 HLTF E/20/T2284C I762V 
1155 rs34628871 MPO E/1/A-65G -- 
1156 rs34825130 GPX6 E/2/A157G Y53H 
1157 rs35003977 UGT1A1 E/1/T674G V225G 
1158 rs35102176 FDXR E/7/G624C C208W 
1159 rs35163653 TP53 E/6/C649T V217M 
1160 rs35338630 MLH1 E/9/C790G H264D 
1161 rs35394555 GPX6 E/4/C408G E136D 
1162 rs35578165 FXYD3 E/6/G118A G40S 
1163 rs35658392 GPX6 E/5/G469A P157S 
1164 rs35660143 FDXR E/10/G1034A T345M 
1165 rs35667202 UPP2 E/8/G674T R225L 
1166 rs35670089 MPO E/11/G1810A R604C 
1167 rs35671174 CDC2 E/6/A665G K222R 
1168 rs35675573 POLH E/8/C986T T329I 
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1169 rs35702888 MPO E/12/C2047G E683Q 
1170 rs35717727 MSH6 E/8/G3700C E1234Q 
1171 rs35737219 MTHFR E/12/G1958A T653M 
1172 rs35993958 TP53 E/10/C1079G G360A 
1173 rs36027551 DPYS E/3/G541A R181W 
1174 rs36040909 SLC22A7 E/6/C973T R325W 
1175 rs3740071 ABCC2 E/20/G2677C E893Q 
1176 rs3740072 ABCC2 E/17/A2153G N718S 
1177 rs3765534 ABCC4 E/18/C2269T E757K 
1178 rs376618 FGFR4 E/3/C407T P136L 
1179 rs3772406 SMARCC1 E/28/G3224T P1075H 
1180 rs3772809 UMPS E/6/A1336G H446Y 
1181 rs377860 APC E/16/A4108C K1370Q 
1182 rs3793510 SMARCA2 E/29/G4247C G1416A 
1183 rs3826192 CES1 E/2/C112T V38I 
1184 rs41295268 MSH6 E/4/G1403A R468H 
1185 rs41295270 MSH6 E/4/C1739T S580L 
1186 rs41306702 FPGS E/2/C103T R35W 
1187 rs41318029 ABCC2 E/21/G2761A G921S 
1188 rs4135038 TDG E/1/G-169A -- 
1189 rs4135113 TDG E/5/G595A G199S 
1190 rs4148323 UGT1A1 E/1/G211A G71R 
1191 rs4148460 ABCC4 E/4/A511C C171G 
1192 rs4150522 ERCC3 E/14/A2203G S735P 
1193 rs41540513 ERCC1 5UR//G-320A -- 
1194 rs41542214 MLH1 E/18/C2065A Q689K 
1195 rs41549213 ERCC6 E/7/C1670T R557H 
1196 rs41552412 ERCC4 E/8/C1563G S521R 
1197 rs41557814 ERCC4 E/8/C1429T R477W 
1198 rs41557921 ERCC6 E/15/C2803G D935H 
1199 rs41559922 ERCC2 E/14/A1343G F448S 
1200 rs4253047 ERCC6 E/5/C1337T G446D 
1201 rs4253206 ERCC6 E/17/T3005C Y1002C 
1202 rs4253219 ERCC6 E/19/C3965A G1322V 
1203 rs4253227 ERCC6 E/21/C4114T G1372R 
1204 rs4253230 ERCC6 E/21/G4322A T1441I 
1205 rs4338942 SMARCAL1 E/2/T569G V190G 
1206 rs45441199 ABCC2 E/23/T3107C I1036T 
1207 rs45458701 SLC29A1 E/12/G1171A E391K 
1208 rs45462493 ABCC2 E/7/A736C M246L 
1209 rs45477596 ABCC4 3DR//C12523T -- 
1210 rs45496998 MTHFR E/10/G1555A R519C 
1211 rs45504892 ABCC4 3DR//C20231A -- 
1212 rs45573936 SLC29A1 E/7/T647C I216T 
1213 rs45589337 DPYD E/8/T775C K259E 
1214 rs45617731 ABCC3 E/8/G941T S314I 
1215 rs458017 REV3L E/13/T3467C Y1156C 
1216 rs4705693 APC E/16/G7567T A2523S 
1217 rs4826245 ATP7A E/21/G4048A E1350K 
1218 rs4851 GPX4 E/7/C680T S227L 
1219 rs4986866 CDKN1A E/2/C11T P4L 
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1220 rs4986867 CDKN1A E/2/C189A F63L 
1221 rs4986949 GSTP1 E/6/G439T D147Y 
1222 rs4997557 CYP2A6 E/6/G881C T294S 
1223 rs520611 FDXR E/2/C120A Q40H 
1224 rs5959130 ATP7A E/22/G4201C V1401L 
1225 rs598078 WDR7 E/3/A235C K79Q 
1226 rs6446261 GPX1 E/2/C580T A194T 
1227 rs6710480 UPP2 E/3/G30T R10S 
1228 rs6941583 POLH E/11/A1939T M647L 
1229 rs7020514 SMARCA2 E/8/T1362G S454R 
1230 rs7080681 ABCC2 E/9/G1058A R353H 
1231 rs728619 MSH6 E/4/A1613C Y538S 
1232 rs7356934 REV3L E/25/G8036A P2679L 
1233 rs7439869 SMARCAD1 E/9/T902C A301V 
1234 rs7483 GSTM3 E/8/C670T V224I 
1235 rs7561584 UPP2 E/5/A232C M78L 
1236 rs769188 GPX5 E/3/C253G L85V 
1237 rs8177445 GPX3 E/4/T382C F128L 
1238 rs8192730 CYP2A6 E/8/C1257G E419D 
1239 rs8192924 CES2 E/5/G809A R270H 
1240 rs927344 ABCC2 E/2/A116T F39Y 
1241 rs9282571 ABCG2 E/14/A1711T F571I 
1242 rs9296419 POLH E/11/C1433T T478M 
1243 rs9333555 POLH E/11/A1783G M595V 
1244 rs1042858 RRM1 E/19/G2232A A744A 
1245 rs1048977 CDA E/4/C435T T145T 
1246 rs1050102 SMARCD3 E/8/G828A H276H 
1247 rs1056806 GSTM1 E/7/C528T D176D 
1248 rs1065767 TK1 E/7/G720A A240A 
1249 rs10964471 SMARCA2 E/2/G177A T59T 
1250 rs11100790 SMARCA5 E/3/T282C Y94Y 
1251 rs11553301 UCK2 E/4/G408A G136G 
1252 rs11568695 ABCC4 3DR//C51485T -- 
1253 rs11568704 ABCC4 3DR//C61070T -- 
1254 rs11682453 UGT1A1 E/4/C1279T L427L 
1255 rs11786893 GGH E/2/C174T A58A 
1256 rs11840224 ATP7B E/13/G2967A D989D 
1257 rs1189466 ABCC4 3DR//A21484G -- 
1258 rs1200937 CES2 E/1/G-140C -- 
1259 rs12532895 PMS2 E/4/G288A A96A 
1260 rs13288443 SMARCA2 E/11/A1827G P609P 
1261 rs13306555 MTHFR E/6/G906A A302A 
1262 rs13427563 ERCC3 E/5/C615T E205E 
1263 rs13428173 ERCC3 E/11/G1740A I580I 
1264 rs17090346 WDR7 E/15/C2542T L848L 
1265 rs17216296 ABCC2 E/30/C4242T H1414H 
1266 rs17510914 REV3L E/13/T4650C P1550P 
1267 rs17849090 PTEN E/7/T723C L241L 
1268 rs1800144 MLH1 E/4/A375G A125A 
1269 rs1800150 MSH2 E/2/G219A K73K 
1270 rs1800369 TP53 E/2/G63A D21D 
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1271 rs1800932 MSH6 E/2/A276G P92P 
1272 rs1800935 MSH6 E/3/T540C D180D 
1273 rs1801018 BCL2 E/2/T21C T7T 
1274 rs1801019 UMPS E/3/G638C -- 
1275 rs1801248 ATP7B E/13/C3045T L1015L 
1276 rs1970951 GPX7 E/2/T237C F79F 
1277 rs2020913 MSH6 E/4/T2253C N751N 
1278 rs2020953 ERCC4 E/11/A2463G P821P 
1279 rs2020958 ERCC4 E/9/A1884G E628E 
1280 rs2066527 SMARCAL1 E/11/T2070C N690N 
1281 rs2228544 ERCC3 E/8/C1119T Q373Q 
1282 rs2229993 APC E/16/G6921A S2307S 
1283 rs2229997 APC E/16/C5250G V1750V 
1284 rs2230761 UPP1 E/7/A606G T202T 
1285 rs2232867 UPB1 E/7/C846T F282F 
1286 rs2232870 UPB1 E/10/T1086C Y362Y 
1287 rs2288845 SMARCA4 E/9/C1557T N519N 
1288 rs2307174 XRCC1 E/3/C150T E50E 
1289 rs2307189 XRCC1 E/2/G126T T42T 
1290 rs2307460 POLH E/6/C678T A226A 
1291 rs28381867 ABCB1 E/9/C738T A246A 
1292 rs28382610 GPX5 E/5/C633T I211I 
1293 rs28382827 CES2 E/12/C1791T L597L 
1294 rs28997580 SMARCA4 E/16/C2388T L796L 
1295 rs28997582 SMARCA4 E/29/C4053T D1351D 
1296 rs3136804 POLB E/13/C888T Y296Y 
1297 rs3212045 XRCC3 E/4/G132A P44P 
1298 rs3218577 REV3L E/27/C8367A L2789L 
1299 rs34219015 WDR7 E/22/C3714A I1238I 
1300 rs34237683 RRM2 E/1/C87T R29R 
1301 rs34308410 SMARCC2 E/13/T1158C E386E 
1302 rs34312619 MSH2 E/2/C336A S112S 
1303 rs34474865 HLTF E/16/T1740C R580R 
1304 rs34566456 MLH1 5UR//G-532C -- 
1305 rs35013010 DPYS E/6/A1062G D354D 
1306 rs35043160 APC E/16/A7704G G2568G 
1307 rs35051203 SMARCD3 E/13/C1422T L474L 
1308 rs35182583 ERCC6 E/10/C2082T P694P 
1309 rs35225190 MLH1 E/7/A552T S184S 
1310 rs35420817 PPAT E/9/T1026C P342P 
1311 rs35464006 ERBB2 5UR//G-15393C -- 
1312 rs35642130 MSH6 E/5/G3354A E1118E 
1313 rs35653697 MTHFR E/9/C1476T P492P 
1314 rs35756610 ERCC6 E/18/T3774C K1258K 
1315 rs35908749 MLH1 E/9/G702A E234E 
1316 rs3737967 MTHFR E12/3UTR /G3288A -- 
1317 rs3916876 ERCC2 E/18/G1737A V579V 
1318 rs41280126 ABCC3 E/16/A2043G L681L 
1319 rs4135119 TDG E/8/C795T L265L 
1320 rs4135120 TDG E/8/C867T Y289Y 
1321 rs41557516 REV3L E/30/G8874A P2958P 
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1322 rs4252610 ERBB2 E/2/G99A L33L 
1323 rs4252655 ERBB2 E/25/C3078T P1026P 
1324 rs4252656 ERBB2 E/27/G3531A K1177K 
1325 rs4253013 ERCC6 E/2/C411T L137L 
1326 rs4253027 ERCC6 E/3/T528C R176R 
1327 rs4253044 ERCC6 E/5/A885G A295A 
1328 rs4253210 ERCC6 E/18/A3534G F1178F 
1329 rs446382 FGFR4 E/2/T162G R54R 
1330 rs452885 FGFR4 E/5/C702T R234R 
1331 rs455732 REV3L E/13/C4290T V1430V 
1332 rs458486 REV3L E/13/T2706C G902G 
1333 rs4647256 MLH1 E/6/C474T N158N 
1334 rs4807542 GPX4 5UR//G-570A -- 
1335 rs507082 SMARCC1 E/5/G532A L178L 
1336 rs6670886 DPYD E/6/C525T S175S 
1337 rs6823404 SMARCAD1 E/15/C1839T D613D 
1338 rs689453 NQO1 E/2/C72T E24E 
1339 rs6947955 UPP1 E/2/C-43T -- 
1340 rs6972869 PMS2 E/11/A1557G Y519Y 
1341 rs7136420 SMARCC2 E/5/T438C P146P 
1342 rs7275 SMARCA4 E/34/T4887C D1629D 
1343 rs7636910 ABCC5 3DR//T2025C -- 
1344 rs7899457 ABCC2 E/29/C4110T L1370L 
1345 rs8182267 ERBB2 5UR//G-4942A -- 
1346 rs8187630 SLC29A1 E/3/G84A P28P 
1347 rs8187706 ABCC2 E/31/G4410A E1470E 
1348 rs8187707 ABCC2 E/31/C4488T H1496H 
1349 rs9105 SMARCA4 E/32/C4584T D1528D 
1350 rs939336 ABCC5 3DR//A16007G -- 
1351 rs1537516 MTHFR E12/3UTR /G2876A -- 
1352 rs17885803 TP53 5UR//C-1564T -- 
1353 rs17886250 TP53 I/1/C148T -- 
1354 rs2119342 HLTF E25/3UTR /T386C -- 
1355 rs28399438 CYP2A6 I/1/A-34C -- 
1356 rs2856857 MPO I/1/G-13A -- 
1357 rs3176626 XPA 5UR//A-951C -- 
1358 rs34957864 HLTF I/1/C235T -- 
1359 rs3829963 CDKN1A 5UR//C-2100A -- 
1360 rs3890213 CES2 5UR//C-1547T -- 
1361 rs408626 DHFR 5UR//T-332C -- 
1362 rs4987707 BCL2 I/1/C-87T -- 
1363 rs11568589 ABCC3 E/28/G4008A L1336L 
1364 rs2307083 SMARCD1 E/4/A423G V141V 
1365 rs3547 XRCC1 E/17/T1896C Q632Q 
1366 rs1042482 DPYD E23/3UTR /C573T -- 
1367 rs1061388 REV3L E32/3UTR /A925C -- 
1368 rs11591427 PTEN E9/3UTR /A2821T -- 
1369 rs1803541 ERCC3 E15/3UTR /C259T -- 
1370 rs2584622 SMARCD2 E13/3UTR /G131A -- 
1371 rs35180794 GPX7 E3/3UTR /T162- -- 
1372 rs41436046 FPGS E15/3UTR /TT442- -- 
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1373 rs4150525 ERCC3 E15/3UTR /T177C -- 
1374 rs4252661 ERBB2 E27/3UTR /T591C -- 
1375 rs45616134 SMARCA2 E33/3UTR /T698C -- 
1376 rs4987864 BCL2 3DR//C193453A -- 
1377 rs4987865 BCL2 3DR//C193630T -- 
1378 rs4987868 BCL2 3DR//G194378T -- 
1379 rs5030760 RRM2 E10/3UTR /T893C -- 
1380 rs5031031 GSTP1 E7/3UTR /A56G -- 
1381 rs7337469 HMGB1 E5/3UTR /T2156C -- 
1382 rs975922 HLTF E25/3UTR /A1326G -- 
1383 rs9955129 WDR7 E27/3UTR /T943C -- 
1384 rs1042927 RRM1 E19/3UTR /C316A -- 
1385 rs1047619 GPX7 E3/3UTR /A315G -- 
1386 rs1047635 GPX7 E3/3UTR /C435A -- 
1387 rs10981708 SLC31A1 E5/3UTR /C3287T -- 
1388 rs11151988 WDR7 E27/3UTR /T1272G -- 
1389 rs11610906 TDG E10/3UTR /C1585G -- 
1390 rs12106470 SLC19A1 E6/3UTR /G701T -- 
1391 rs12329692 SLC19A1 E6/3UTR /G172A -- 
1392 rs16948421 TYMS E7/3UTR /G398A -- 
1393 rs16950472 ABCC4 3DR//A75520G -- 
1394 rs16956880 TP53 E11/3UTR /C205T -- 
1395 rs17135042 APC E16/3UTR /T1050C -- 
1396 rs17225060 MSH2 E16/3UTR /A226G -- 
1397 rs2230303 GPX3 E5/3UTR /T138G -- 
1398 rs2735347 PTEN E9/3UTR /T957G -- 
1399 rs28382578 SMARCB1 5UR//G-3038A -- 
1400 rs3176359 CDKN1A E3/3UTR /G1165A -- 
1401 rs3733326 PPAT E11/3UTR /G284C -- 
1402 rs3742106 ABCC4 3DR//A74234C -- 
1403 rs3772810 UMPS E6/3UTR /A28G -- 
1404 rs397768 APC E16/3UTR /G1753A -- 
1405 rs4835 FXYD3 E9/3UTR /A173T -- 
1406 rs699517 TYMS E7/3UTR /C19T -- 
1407 rs8177450 GPX3 E5/3UTR /A255G -- 
1408 rs8177452 GPX3 E5/3UTR /A608G -- 
1409 rs8192925 CES2 E12/3UTR/A69G -- 
1410 rs873652 FGFR4 E16/3UTR /A26T -- 
1411 rs9468385 GPX6 E5/3UTR /C457T -- 
1412 rs9516521 ABCC4 3DR//T74903C -- 
1413 rs9835477 SMARCC1 E28/3UTR /T412G -- 
1414 rs10106 FPGS E15/3UTR /T192C -- 
1415 rs1016860 BCL2 3DR//C190113T -- 
1416 rs1042710 UGT1A1 E5/3UTR /A3G -- 
1417 rs1045411 HMGB1 E5/3UTR /C2262T -- 
1418 rs1050569 GPX1 E1/3UTR /T695G -- 
1419 rs10513202 SLC31A1 E5/3UTR /A2206G -- 
1420 rs1051332 ATP7B E17/3UTR /C1172T -- 
1421 rs10513347 HLTF E25/3UTR /T1491C -- 
1422 rs10517 NQO1 E5/3UTR /A1119G -- 
1423 rs1059316 GPX3 E5/3UTR /C713T -- 
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1424 rs10636 MT2A E3/3UTR /G77C -- 
1425 rs1065769 TK1 E7/3UTR /C105T -- 
1426 rs10929303 UGT1A1 E5/3UTR /T211C -- 
1427 rs11375183 SMARCC1 E28/3UTR /-898G -- 
1428 rs1143245 SLC31A1 E5/3UTR /G3502C -- 
1429 rs12010382 ATP7A E23/3UTR /T1819C -- 
1430 rs12189 APC E16/3UTR /C434T -- 
1431 rs12852 FXYD3 E9/3UTR /A818G -- 
1432 rs13048427 SLC19A1 E6/3UTR /G23A -- 
1433 rs1537514 MTHFR E12/3UTR /G2669C -- 
1434 rs16842633 UPP2 E9/3UTR /C962T -- 
1435 rs16861315 HLTF E25/3UTR /C1641T -- 
1436 rs16948409 TYMS E7/3UTR /G214T -- 
1437 rs17225053 MSH2 E16/3UTR /T141G -- 
1438 rs17387924 SMARCA2 E33/3UTR /G431A -- 
1439 rs17511602 REV3L E32/3UTR /T293C -- 
1440 rs1787474 WDR7 E27/3UTR /T275C -- 
1441 rs17880487 SOD1 E5/3UTR /C339T -- 
1442 rs17881366 TP53 E11/3UTR /C328T -- 
1443 rs1804447 SOD1 E5/3UTR /C2T -- 
1444 rs2020906 MSH6 E10/3UTR /T85A -- 
1445 rs2074954 UPP2 E9/3UTR /T123G -- 
1446 rs2077360 MTHFR E12/3UTR /A1858G -- 
1447 rs2290736 SMARCD3 E13/3UTR /C65G -- 
1448 rs2635723 DPYD E23/3UTR /G466T -- 
1449 rs2736630 PTEN E9/3UTR /T1133C -- 
1450 rs2790 TYMS E7/3UTR /A89G -- 
1451 rs28364275 ABCB1 E29/3UTR /A21G -- 
1452 rs28364277 ABCB1 E29/3UTR /C146T -- 
1453 rs28364279 ABCB1 E29/3UTR /T252G -- 
1454 rs28364280 ABCB1 E29/3UTR /C316T -- 
1455 rs28364281 ABCB1 E29/3UTR /A562G -- 
1456 rs28364610 SMARCA5 5UR//G-130A -- 
1457 rs28382662 POLM E11/3UTR /T139C -- 
1458 rs28382664 POLM E11/3UTR /C676T -- 
1459 rs3136391 SMUG1 E4/3UTR /A260G -- 
1460 rs3136392 SMUG1 E4/3UTR /C334T -- 
1461 rs3176358 CDKN1A E3/3UTR /G385A -- 
1462 rs3176753 XPA E6/3UTR /A278G -- 
1463 rs3176754 XPA E6/3UTR /T464C -- 
1464 rs3177111 GPX4 E7/3UTR /C140A -- 
1465 rs3212116 XRCC3 E10/3UTR /A145G -- 
1466 rs3212117 XRCC3 E10/3UTR /G448T -- 
1467 rs3212125 XRCC3 E10/3UTR /A868C -- 
1468 rs3212126 XRCC3 E10/3UTR /C1094T -- 
1469 rs34874603 GPX6 E5/3UTR /A908G -- 
1470 rs35091626 GPX7 E3/3UTR /A549T -- 
1471 rs35481105 PTEN E9/3UTR /A1697G -- 
1472 rs35919705 TP53 E11/3UTR /G105A -- 
1473 rs3744935 BCL2 3DR//C190507T -- 
1474 rs3745030 WDR7 E27/3UTR /C2176G -- 
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1475 rs3745032 WDR7 E27/3UTR /C112T -- 
1476 rs3745033 WDR7 E27/3UTR /C14T -- 
1477 rs3749440 ABCC5 E7/3UTR /A633G -- 
1478 rs3749444 ABCC5 3DR//C62512T -- 
1479 rs3805114 ABCC5 3DR//T63819G -- 
1480 rs3895070 PTEN E9/3UTR /T320G -- 
1481 rs4097504 HMGB1 E5/3UTR /T1167C -- 
1482 rs41275468 MTHFR E12/3UTR /G2594A -- 
1483 rs41292780 ATP7B E17/3UTR /C1385T -- 
1484 rs41297348 ABCB1 E29/3UTR /A393G -- 
1485 rs41483150 FPGS E15/3UTR /A629C -- 
1486 rs4148551 ABCC4 3DR//T74507C -- 
1487 rs4148555 ABCC4 3DR//A75760T -- 
1488 rs4148595 ABCC5 3DR//G63298A -- 
1489 rs4150523 ERCC3 E15/3UTR /G29A -- 
1490 rs4252658 ERBB2 E27/3UTR /C66T -- 
1491 rs4253231 ERCC6 E21/3UTR /A53G -- 
1492 rs448475 APC E16/3UTR /C1556G -- 
1493 rs45574135 MTHFR E12/3UTR /C1070T -- 
1494 rs45593641 NQO1 E5/3UTR /C380T -- 
1495 rs45625835 MTHFR E12/3UTR /C543T -- 
1496 rs4968187 TP53 E11/3UTR /C485T -- 
1497 rs4987843 BCL2 3DR//C189646T -- 
1498 rs4987844 BCL2 3DR//T189914G -- 
1499 rs4987845 BCL2 3DR//C189999T -- 
1500 rs4987848 BCL2 3DR//C190271T -- 
1501 rs4987850 BCL2 3DR//C190671T -- 
1502 rs4987851 BCL2 3DR//C190928T -- 
1503 rs4987852 BCL2 3DR//T191266C -- 
1504 rs4987854 BCL2 3DR//C191561T -- 
1505 rs4987856 BCL2 3DR//C191693T -- 
1506 rs4987858 BCL2 3DR//A192393G -- 
1507 rs4987860 BCL2 3DR//C192600T -- 
1508 rs4987866 BCL2 3DR//T193866C -- 
1509 rs4987867 BCL2 3DR//C194115T -- 
1510 rs4987869 BCL2 3DR//T194457G -- 
1511 rs6594650 APC E16/3UTR /A1203C -- 
1512 rs6650282 ABCC4 E21/3UTR /T168C -- 
1513 rs6899628 POLH E11/3UTR /C290T -- 
1514 rs6919 SMARCD2 E13/3UTR /T813A -- 
1515 rs701848 PTEN E9/3UTR /T1516C -- 
1516 rs7032466 SLC31A1 E5/3UTR /T2808G -- 
1517 rs7048532 SMARCA2 E33/3UTR /T620C -- 
1518 rs757412 SMARCE1 E11/3UTR /G110A -- 
1519 rs7778745 POLM E11/3UTR /A361G -- 
1520 rs8026 SMARCAD1 E24/3UTR /A1500G -- 
1521 rs8056468 NQO1 E5/3UTR /G776A -- 
1522 rs8065799 TP53 E11/3UTR /T9G -- 
1523 rs8330 UGT1A1 E5/3UTR /G440C -- 
1524 rs8336 SMARCAD1 E24/3UTR /T925C -- 
1525 rs868014 MTHFR E12/3UTR /A1290G -- 
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1526 rs9516520 ABCC4 3DR//T75167C -- 
1527 rs9535794 ATP7B E17/3UTR /G1744A -- 
1528 rs9590161 ABCC4 3DR//A75889G -- 
1529 rs9680103 SLC19A1 E6/3UTR /C421A -- 
1530 rs971 SMUG1 E4/3UTR /T422C -- 
1531 rs10609062 UCK1 E7/3UTR/GTGA426- -- 
1532 rs2266636 GSTT1 E/4/C354T V118V 
1533 rs28364609 SMARCA5 5UR//T-740C -- 
1534 rs28606552 SMARCA5 5UR//T-3655A -- 
1535 rs3218658 POLM E/8/C1032T A344A 





Supplementary Table 2: The 14 markers not suitable to be genotyped by 
GoldenGate array and  genotyped by other methods 
 
# rs No Gene  mRNA Location AA Change 
1 rs2853542 TYMS E/1/G-58C  -- 
2 rs34743033  TYMS 
28 bp VNTR in 
5UTR -- 
3 rs16430  TYMS 6 bp InDel in 3UTR -- 
4 rs3786362 TYMS E/3/A381G I127I 
5 rs1801159 DPYD E/13/T1627C I543V 
6 rs2297595 DPYD E/6/T496C M166V 
7 rs11479 TYMP E/10/G1412A S471L 
8 rs9628204 TYMP E/7/C787T G263R 
9 rs17851631 TYMP E/5/G585T D195E 
10 rs28931613 TYMP E/2/C131T R44Q 
11 rs3210145 TYMP I/6/T-2A -- 
12 rs470119 TYMP I/4/T27C -- 
13 rs1061205 TYMP E/10/G1401A F467F 
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5-FU PK RRM1,UMPS,SLC29A1,ABCC4,UPP2,CDA,DPYS,TK1,DPYD,CES2, 
UCK2,ABCG2,CES1,UPP1,ABCC5,UPB1,RRM2,TYMP, 
ABCC3,PPAT,CYP2A6,UCK1,SLC22A7 
5-FU PD MTHFR,ERCC2,GGH,FPGS,TYMS,SMUG1,TP53, 
XRCC3,TDG,DHFR 
Platinum 
pathway 
POLH,ERCC6,SMARCA1,SMARCA2,SLC31A1,NQO1,ATP7A,POLB, 
ATP7B,SMARCD1,ABCC2,REV3L,MT2A,ERCC4,MT1A,XRCC1, 
ERCC2,SOD1,ATOX1,PMS2,SLCO6A1,GSTM1,SMARCAD1, 
MSH6,SMARCD3,ABCG2,GSTP1,ERCC1,SMARCA5,SMARCD2, 
SMARCAL1,XPA,POLM,SMARCB1,MSH2,SMARCA4, 
HLTF,MLH1,HMGB1,SMARCE1,SMARCC1,GSTT1, 
ERCC3,MPO,SMARCC2 
5-FU and 
Platinum 
Pathway 
POLH,ERCC6,SMARCA1,SMARCA2,SLC31A1,NQO1,ATP7A, 
POLB,ATP7B,SMARCD1,ABCC2,REV3L,MT2A,ERCC4,MT1A, 
XRCC1,ERCC2,SOD1,ATOX1,PMS2,SLCO6A1,GSTM1,SMARCAD1, 
MSH6,SMARCD3,ABCG2,GSTP1,ERCC1,SMARCA5,SMARCD2, 
SMARCAL1,XPA,POLM,SMARCB1,MSH2,SMARCA4,HLTF, 
MLH1,HMGB1,SMARCE1,SMARCC1,GSTT1,ERCC3,MPO, 
SMARCC2,RRM1,UMPS,SLC29A1,ABCC4,UPP2,CDA,DPYS, 
TK1,DPYD,CES2,UCK2,TYMS,CES1,UPP1,ABCC5,UPB1, 
RRM2,TYMP,ABCC3,PPAT,CYP2A6,UCK1,SLC22A7, 
MTHFR,GGH,FPGS,SMUG1,TP53,XRCC3,TDG,DHFR 
Colorectal 
Cancer 
Associated 
DLG5,ERCC6,UMPS,ERBB2,PTEN,CYP19A1,EXO1,ABCB1,APC,NQO1, 
MGMT,POLB,HIF1A,EGF,MTHFR,ERCC4,DPYD,XRCC1,CES2,CYP1B1, 
ERCC2,CDKN1A,IL1B,PMS2,GSTM1,TYMS,MSH6,CES1,TP53,GSTP1, 
FAS,UGT1A1,IL8,CDKN1B,ERCC1,TFRC,XPA,SHMT1,XRCC3,MSH2, 
RB1,GSTM3,PLD2,PTGS2,MLH1,XPC,ALDH2,NAT2,CASR,ARL11, 
CYP1A2,GSTT1,IL12A,CYP2A6,ERCC3,ERCC5,FGFR4 
,MMP9,ATM,BARD1,CDH1,CYBA,CYP2C9,CYP2E1,CYP7A1, 
MMP2,MTHFD1,NAT1,PARP1,VDR,UGT2B7,PMS1,OGG1 
,MLH3,GPX1,DCC,CYP3A4,CYP2C19,CDKN2A,BAX 
 
